{"title": "One-Minute Telegram Archiv 2022 - Wissen @ AMBOSS", "author": null, "url": "https://www.amboss.com/de/wissen/one-minute-telegram-archiv-2022", "hostname": "amboss.com", "description": "This article contains a collection of content written for the One-Minute Telegram, a biweekly newsletter that presents the newest medical research condensed into just one minute of reading. This ne...", "sitename": "amboss.com", "date": "2023-01-17", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Introduction\nThis article contains a collection of content written for the One-Minute Telegram, a biweekly newsletter that presents the newest medical research condensed into just one minute of reading. This newsletter is designed for all of our colleagues who want to stay current on the latest medical literature without having to comb through and dissect medical studies themselves. It is peer-reviewed by our team of physician editors and integrated into the\n[Amboss](/de/wissen/Ohr#Z2e6489810ab8a5524d8534501fcab9be) library. Even after a long night shift or a busy day on the wards, it should go down easy. Sign up via the link in \u201cTips and Links\u201d below.\nSee also our\n[One-Minute Telegram Archiv 2021](/de/wissen/One-Minute_Telegram_Archiv_2021#Zedc2f5a9b0e39469c09137ff9a4dcb1e) and [One-Minute Telegram Archiv 2020](/de/wissen/One-Minute_Telegram_Archiv_2020#Ze765573a3b5d8aa28f098b044fb31e6e).\nQ4 2022\n-\n[One-Minute Telegram 65-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zf711b4870ad13181acb218f8fd0622f2)\n- 2022 U.S. Preventive Services Task Force: summary of recommendations\n- Better outcomes with alternative\n[defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)strategies\n- Misunderstanding of medical jargon in the general population\n-\n[One-Minute Telegram 64-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z355dd0b48218ecfed69684867197617d)\n-\n[One-Minute Telegram 63-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z082a198bfd1623e0f33a6bc551593706)\n-\n[Apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911): the right pick for atrial [fibrillation]?\n- The interval between hemodialysis and surgery matters\n- No revelations on the best anticoagulant for patients with end-stage kidney disease\n-\n-\n[One-Minute Telegram 62-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zd95085b87e17463a84517e38b3969fe5)\n- K+ may be more than OK at making bad rhythms go away\n-\n[ECT]more effective than ketamine in major [depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)episode\n- Colonoscopy for colorectal cancer screening saves lives, but only if you get one\n-\n[One-Minute Telegram 61-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z2ef2e61010b49cf63cdedddd29e9f47e)\n- Restock your\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)and laceration repair kits - it\u2019s almost Halloween!\n- Pain control after arthroscopy: Just say no to (more) narcotics!\n- Fluoroquinolones are not associated with increased suicidality\n- Restock your\n-\n[One-Minute Telegram 60-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zae733a415ab7ec45063f7531ca946121)\n- Real-time prescription price transparency reduces costs for patients\n- Glargine and\n[liraglutide](/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98)make the GRADE\n- Yoga improves function in knee OA (but only if you actually do it).\nEdition 65 - December 17, 2022\n2022 U.S. Preventive Services Task Force: summary of recommendations\nOne-Minute Telegram 65-2022-1/3: Happy holidays! The AMBOSS team is here to share some of the most relevant updates to the U.S. Preventive Services Task Force (USPSTF) recommendations this holiday season. A searchable overview of the recommendations can be found here. [1]\n- Primary prevention\n- Statins for primary\n[atherosclerotic cardiovascular disease](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)( [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)) prevention [2][3]\n- USPSTF continues to recommend statins for adults aged 40\u201375 years with an estimated\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)risk of \u2265 10%; shared decision-making is recommended for adults with lower risk (7.5% to < 10%). [4]\n- Benefits and risks of primary prevention for adults aged < 40 years and those > 75 years remain uncertain.\n- USPSTF continues to recommend statins for adults aged 40\u201375 years with an estimated\n- Dietary supplements to prevent\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)and cancer [5][6]\n- USPSTF reaffirms its 2014 recommendations against the use of beta carotene and\n[vitamin E](/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d)supplements.\n- Evidence is insufficient to recommend for or against other dietary supplements.\n- USPSTF reaffirms its 2014 recommendations against the use of beta carotene and\n-\n[Aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)use for primary prevention of [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)and colorectal cancer [7][8]\n- USPSTF recommends against starting low-dose\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)for primary prevention of [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)in adults aged \u2265 60 years.\n- Based on evidence of a small net benefit, daily low-dose\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)may be considered on an individual basis in adults aged 40\u201359 years with a 10-year [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)risk of \u2265 10% and a low risk of bleeding.\n- Whether low-dose\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)reduces the risk of colorectal cancer remains unclear.\n- USPSTF recommends against starting low-dose\n-\n[Hormone](/de/wissen/Allgemeine_Endokrinologie#Z5f7d7972b934850e5dc5e2efdb60e476)therapy after [menopause](/de/wissen/Klimakterium#Z6968f8f221cf989eebc438d5fde47c8e)for primary prevention of chronic conditions [9][10]\n- In\n[postmenopausal](/de/wissen/Klimakterium#Zac4b020fde98661beb72a24ef0b8c067)persons, the USPSTF recommends against using [estrogen](/de/wissen/Sexualhormone#Z3125e0c64f510742be94df34078cd5d7)and progestin combinations for primary prevention of chronic conditions.\n- In\n[postmenopausal](/de/wissen/Klimakterium#Zac4b020fde98661beb72a24ef0b8c067)persons who have had a hysterectomy, the USPSTF recommends against [estrogen](/de/wissen/Sexualhormone#Z3125e0c64f510742be94df34078cd5d7)alone for primary prevention of chronic conditions.\n- In\n- Statins for primary\n- Screening\n- Atrial\n[fibrillation](AF): As in 2018, there is insufficient evidence to recommend for or against screening for asymptomatic AF in adults aged \u2265 50 years. [11][12]\n- Obstructive sleep apnea (\n[OSA](/de/wissen/Schlafbezogene_Atmungsst\u00f6rungen#Zaebb63000e831edd3e9c58bf2efbbd9e)): As in 2017, there is insufficient evidence to support screening for [OSA](/de/wissen/Schlafbezogene_Atmungsst\u00f6rungen#Zaebb63000e831edd3e9c58bf2efbbd9e)in the general adult population. [13][14]\n-\n[Syphilis](/de/wissen/Syphilis#Z2978df89d56acd6a80ead95a0b83e30d): As in 2016, the USPSTF recommends screening for [syphilis](/de/wissen/Syphilis#Z2978df89d56acd6a80ead95a0b83e30d)in asymptomatic, nonpregnant adolescents and adults with an increased risk of infection. [15][16]\n- Atrial\nThe take-home message?\nEvidence-based prevention is the best medicine!\n- AMBOSS links:\n[Kolorektales Karzinom](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)| [Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Karotisstenose](/de/wissen/Isch\u00e4mischer_Schlaganfall#Z6e7c1441e1326e8a7ff985260cd12d31)| [Vorhofflimmern](/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266)| [Obstruktives Schlafapnoe-Syndrom](/de/wissen/Schlafbezogene_Atmungsst\u00f6rungen#Zaebb63000e831edd3e9c58bf2efbbd9e)| [Syphilis](/de/wissen/Syphilis#Z2978df89d56acd6a80ead95a0b83e30d)| [Menopause](/de/wissen/Klimakterium#Z6968f8f221cf989eebc438d5fde47c8e)\nBetter outcomes with alternative\n[defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7) strategies\nOne-Minute Telegram 65-2022-2/3\n- Background: Ventricular\n[fibrillation](VF) is often refractory to initial [defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)attempts. [17] Modifications to [defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)techniques may lead to earlier successful [defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)and better outcomes. This study compared standard [defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)vs. double sequential external [defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)(DSED) or vector-change (VC) [defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)in out-of-hospital refractory VF.\n- Study population\n- 405 adults with refractory VF (i.e., persistent VF after delivery of three consecutive shocks)\n- Mean age 63.6 years, 84.4% male\n- Methods: cluster randomized controlled trial\n- Three intervention groups\n- Standard\n[defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7): [defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)pads in anterior and lateral positions (n = 136)\n- VC\n[defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7): [defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)pads in anterior and posterior positions (n = 144)\n- DSED: rapid sequential shocks from two defibrillators (n = 125)\n- Standard\n- Primary outcome: survival to hospital discharge\n- Secondary outcomes included:\n- Termination of VF\n[Return of spontaneous circulation](/de/wissen/Grundlagen_der_Reanimation#Z56dd86d31686ff69493223c49fc7e4c6)\n- Good neurologic outcome\n- Three intervention groups\n- Main results\n- Survival to hospital discharge\n- Standard group: 13.3%\n- VC group: 21.7% (RR vs. standard, 1.71; 95% CI, 1.01\u20132.88)\n- DSED group: 30.4% (RR vs. standard, 2.21; 1.33\u20133.67)\n- Compared to the standard group, all secondary outcomes occurred more frequently in the DSED group; termination of VF also occurred more frequently in the VC group.\n- Survival to hospital discharge\n- Limitations include:\n- Trial stopped before the planned sample size was achieved due to\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)-related logistical challenges.\n- Small number of primary outcome events may overestimate treatment effect.\n- Lack of follow-up after hospital discharge\n- Trial stopped before the planned sample size was achieved due to\nThe take-home message?\nIn this trial, patients who received DSED for refractory VF in out-of-hospital settings had improved survival and neurologic outcomes compared to those who received standard\n[defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7). Further studies are needed to assess if these results are reproducible and applicable to other treatment settings.\n- AMBOSS links:\n[Kammerflimmern](/de/wissen/Kammerflattern_und_-flimmern#Z5002c993f89f145d9abc89b7718e10cd)| [Herzrhythmusst\u00f6rungen](/de/wissen/Herzrhythmusst\u00f6rungen#Z0adf32b5318acb24e79e61cb74b19e5a)| [Grundlagen der Reanimation](/de/wissen/Grundlagen_der_Reanimation#Z2eec26f6bbfd145d133e7674ac992bd5)\n- Original study:\n[Defibrillation](/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7)strategies for refractory ventricular [fibrillation][18]\n- Authors: Cheskes S et al.\n- Journal: NEJM\n- Study funding: Heart and Stroke Foundation of Canada\nMisunderstanding of medical jargon in the general population\nOne-Minute Telegram 65-2022-3/3\n- Background: Health care workers frequently use technical terms and medical jargon while communicating with patients. This study assessed the understanding of common medical phrases among members of the general public.\n- Study population: 215 English-speaking adults with no medical training (mean age 42 years, 63% female)\n- Methods: cross-sectional study\n- Participants were randomized to a written or verbal 13-question survey including multiple-choice and open-ended questions about frequently used medical jargon.\n- Responses were collected at the 2021 Minnesota State Fair.\n- Main results\n- Understood terms for good news\n- Negative cancer screening: 96.3%\n- Negative blood culture: 86.5%\n- Unremarkable chest x-ray: 79.5%\n- Understood terms for bad news\n-\n[Tumor](/de/wissen/Allgemeine_Onkologie#Z96dbcb525ee590dbfa7e193aeb93cb24)is progressing: 79.1%\n- Positive nodes: 66.5%\n- Febrile: 9.3%\n- Bugs in urine: 28.8%\n-\n- Understanding of jargon vs. nonjargon\n- Blood culture was negative (86.5%) vs. blood culture showed no infection (96.7%); P < 0.001\n- NPO (11.2%) vs. nothing by mouth (75.3%); P < 0.001\n- Understood terms for good news\n- Limitations include:\n-\n[Selection bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de): Participants were visitors to a university research building, which also had a mask mandate.\n- Generalizability: Participants had above-average education levels.\n- Multiple-choice questions may have made answers easier to guess.\n-\nThe take-home message?\nThese survey results suggest that common medical jargon may often be poorly understood by the general public. Health care workers should be trained to avoid medical jargon when communicating with patients.\n- AMBOSS links:\n[Asymmetrische Kommunikation](/de/wissen/Arzt-Patient-Beziehung#Z7566eec9f8d0ee04b7494fddfdf78e42)| [Untersuchung und Gespr\u00e4ch](/de/wissen/Untersuchung_und_Gespr\u00e4ch#Z1f3539196e38cec918c8e608227e5627)\n- Original study: Accuracy in patient understanding of common medical phrases [19]\n- Authors: Gotlieb R et al.\n- Journal: JAMA Netw Open\n- Study funding: NIH National Center for Advancing Translational Sciences; University of Minnesota\nEdition 64 - December 03, 2022\nCrossword puzzles beat cognitive games\nOne-Minute Telegram 64-2022-1/3\n- Background: Complex mental activity has been shown to reduce the risk of dementia [20] and improve everyday function [21] in older adults, but studies on individuals with preexisting mild cognitive impairment (MCI) are scarce. This study sought to examine the effect of cognitive training with web-based cognitive games versus web-based crossword puzzles on cognition and functional performance in older adults with MCI.\n- Study population: 107 patients with MCI (mean age 71.2 years, 58% female)\n- Methods: two-site, single-blinded, randomized treatment trial\n- Intervention: patients randomized 1:1 to train with crossword puzzles (n = 51) or cognitive games (n = 56)\n- Primary outcome: change in cognitive performance from\n[baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293)to week 78 (measured using ADAS-Cog score [22]; range from 0 to 70; higher scores indicate greater cognitive impairment)\n- Secondary outcomes\n- Change in functional performance (measured using UPSA scores [23]) and/or impairment in instrumental activities of daily living (measured using FAQ scores [24])\n- Change in hippocampal volume and cortical thickness on MRI\n- Main results\n- Significant difference in ADAS-Cog score between groups\n- Mean scores worsened with games (mean +0.4 points; from 9.53 to 9.93) and improved with crosswords (mean -1 point; from 9.59 to 8.61).\n- Improvement of \u2265 2 points: seen in 25% of participants in the games group vs. 37.3% in the crosswords group\n- FAQ score worsened more in the games than in the crosswords group; there were no differences in UPSA scores.\n- MRI: greater decrease in hippocampal volume and cortical thickness in the games group\n- Limitations include:\n- Uncertain clinical relevance of small ADAS-Cog score changes in patients with MCI\n-\n[Absence](/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Z93dedd171a6efaddb5d27c931860ee21)of a control group: The effect of crossword puzzles compared to no cognitive training was not assessed.\n- Limited generalizability: On average, participants had high education levels.\nThe take-home message?\nIn this trial of patients with MCI, at 78 weeks, crossword puzzle training was associated with improved mean cognition scores, while cognitive game training was associated with worsened cognition scores. However, the implications of these results for clinical practice remain uncertain. Further studies are needed to assess whether game-based cognitive training has any significant effect on the progression of MCI compared to no training.\n- AMBOSS links:\n[\u00dcbersicht Geriatrie](/de/wissen/\u00dcbersicht_Geriatrie#Z1184db8a6ce52feb7970e8cbc965742e)| [Demenz](/de/wissen/Demenz#Z550bcfc577560faea37bbddda0e01e7b)| [Morbus Alzheimer](/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874)\n- Original study: Computerized games versus crosswords training in mild cognitive impairment [25]\n- Authors: Devanand DP et al.\n- Journal: NEJM Evidence\n- Study funding: National Institute on Aging\nNew weapon in the fight against\n[malaria](/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f)\nOne-Minute Telegram 64-2022-2/3\n- Background: There were an estimated 627,000\n[malaria](/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f)deaths [26] in 2020 despite a wide variety of preventive strategies and treatment options. Efforts to decrease the [malaria](/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f)mortality rate have stalled and the development of a vaccine [27] is progressing slowly. This study sought to determine the safety and [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)of a single prophylactic monoclonal antibody (CIS43LS) [infusion](/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81)against [Plasmodium falciparum](/de/wissen/Allgemeine_Parasitologie#Z800da2c0c51c6f64339721abecbdf95a)infection.\n- Study population: healthy nonpregnant adults aged 18\u201355 years living in areas with endemic P. falciparum\n[malaria](/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f)in Mali\n- Part A (safety)\n- Methods: open-label, dose-escalation study in 18 participants\n- Main results:\n[Adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)were mild-to-moderate at 24 weeks; risk of moderate headache was higher with 40 mg/kg CIS43LS compared to [placebo](risk ratio, 3.3; 95% CI, 1.1\u20139.7).\n- Part B (\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f))\n- Methods: double-blind, randomized,\n[placebo]-controlled trial\n- Main results\n- Infection rate over 24 weeks: 78.2% in\n[placebo]group, 35.5% in 10 mg/kg CIS43LS group, 18.2% in 40 mg/kg CIS43LS group\n- Compared to\n[placebo], the [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)of CIS43LS in preventing P. falciparum infection over a 6-month period was:\n- 88.2% (95% CI, 79.3\u201393.3%) in the 40 mg/kg group.\n- 75.0% (61.0\u201384.0%) in the 10 mg/kg group.\n- Infection rate over 24 weeks: 78.2% in\n- Methods: double-blind, randomized,\n- Limitations include:\n- Limited generalizability: Participants were healthy, nonpregnant adults from a single country.\n- Reasons for breakthrough infections are unclear.\nThe take-home message?\nThis study demonstrated that a single dose of monoclonal antibodies was well-tolerated and provided effective protection against P. falciparum infection in healthy, nonpregnant adults during a 6-month\n[malaria](/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f) season in Mali. Further research on the use of monoclonal antibodies in preventing [malaria](/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f) is ongoing [28], but this promising addition to the global fight against [malaria](/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f) is an exciting development.\n- AMBOSS link:\n[Malaria](/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f)\n- Original study: Safety and\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)of a monoclonal antibody against [malaria](/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f)in Mali [29]\n- Authors: Kayentao K et al.\n- Journal: NEJM\n- Study funding: National Institute of Allergy and Infectious Disease\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)-related stress may cause menstrual irregularity\nOne-Minute Telegram 64-2022-3/3\n- Background: Menstrual health [30] offers insight into women\u2019s overall well-being and is affected by many factors, including high stress levels. The authors of this study investigated the hypothesis that women with high levels of\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)-related stress would report more changes in their menstrual parameters than women with lower stress.\n- Study population: 354 women aged 18\u201345 years with menstrual cycles not altered by factors such as pregnancy, postpartum period (< 3 months), use of hormonal birth control, recent infertility treatment, or hysterectomy\n- Methods: cross-sectional study\n- Main results\n-\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)-related stress was classified as low in 89.5% (n = 317) and high in 10.5% (n = 37).\n- High\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)-related stress was associated with changes in cycle length (OR, 2.32; 95% CI, 1.12\u20134.85), period duration (2.38; 1.14\u20134.98), and [spotting](/de/wissen/Menstruationszyklus_und_Zyklusanomalien#Z283c4dff28dc7e7c4c5131a8a539d187)between cycles (2.32; 1.03\u20135.22), but not significantly associated with changes in menstrual flow (1.61; 0.77\u20133.34).\n- Results were independent of age, education, non-\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)-related mental health, smoking, and weight.\n-\n- Limitations include:\n- Potential for\n[recall bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Z34d41b30a792b17afcdd32b43ce85f19)in participant responses\n- Possible\n[selection bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de)with online survey\n- Potential for\nThe take-home message?\nThis study demonstrated that a high level of stress attributed to the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) pandemic was associated with multiple changes in the menstrual cycle. Health care providers should be aware of potential [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)-related stress when addressing patients\u2019 menstrual health.\n- AMBOSS links:\n[Menstruationszyklus und Zyklusanomalien](/de/wissen/Menstruationszyklus_und_Zyklusanomalien#Za9dde6254dc902b890e9b4bf33be57b8)| [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\n- Original study:\n[Coronavirus](/de/wissen/Allgemeine_Virologie#Zd33e47448cef27ccc69577a4a25749a9)disease 2019 ( [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7))\u2013related stress and menstrual changes [32]\n- Authors: Anto-Ocrah M et al.\n- Journal: Obstet Gynecol\n- Study funding: National Institute of Health\nEdition 63 - November 19, 2022\n[Apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911): the right pick for atrial [fibrillation]?\nOne-Minute Telegram 63-2022-1/3\n- Background: The AHA/\n[ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)recommends direct [oral]anticoagulants (DOACs) for the prevention of thromboembolism in most patients with atrial [fibrillation](AF), but which [DOAC](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721)is preferred remains unclear. This study compared the safety and [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)of four commonly prescribed DOACs in patients with AF. [33]\n- Study population: adult patients with AF not previously treated with any of the compared DOACs (n = 527,226)\n- Methods: multinational population-based cohort study\n- Patients identified from five large databases in Europe and the US\n- Head-to-head comparison of\n[apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911), [dabigatran](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zf1157dfb62b05f3e741ccd036588d15f), [rivaroxaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z22bbeb78e62fcd17cbdcc573e8ff87cd), and [edoxaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z5c892255c4fb7d1881dd4e503d8aad18)\n- Outcomes of interest: ischemic and hemorrhagic stroke, systemic embolism,\n[gastrointestinal](/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10)bleed (GIB), and all-cause mortality\n- Main results\n- Lower risk of GIB with\n[apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911)than with other DOACs, i.e., [dabigatran](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zf1157dfb62b05f3e741ccd036588d15f)(HR, 0.81; 95% CI, 0.70\u20130.94), [rivaroxaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z22bbeb78e62fcd17cbdcc573e8ff87cd)(HR, 0.72; 0.66\u20130.79), [edoxaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z5c892255c4fb7d1881dd4e503d8aad18)(HR, 0.77; 0.66\u20130.91)\n- No substantial difference in other outcomes of interest\n- Lower risk of GIB with\n- Limitations include:\n- Potential for residual\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1)because of the observational study design\n- Severity of GIB was not assessed.\n- Potential for residual\nThe take-home message?\nIn this large international observational study of DOACs in the management of AF,\n[apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911) was associated with a similar risk of stroke and systemic embolism as other commonly used DOACs, but with a lower risk of GIB. These results point to a preference for [apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911) for the prevention of thromboembolism in the management of AF, but risks and benefits should be considered individually for each patient.\n- AMBOSS links:\n[Vorhofflimmern](/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266)\n- Original study: Comparative effectiveness and safety between\n[apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911), [dabigatran](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zf1157dfb62b05f3e741ccd036588d15f), [edoxaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z5c892255c4fb7d1881dd4e503d8aad18), and [rivaroxaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z22bbeb78e62fcd17cbdcc573e8ff87cd)among patients with atrial [fibrillation]: a multinational population-based cohort study [34]\n- Authors: Lau WCY et al.\n- Journal: Ann Intern Med\n- Study funding: none\nThe interval between hemodialysis and surgery matters\nOne-Minute Telegram 63-2022-2/3\n- Background: Patients with end-stage kidney disease (ESKD) on chronic hemodialysis (HD) have an elevated risk for postoperative complications, but high-quality evidence on the optimal timing of dialysis prior to surgery is lacking. The goal of this study was to assess whether a longer interval between HD and elective surgery is associated with higher postoperative mortality. [35]\n- Study population: 1,147,846 elective surgical procedures in 346,828 Medicare fee-for-service-insured adults (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age 65 years; 43% female) on long-term HD\n- Methods: retrospective cohort study\n- Data obtained from a US national database of patients on HD\n- Exposures:\n- Number of days between last outpatient HD and surgical procedure\n- HD vs. no HD on day of surgery\n- Outcome: 90-day postoperative mortality\n- Main results\n- Longer intervals between HD and surgery were associated with a higher absolute risk of 90-day mortality.\n- 2 days vs. 1 day: 4.7% vs. 4.2%; adjusted HR, 1.14 (95% CI, 1.10\u20131.18)\n- 3 days vs. 1 day: 5.2% vs. 4.2%; adjusted HR, 1.25 (1.19\u20131.31)\n- 3 days vs. 2 days: 5.2% vs. 4.7%; adjusted HR, 1.09 (1.04\u20131.13)\n- HD on the day of surgery was associated with a lower risk of 90-day mortality: 4.0% vs. 4.5%; adjusted HR, 0.88 (95% CI, 0.84\u20130.91)\n- Longer intervals between HD and surgery were associated with a higher absolute risk of 90-day mortality.\n- Limitations include:\n- Findings not generalizable to emergency surgery\n- Potential for residual\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1)given the observational study design\nThe take-home message?\nThis study suggests that a shorter interval between HD and surgery decreases the risk of postoperative mortality. Since the absolute risk differences associated with different time intervals were small and subject to residual\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1), prospective studies are warranted.\n- AMBOSS links:\n[Chronische Nierenerkrankung](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)| [Perioperatives Management](/de/wissen/Perioperatives_Management#Z3a7bd0c1bd5a355d4ac6d1ae3fc9717c)\n- Original study: Association between preoperative hemodialysis timing and postoperative mortality in patients with end-stage kidney disease [36]\n- Authors: Fielding-Singh V et al.\n- Journal: JAMA\n- Study funding: Institutional and federal grant funded\nNo revelations on the best anticoagulant for patients with end-stage kidney disease\nOne-Minute Telegram 63-2022-3/3\n- Background: Studies demonstrating the superior safety and\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)of [apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911)over [warfarin](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc)in reducing the risk of stroke or systemic embolism in patients with atrial [fibrillation](AF) have traditionally excluded patients with end-stage kidney disease (ESKD). The aim of this study was to compare the risk of major or clinically relevant non-major bleeding (CRNMB) between [apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911)and [warfarin](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc)in patients with AF and ESKD on hemodialysis (HD). [37][38]\n- Study population: 154 patients (\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age 68 years; 36% female; 45% Black) with ESKD on HD and AF with a CHA2DS2-VASc score \u2265 2 on [apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911)(n = 82) or [warfarin](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc)(n = 72)\n- Methods: prospective, randomized, open-label, blinded-outcome evaluation\n- Main results\n- Limitations include:\nThe take-home message?\nNo conclusions on the preferred approach to stroke and thromboembolism prevention in patients with ESKD and AF can be drawn from this study. While patients who received\n[apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911) had higher rates of clinically significant bleeding than those who received [warfarin](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc), results should be interpreted with caution due to major study limitations. Prospective studies are still needed to determine the safest and most effective approach to thromboembolism prevention in this high-risk population.\n- AMBOSS links:\n[Vorhofflimmern](/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266)| [Chronische Nierenerkrankung](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)\n- Original study:\n[Apixaban](/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911)for patients with atrial [fibrillation]on hemodialysis: a multicenter randomized controlled trial [39]\n- Authors: Pokorney SD et al.\n- Journal: Circulation\n- Study funding: Bristol-Myers Squibb and Pfizer; National Institutes of Health\nEdition 62 - November 5, 2022\nK+ may be more than OK at making bad rhythms go away\nOne-Minute Telegram 62-2022-1/3\n- Background: Although hypokalemia [40] and hypomagnesemia [41] are associated with the development of atrial\n[fibrillation](AF), there is limited evidence on the benefit of electrolyte administration in the acute treatment of AF. The aim of this study was to examine whether administration of IV potassium and [magnesium](/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a)increased the probability of spontaneous conversion (SCV) to sinus rhythm in patients with nonpermanent AF or atrial [flutter](AFL).\n- Study population: adult patients presenting to the emergency department (ED) with nonpermanent AF (2546 episodes;\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age: 68 years; 55.4% men) or AFL (573 episodes; [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age: 68 years; 57.9% men)\n- Methods: single-institution registry-based cohort study\n- Episodes identified from a registry of ED patients with supraventricular tachycardia\n- Electrolyte solution was administered at the discretion of the treating physician.\n- Exposure: IV administration of a prefabricated electrolyte solution containing 24 mEq of potassium and 145.8 mg of\n[magnesium](/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a)per 250 ml bag.\n- Primary outcome: probability of SCV while in the ED\n- Main results\n- Potassium and\n[magnesium](/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a)were administered in 56.5% of episodes ( [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)dosage: 1 bag).\n- AF:\n- AFL: no change in\n[odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c)of SCV with potassium and [magnesium](/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a)administration (13.0% vs. 12.5%; OR, 1.05; 95% CI, 0.65\u20131.69)\n- Potassium and\n- Limitations include:\n- Cohort study design does not prove causality.\n- Single-center study in a relatively homogeneous population\n-\n[Selection bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de): management at the discretion of the treating physician\n- Registry data did not include out-of-hospital rate and rhythm control.\nThe take-home message?\nIntravenous potassium and\n[magnesium](/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a) may improve the probability of spontaneous conversion to sinus rhythm in patients with nonpermanent atrial [fibrillation] and a [baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293) potassium level < 4 mEq/L. While this simple treatment strategy for a common medical problem appears promising, prospective controlled trials are needed to confirm these findings.\n- AMBOSS links:\n[Vorhofflimmern](/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266)| [Hypokali\u00e4mie](/de/wissen/Elektrolytst\u00f6rungen_Kalium#Z946655e8d52337a1e834b7224308cea4)| [Magnesium](/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a)( [Laboratoriumsmedizin](/de/wissen/Laboratoriumsmedizin#Zbb8375deba4850bda2ecad81d8dcdb10)\u2192 [Elektrolyte](/de/wissen/Laboratoriumsmedizin#Zf9be1a2cd69e5462e03f10aee4604b96))\n- Original study: Association of intravenous potassium and\n[magnesium](/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a)administration with spontaneous conversion of atrial [fibrillation]and atrial [flutter]in the emergency department [42]\n- Authors: Cacioppo F et al.\n- Journal: JAMA Netw Open\n- Study funding: Institutional\n[ECT] more effective than ketamine in major [depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473) episode\nOne-Minute Telegram 62-2022-2/3\n- Background: Treatment-resistant\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)is associated with significant morbidity and mortality. This study set out to compare the effectiveness of ketamine vs. electroconvulsive therapy ( [ECT]), in patients who qualify for [ECT]for treatment of a major [depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)episode (MDE).\n- Study population: 340 patients (n = 178 ketamine, n = 162\n[ECT])\n- Methods: systematic review and metaanalysis of six trials comparing ketamine and\n[ECT]for the treatment of MDE\n- Changes in\n[depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)symptoms were reported with standardized mean differences (SMDs).\n- Main outcomes:\n- Clinical:\n[depression](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)severity, cognition, and memory performance\n- Safety: serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)(e.g., suicide attempts and death), other [adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)\n- Clinical:\n- Changes in\n- Main results\n-\n[ECT]was superior to ketamine for improvement of [depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)symptoms (SMD, -0.69; 95% CI, -0.89 to -0.48).\n- No significant difference was seen between groups in studies that assessed cognition, memory, and serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c).\n-\n[ECT]and ketamine were equally effective in reducing suicidal ideation (1 study).\n- Patients in the ketamine group had better short-term post-treatment neurocognitive performance (1 study).\n- Headache and muscle pain were more common after\n[ECT](3 studies).\n- Transient vision changes and dissociative symptoms were more common after ketamine (2 studies).\n-\n-\n- Limitations include:\n- Small sample sizes\n- Limited long-term follow-up data\n- Variability in study design and treatment protocols among analyzed studies\nThe take-home message?\nWhile this systematic review and metaanalysis found that both interventions improve\n[depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473) symptoms in patients with major [depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473) episode, the results suggest that [ECT] may be more effective than ketamine. Limited long-term follow-up data and the different side-effect profiles of [ECT] and ketamine warrant further prospective trials to help clarify which patients would benefit most from each of these therapeutic options.\n- AMBOSS link:\n[Schwere Depression](/de/wissen/Unipolare_Depression#Z1306410c7b9121ddcd89ca401566a5ed)\n- Original study:\n[Efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)and safety of ketamine vs electroconvulsive therapy among patients with major [depressive](/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473)episode: a systematic review and meta-analysis [43]\n- Authors: Rhee TG et al.\n- Journal: JAMA Psychiatry\n- Study funding: Institutional\nColonoscopy for colorectal cancer screening saves lives, but only if you get one\nOne-Minute Telegram 62-2022-3/3\n- Background: Many countries recommend screening adults (e.g., at age 45\u201375 years per USPSTF recommendations) [44] for colorectal cancer (\n[CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)), but screening methods vary and patient participation [45] in screening programs remains low. This study set out to investigate the impact of an invitation to receive a screening colonoscopy vs. no intervention on the rate of [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)and [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)-related death in countries that had no prior organized [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)screening programs.\n- Study population: healthy adults aged 55\u201364 years (n = 84,585) from Norway, Sweden, and Poland with no prior\n[CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)screening\n- Methods: pragmatic randomized controlled trial\n- Main results\n- 42% of the invited group underwent screening colonoscopy\n- Compared to the control group, the invitation group had (\n[intention-to-treat](/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19)analysis):\n- However, an adjusted per-protocol analysis suggested that had all invited participants undergone a colonoscopy, both\n[CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)and [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)-related deaths would have been significantly reduced.\n- Limitations include:\n- Generalizability: Low screening rates among invited participants limit ability to generalize to settings with more established screening programs.\n- Lack of information about polyp surveillance\n- Follow-up may have been too short to demonstrate survival benefit.\nThe take-home message?\nThis study showed that a single invitation to a screening colonoscopy resulted in low colonoscopy rates, had only a modest effect on the risk of\n[CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7), and had no effect on [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)-related death at 10 years. However, the results of this study should not be overgeneralized as pragmatic US screening programs with higher colonoscopy uptake rates have demonstrated significant reduction in [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7) and [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)-related death. [46]\n- AMBOSS links:\n[Kolorektales Karzinom](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)| [Kolonpolypen](/de/wissen/Kolonpolypen#Z7d836a80066e57b74c74add53eea2731)\n- Original study: Effect of colonoscopy screening on risks of colorectal cancer and related death [47]\n- Authors: Bretthauer M et al.\n- Journal: NEJM\n- Study funding: Research Council of Norway and others\nEdition 61 - October 22, 2022\nRestock your\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) and laceration repair kits - it\u2019s almost Halloween!\nOne-Minute Telegram 61-2022-1/3\n- Candy crush(ing chest pain) \u2013 Sugar crashes and hangovers may be common adverse effects of Halloween-related overindulgence, but what about myocardial infarction (MI)? This time-stratified case-crossover study [48] of patients with MI in Quebec, Canada, set out to determine if the\n[odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c)of having an MI were higher on November 1st (the day after Halloween) than on control days. The analysis demonstrated that MIs were more likely to occur the day after Halloween (OR, 1.13; 95% CI, 1.07\u20131.20). Post-Halloween MIs were most common in men and individuals aged 65\u201384 years. The study was not designed to establish causality (e.g., candy corn overdose vs. yelling at the kids to stay off the lawn).\n- More gore than you were asking for \u2013 Crafting the spookiest jack-o\u2019-lantern is a joyful Halloween tradition and may also increase the likelihood of roasting and consuming delicious pepitas. However, slippery fingers from slimy pumpkin guts can lead to serious gourd-carving cuts. This study used the National Electronic Injury Surveillance System to investigate all pumpkin-related knife injuries (PRKIs) [49] between 2012 and 2021. There were nearly 21,000 PRKIs recorded, most of which were\n[hand](/de/wissen/Hand#Zbec311d267e59b3560e01b78c0e2b870)lacerations. PRKIs occurred primarily in October (83.5% of cases), with nearly half of the overall cases reported on the week of Halloween. Children aged 10\u201319 years were most commonly afflicted, followed by children aged < 10 years.\n- Don\u2019t blame it on the moonlight - While many doctors love to blame the full moon for an overcapacity emergency department, increased admissions, bad call nights, and werewolf attacks, many of these notions have been debunked in the scientific literature. [50] But what about seizures? This retrospective study explored whether there was a relationship between the timing of a first-ever seizure and the lunar cycle. [51] Alas, among 1710 patients with first-ever seizures, onset was evenly distributed across all lunar phases.\nThe take-home message?\nThis Halloween, remind your grandpa to go easy on the candy, don\u2019t let children play with knives, and EDs: prep your laceration repair kits, but don\u2019t worry about a full moon!\n- AMBOSS links:\n[Akutes Koronarsyndrom](/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b)| [Messerstichverletzung](/de/wissen/Wundbehandlung#Z762a7005d27ad3b5c668c1c1464d21a1)| [Epileptischer Anfall](/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Zef26c06cb65b06456ccd4c6763eda385)\nPain control after arthroscopy: Just say no to (more) narcotics!\nOne-Minute Telegram 61-2022-2/3\n- Background: Pain management strategies [52] employing nonopioid analgesics have been shown to decrease postoperative\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)requirements, but the prescription and use of narcotics [53] following arthroscopic surgery remain high. The aim of this study was to evaluate the effect of a simple [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)-sparing protocol on [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)use following arthroscopic surgery.\n- Study population: 193 adult patients (mean age 43 years, 38% women) having elective arthroscopic knee or shoulder surgery (surgical time \u2264 3 hours) with no history of chronic\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)use\n- Methods: multicenter superiority\n[RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28)\n- Main results\n- The\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)-sparing protocol group had:\n- No significant differences in pain scores, patient satisfaction, or\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)refills\n- The\n- Limitations include:\nThe take-home message?\nA simple pain management protocol utilizing common OTC nonopioid analgesics may reduce both\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) use and the quantity of [opioids](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) prescribed for pain following arthroscopic surgery. These results are consistent with those of other studies that support efforts to minimize the contribution of perioperative pain control to the [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) crisis. [54]\n- AMBOSS links:\n[Opioidabh\u00e4ngigkeit](/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z9f4a33561601fe529f3c7dfbe30ba130)| [Schmerztherapie](/de/wissen/Schmerztherapie#Zb6afc2d58dceca8cf94c49d2488655a7)| [WHO-Stufenschema](/de/wissen/Schmerztherapie#Z96e267f8c130a28a13641263162bf5d5)\n- Original study: Effect of a postoperative multimodal\n[opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)-sparing protocol vs standard [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)prescribing on postoperative [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)consumption after knee or shoulder arthroscopy: a randomized clinical trial [55]\n- Authors: The\n[NO](/de/wissen/Signaltransduktion#Z1fd25aa0c628bffbc87aca80bc99759d)PAin Investigators\n- Journal: JAMA\n- Study funding: Hamilton Health Sciences New Investigator Fund and Physicians\u2019 Services Inc Research Grant\nFluoroquinolones are not associated with increased suicidality\nOne-Minute Telegram 61-2022-3/3\n- Background: In 2016, the\n[FDA]added a black box warning to fluoroquinolones for suicidal ideation [56] based on multiple case reports. The aim of this investigation was to assess the association between fluoroquinolone use and suicidality in a large cohort of patients.\n- Study population: 2,756,268 adults (\u2265 18 years of age) initiated on an antibiotic for pneumonia or UTI\n- Methods: population-based cohort study\n- Data was from a commercial US health insurance database.\n- Adults were initiated on a fluoroquinolone or comparator antibiotic.\n-\n[Azithromycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zed86c2e393675ed178e06abfbbb3f4bc)for pneumonia\n- Trimethoprim-sulfamethoxazole for UTI\n-\n- Study outcome: emergency department visit or hospital admission for suicidal ideation, suicide, or self-inflicted harm within 60 days of treatment initiation\n- Main results\n- Risk of suicidality was similar with fluoroquinolones and comparator antibiotics.\n- Fluoroquinolone vs.\n[azithromycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Zed86c2e393675ed178e06abfbbb3f4bc): HR, 1.01 (95% CI, 0.76\u20131.36)\n- Fluoroquinolone vs. trimethoprim-sulfamethoxazole: HR, 1.03 (0.91\u20131.17)\n- Fluoroquinolone vs.\n- Absolute risk of suicidality was low (< 0.1%) in all groups and was consistent with historical figures for the general population.\n- Risk of suicidality was similar with fluoroquinolones and comparator antibiotics.\n- Limitations include:\n-\n[Selection bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de): Risk of suicidality was based only on hospital admissions and emergency department visits.\n- Generalizability: did not assess long-term fluoroquinolone use\n- Residual\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1): Using data from an insurance claims database limits the ability to control for [confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1)patient characteristics.\n-\nThe take-home message?\nThough multiple\n[FDA] black box warnings [57] have led to decreased fluoroquinolone use, this large population-based cohort study did not find an increased risk of suicidality with short-term fluoroquinolone use.\n- AMBOSS links:\n[Antibiotika - \u00dcbersicht](/de/wissen/Antibiotika_-_\u00dcbersicht#Z58bcc7711752096ecca5b2bfd6b56f92)| [Suizid](/de/wissen/Suizidalit\u00e4t#Z090c4f23b9ddf810e4921befa5d31468)\n- Original study: Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study [58]\n- Authors: Wang J et al.\n- Journal: BMJ\n- Study funding: Brigham and Women\u2019s Hospital\nEdition 60 - October 8th, 2022\nReal-time prescription price transparency reduces costs for patients\nOne-Minute Telegram 60-2022-1/3\n- Background: Many providers do not accurately estimate the true out-of-pocket medication costs paid by their patients, and drug costs are a significant factor for medication nonadherence in patients with chronic disease. [59][60] This study set out to assess the patient cost-savings generated through use of a real-time prescription benefit (RTPB) system that recommended lower cost alternatives for prescriptions in the ambulatory setting.\n- Study population: adults receiving outpatient prescriptions in a large, urban, academic health-care system in the US\n- Methods\n- Cluster randomized trial of 255 practices\n- Medical practices randomized to either:\n- No recommendations (control)\n- RTPB system (intervention): recommendations given if an alternative medication, different pharmacy, and/or a larger supply (e.g., 90 vs. 30 days) enabled cost-savings\n- Main results\n- Mean out-of-pocket drug costs for 30-day prescriptions were significantly lower for the intervention group compared to the control group ($39.90 vs. $67.80; adjusted effect estimate, -11.2%; 95% CI, -15.7% to -6.4%).\n- Effect was highest for drugs that cost > $106.50 per 30-day supply (-38.9%; -47.6% to -28.7%).\n- Limitations include:\n- Generalizability: single academic health-care system\n- RTPB recommendations were generated for < 5% of prescriptions.\n- Unknown effect on total out-of-pocket drug spending\nThe take-home message?\nThis study demonstrated that providing real-time feedback to prescribers about lower cost alternatives to prescribed medications led to a reduction in out-of-pocket costs for their patients. Whether an RTPB system results in improved medication adherence remains to be seen.\n- AMBOSS Links:\n[Patientenversorgung und Gesundheitssystem](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z865d37347a16e85f2cb7f1265b6c766b)\n- Original study: Effects of real-time prescription benefit recommendations on patient out-of-pocket costs: a cluster randomized clinical trial [61]\n- Authors: Desai SM et al.\n- Journal: JAMA Intern Med\n- Study funding: NYU Langone Health\nGlargine and\n[liraglutide](/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98) make the GRADE\nOne-Minute Telegram 60-2022-2/3\n- Background: This study set out to compare the effectiveness of four antidiabetic medications when added to\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)for glycemic control.\n- Study population\n- Methods\n- Multicenter, parallel-group, comparative effectiveness\n[RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28)\n- Participants randomized to either glargine (titrated to effect), glimepiride (max. dose 8 mg/day),\n[liraglutide](/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98)(max. dose 1.8 mg/day), or [sitagliptin](/de/wissen/Antidiabetika#Z61dd0ba2238ee701aa5ef71a72f52d43)(max. dose 100 mg/day)\n- All received max. tolerated\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)dose (up to 2 g/day).\n- Mean follow-up of 5 years\n- Glargine added for participants in the other treatment arms if\n[HbA1c](/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4)\u2265 7.5%\n- Multicenter, parallel-group, comparative effectiveness\n- Main results\n- Rate of metabolic failure (i.e.,\n[HbA1c](/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4)\u2265 7%) was overall high but lower in the glargine (67%) and [liraglutide](/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98)(68%) groups, followed by the glimepiride (72%) and [sitagliptin](/de/wissen/Antidiabetika#Z61dd0ba2238ee701aa5ef71a72f52d43)(77%) groups (P < 0.001).\n- The highest rate of severe hypoglycemia was seen in the glimepiride group, followed by the glargine group (2.2% and 1.3%).\n- Rate of metabolic failure (i.e.,\n- Limitations include:\n- Some classes of antidiabetic medications (e.g., SGLT2i) and commonly used medications (e.g., semaglutide) were not included.\n- Lack of blinding\n- Treatment protocols may be hard to replicate in real-world practice.\nThe take-home message?\nIn this\n[RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28), achieving and sustaining target glycated hemoglobin levels was difficult, even under ideal treatment circumstances (e.g., close clinical follow-up and free medications). The addition of [liraglutide](/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98) or glargine [insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce) to [metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) was more successful in achieving and sustaining a target [HbA1c](/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4) level of < 7% than the addition of glimepiride or [sitagliptin](/de/wissen/Antidiabetika#Z61dd0ba2238ee701aa5ef71a72f52d43), even though all four agents meaningfully decreased [HbA1c](/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4) levels.\n- AMBOSS Links: Diabetes Mellitus |\n[Insuline](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce)\n- Original study: Glycemia reduction in type 2 diabetes \u2014 glycemic outcomes [62]\n- Authors: The GRADE Study Research Group\n- Journal: NEJM\n- Study funding: US Government funded; medications donated by multiple pharmaceutical companies\nYoga improves function in knee OA (but only if you actually do it).\nOne-Minute Telegram 60-2022-3/3\n- Background: Yoga has many health benefits, but in-person classes are not universally accessible due to cost and convenience. This study set out to assess the benefit of a home-based online yoga program for reduction of symptoms in knee osteoarthritis (OA).\n- Study population: adults with symptomatic knee OA\n- Methods\n- Two-group superiority\n[RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28)\n- Unsupervised online yoga program for 12 weeks (n = 107) vs. control (n = 105)\n- Outcomes assessed at 12 and 24 weeks\n- Both groups received online OA education.\n- Two-group superiority\n- Main results\n- At 12 weeks, the yoga group had improved function but not improved knee pain with walking compared to the control group (primary outcome).\n- Self-reported participation among yoga group participants:\n- During 12 week intervention: mean of 2.5 (\u00b10.7) sessions per week\n- After 12 week intervention: mean of 2.5 (\u00b16.4) sessions total\n- There were no serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c).\n- Effects were not sustained at 24 weeks.\n- Limitations include: lack of blinding\nThe take-home message?\nThis study demonstrated that an unsupervised online yoga program improves function for patients with symptomatic OA of the knee, but those benefits are lost if the practice is not maintained. Whether ongoing yoga practice can maintain these benefits remains to be seen.\n- AMBOSS Links:\n[Arthrose](/de/wissen/Arthrose#Z02ddc3c6fe4fae13fc187533ee2e65ba)\n- Original study: Effectiveness of an unsupervised online yoga program on pain and function in people with knee osteoarthritis: a randomized clinical trial [63]\n- Authors: Bennell KL et al.\n- Journal: Ann Intern Med\n- Study funding: National Health and Medical Research Council and Centres of Research Excellence (Australia).\nQ3 2022\n-\n[One-Minute Telegram 59-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zf5c4ddaf1a8881d5d1237ecf2a8aede3)\n- Sugar free is not risk free\n- Asporvapril? Ramaspastatin? Single polypill for secondary\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)prevention better than usual care\n- The rhythm is gonna get you: early rhythm control in low-risk AF\n-\n[One-Minute Telegram 58-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z73dc9dd39e0d7e100513ef4b19a69ee3)\n- The trip to abstinence:\n[Psilocybin](/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187)improves outcomes in alcohol use disorder.\n- 2022 USPSTF recommendations on statins for primary\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)prevention\n- The well-being of intensivists in the time of COVID\n- The trip to abstinence:\n-\n[One-Minute Telegram 57-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z7f8f958f877813a83e2388e630e74695)\n- Cooling after out-of-hospital cardiac arrest mitigates the association between higher\n[epinephrine](/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d)doses and poor neurological outcomes\n- Intermittent fasting effective for weight loss\n-\n[HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981)reinfection rates low among drug users receiving [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)agonists\n- Cooling after out-of-hospital cardiac arrest mitigates the association between higher\n-\n[One-Minute Telegram 56-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z51ecbae767f453990a5f850451916dd2)\n-\n[Monkeypox](/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c)infection: New perspectives on the current [monkeypox](/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c)outbreak?\n- Doubling the dose of\n[levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87)-based emergency contraception to improve [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)in individuals with obesity\n-\n[Vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)for fracture prevention\n-\n-\n[One-Minute Telegram 55-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z03e4363950b8f023d5c14bddabeeec06)\n- Do weekend warriors benefit from exercise as much as those who work out more regularly?\n- Updated USPSTF recommendations on dietary supplements to prevent cardiovascular disease and cancer\n- Uptake of\n[hepatitis C](/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b)treatment in people who inject drugs\n-\n[One-Minute Telegram 54-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Ze758a4bd3263bafdeb559d13f4a30e11)\n- Google searches for abortion pills after SCOTUS leak\n- Racial and ethnic disparities in the residency match\n- Should we rethink resuscitation in septic shock?\n-\n[One-Minute Telegram 53-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zcdaae1ceb4ae92b3c880994fec0298f1)\nEdition 59 - September 24, 2022\nSugar free is not risk free\nOne-Minute Telegram 29-2022-1/3\n- Background: This study set out to investigate whether artificial sweeteners have a negative effect on cardiovascular health.\n- Study population\n- 103,388 adults (mean age 42.2\u00b114.4, 79.8% female), recruited via the \u00c9tude NutriNet-Sant\u00e9 website\n- Individuals with cardiovascular disease (CVD) or preexisting diabetes were excluded.\n- Methods\n- Main results\n- 37.1% of participants consumed artificial sweeteners.\n- Higher total artificial sweetener intake (independent of other CVD risk factors) was associated with an increased risk of:\n- Cardiovascular disease (HR 1.09; 95% CI, 1.01\u20131.18)\n- Cerebrovascular disease (HR 1.18; 1.06\u20131.31)\n- Limitations include:\n- Observational design: Causality cannot be established.\n- Generalizability: Nearly 80% of participants were female; individuals with preexisting diabetes or CVD were excluded.\n- Classification\n[bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0): Consumption was self-reported.\nThe take-home message?\nWith mounting evidence of the harmful health effects of added sugars, the food industry and consumers have increasingly turned to artificial sweeteners as an alternative. However, results from this prospective cohort study show that intake of artificial sweeteners is associated with higher cardiovascular disease risk, adding to the growing evidence [64] that sugar-free products are not necessarily risk-free.\n- AMBOSS Links:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Isch\u00e4mischer Schlaganfall](/de/wissen/Isch\u00e4mischer_Schlaganfall#Z132d7774d1cef997981d05c36a439551)| [Akutes Koronarsyndrom](/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b)\n- Original study: Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Sant\u00e9 cohort [65]\n- Authors: Debras C et al.\n- Journal: BMJ\n- Study funding: Public grants\nAsporvapril? Ramaspastatin? Single polypill for secondary\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8) prevention better than usual care\nOne-Minute Telegram 29-2022-2/3\n- Background: This study investigated if combining key medications into a single polypill affects cardiovascular outcomes and medication adherence.\n- Study population: 2499 older adults (age > 75 years or > 65 years with risk factors) who had had a type 1 myocardial infarction \u2264 6 months prior to study inclusion\n- Methods\n- Phase 3\n[RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28)with a 36-month follow-up\n- Polypill (\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)100 mg; [ramipril](/de/wissen/RAAS-Inhibitoren#Z4cb19ed9db989ac77a27bb618fe50541)2.5, 5, or 10 mg; and [atorvastatin](/de/wissen/Lipidsenker#Zc0c8744cee387048609bafe6c953e2dd)20 or 40 mg) vs. usual care\n- Primary composite outcome: cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or urgent revascularization\n- Phase 3\n- Main results\n- Primary composite outcome was lower in the polypill group compared to the usual care group (9.5% vs. 12.7%; HR, 0.76; 95% CI, 0.60\u20130.96).\n- Adherence was higher in the polypill group compared to the usual care group (70% vs. 62.7%; risk ratio, 1.13; 1.06\u20131.20).\n- Results were consistent across prespecified subgroups (e.g., country, age, sex, health history).\n-\n[Adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)similar between groups\n- Limitations include: lack of blinding\nThe take-home message?\nAdherence to secondary\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8) prevention medications is low [66] and decreases with more complex medication regimens. [67] In this [RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28), a polypill strategy was associated with a significantly lower risk of major adverse cardiovascular events and significantly better adherence than usual care, further contributing to the large body of high-level evidence favoring the polypill strategy; [68] but will this become the standard of care anytime soon?\n- AMBOSS Links:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Isch\u00e4mischer Schlaganfall](/de/wissen/Isch\u00e4mischer_Schlaganfall#Z132d7774d1cef997981d05c36a439551)| [Akutes Koronarsyndrom](/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b)\n- Original study: Polypill strategy in secondary cardiovascular prevention [69]\n- Authors: Castellano JM et al.\n- Journal: NEJM\n- Study funding: Public grants\nThe rhythm is gonna get you: early rhythm control in low-risk AF\nOne-Minute Telegram 59-2022-3/3\n- Background: This study investigated whether early rhythm control may be beneficial for patients with atrial\n[fibrillation](AF) who are at low risk of cardiovascular complications.\n- Study population\n- 54,216 patients with AF who received rhythm control (with either antiarrhythmic drugs or ablation) or rate control within 1 year of AF diagnosis\n- Divided into 2 groups according to their CHA2DS2-VASc score:\n- Methods\n- Population-based retrospective cohort study\n- Primary composite outcome: cardiovascular death, ischemic stroke, hospitalization for heart failure, or myocardial infarction\n- Follow-up:\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)of 3 years (IQR, 1.9\u20134.1 years)\n- Main results\n- Early rhythm control was associated with lower risk for the primary composite outcome in both the low-risk group (HR, 0.81; 95% CI, 0.66\u20130.98) and the high-risk group (0.86; 0.81\u20130.92).\n- Safety outcomes did not differ between groups.\n- Limitations include\n- Residual\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1): Data was extracted from a claims-based database.\n- Generalizability: Patients treated with catheter ablation at\n[baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293)were underrepresented.\n- Residual\nThe take-home message?\nEarly rhythm control has previously been shown to be beneficial for patients with AF who are at high risk of cardiovascular complications (i.e., CHA2DS2-VASc score \u2265 2). [70] Results from this study show that early rhythm control in AF is associated with a reduced risk of cardiovascular events, even in patients with CHA2DS2-VASc score < 2. Early rhythm control should, therefore, be considered for all patients with AF.\n- AMBOSS Links:\n[Vorhofflimmern](/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266)\n- Original study: Early rhythm control therapy for atrial\n[fibrillation]in low-risk patients: a nationwide propensity score\u2013weighted study [71]\n- Authors: Kim D et al.\n- Journal: Ann Intern Med\n- Study funding: The Ministry of Health and Welfare and the Ministry of Food and Drug Safety, Republic of Korea\nEdition 58 - September 10, 2022\nThe trip to abstinence:\n[Psilocybin](/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187) improves outcomes in alcohol use disorder.\nOne-Minute Telegram 58-2022-1/3\n- Background: This study investigated whether the addition of\n[psilocybin](/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187)to psychotherapy improves the treatment of alcohol use disorder (AUD).\n- Study population: adults with alcohol dependence and \u2265 4 heavy drinking days/week (\u2265 5 drinks/day for men and \u2265 4 drinks/day for women) during the 30 days prior to screening\n- Methods\n- Randomized controlled trial: 95 adults aged 25\u201365 years (mean age 46 years; 44.2% female)\n- All participants received 12 weeks of psychotherapy during the course of the study.\n- Participants were randomized to receive either high-dose\n[psilocybin](/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187)or diphenhydramine (active [placebo]) during 2 day-long medication sessions at weeks 4 and 8.\n- Follow-up: 32-week double-blind period after the first dose of study medication\n- Main results\n- Lower percentage of heavy drinking days during follow-up in the\n[psilocybin](/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187)group (9.7%) compared to the active [placebo]group (23.6%); mean difference 13.9% (95% CI, 3.0\u201324.7)\n- No serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)among participants who received [psilocybin](/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187)\n- Lower percentage of heavy drinking days during follow-up in the\n- Limitations include:\n- Blinding: Over 90% of participants were able to identify the assigned intervention after each medication session.\n- Generalizability: The study population had a lower drinking intensity than in comparable trials. [72]\n- Lasting effects: No information was available for outcomes after 32 weeks.\nThe take-home message?\n[Psilocybin](/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187)-assisted treatment for AUD resulted in a significant and sustained reduction in alcohol consumption compared to [placebo] in this [RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28). This study adds to the growing body of evidence for the benefits of psychedelics in the treatment of psychiatric disorders. It is still too early to tell whether these effects persist long-term. [73]\n- AMBOSS links:\n[Therapie der Alkoholabh\u00e4ngigkeit](/de/wissen/Alkohol_(Intoxikation_und_Abh\u00e4ngigkeit)#Z52baf857a1289ec95344be1a8fe96f59)\n- Original study: Percentage of heavy drinking days following\n[psilocybin](/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187)-assisted psychotherapy vs [placebo]in the treatment of adult patients with alcohol use disorder: a randomized clinical trial [74]\n- Authors: Bogenschutz MP et al.\n- Journal: JAMA Psychiatry\n- Study funding: Heffter Research Institute, the New York University-Health, and Hospitals Corporation Clinical and Translational Science Institute\n2022 USPSTF recommendations on statins for primary\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8) prevention\nOne-Minute Telegram 58-2022-2/3\n- Background: The United States Preventive Services Task Force (USPSTF) has updated its 2016 recommendations on\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)therapy for the primary prevention of [atherosclerotic cardiovascular disease](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)( [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)) after commissioning a systematic review. [75][76]\n- Updated 2022 recommendations:\n- Adults aged 40\u201375 years\n- Clinicians should offer a low- to moderate-dose\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)to individuals with all of the following (moderate net benefit):\n- Clinicians may selectively offer a\n[statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)to individuals with \u2265 1 [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)risk factors who have an estimated [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)risk of 7.5% to < 10% using shared decision-making (small net benefit).\n- Clinicians should offer a low- to moderate-dose\n- Adults 76 years or older: Insufficient evidence exists to recommend or advise against statins.\n- Adults aged 40\u201375 years\n- Limitations include:\n- Evidence was not sufficient for stronger recommendations.\n- Recommended risk stratification is based on PCEs (that include only traditional\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)risk factors). However, PCEs have several limitations, including the underestimation of [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)probability in patients with [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)risk-enhancing factors (e.g., inflammatory disease, [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)). [78]\n- Note: Recommendations differ slightly from the 2018 and 2019\n[ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)/AHA guidelines. [79][80]\nThe take-home message?\nThe USPSTF continues to recommend primary\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8) prevention with statins in adults 40\u201375 years with an estimated [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8) risk of \u2265 10%, and recommends shared decision-making for patients in lower risk categories (7.5 to < 10%). Benefits and harms of primary prevention for patients < 40 years or > 75 years remain uncertain.\n- AMBOSS links: Artherosklerose und\n[kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zd0459584edd44b5da8fb1e7b193d633e)| [Koronare Herzkrankheit](/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1)| [Myokardinfarkt](/de/wissen/Myokardinfarkt#Z05d22ce34ae3c47e1ae4298d65578dca)| [Lipidsenker](/de/wissen/Lipidsenker#Zd0a8cd906313c9da1ec7e9bcbbe94d4b)\n- Original study:\n[Statin](/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25)use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement [3]\n- Authors: USPSTF\n- Journal: JAMA\n- Study funding: USPSTF\nThe well-being of intensivists in the time of COVID\nOne-Minute Telegram 58-2022-3/3\n- Background: The\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)pandemic and related changes in hospital policy have led to increased stress among critical care physicians. How best to counteract the negative impact of the pandemic on intensivists' well-being remains an open question.\n- Study population: 33 intensivists (12 female), from seven tertiary and six community hospitals\n- Methods\n- Qualitative study: single semistructured interviews (45\u201390 min)\n- Time frame: August 6 to November 4, 2020\n- Main results\n- Factors identified as decreasing well-being:\n- Interventions identified as potentially improving well-being include:\n- Proactive provision of mental health care\n- Establishment of formal backup systems\n- Protocols for provision of scarce resources\n- Limitations include:\n- Generalizability\n- Underrepresentation of women\n- No data on age, race, or ethnicity was collected.\n- Interviews were conducted in 2020, potentially not reflecting the current situation in hospitals today.\n- Moral\n[distress](/de/wissen/Stressmodelle#Z6c7eef5a913c582156005f60a0dd88f1)and symptoms of [burnout](/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70)were not measured quantitatively, making comparisons within the study population and across different populations difficult.\n- Generalizability\nThe take-home message?\nThis study sheds further light on how the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) pandemic and related changes in hospital policy have increased moral [distress](/de/wissen/Stressmodelle#Z6c7eef5a913c582156005f60a0dd88f1) and [burnout](/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70) in intensivists. The findings emphasize the negative impact that workplace deficits have had on intensivists during the pandemic and provide guidance on what measures can be undertaken to improve their well-being.\nEdition 57 - August 27, 2022\nCooling after out-of-hospital cardiac arrest mitigates the association between higher\n[epinephrine](/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d) doses and poor neurological outcomes\nOne-Minute Telegram 57-2022-1/3\n- Research question: Can targeted temperature management (TTM) mitigate the association between higher\n[epinephrine](/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d)doses during cardiac resuscitation and poor neurological outcomes?\n- Study population\n- 5253 adults with out-of-hospital cardiac arrest who were admitted to a hospital\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age 63 years; 65.8% male\n- Methods\n- Retrospective cohort study\n- Data sources: dispatch recordings, EMS records, defibrillator recordings, patient records\n- TTM: application of surface cooling pads or an endovascular cooling catheter\n- Main results\n- Overall outcomes\n- Survived to discharge: 41.4%\n- Survived with favorable neurological outcomes: 36%\n-\n[Epinephrine](/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d)\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)dose 2 mg (IQR, 1.0\u20133.0 mg)\n- Increasing doses of\n[epinephrine](/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d)were associated with decreased [odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c)of favorable neurological outcomes (OR, 0.46; 95% CI, 0.42\u20130.50) and survival (0.47; 0.43\u20130.51).\n-\n- TTM\n- Received: 58.1%\n- For each additional milligram of\n[epinephrine](/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d), TTM was associated with increased [odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c)of favorable neurological outcomes (OR, 1.36; 95% CI, 1.22\u20131.51) and survival (1.37; 1.24\u20131.51).\n- Overall outcomes\n- Limitations include:\n- Observational study design: potential for\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1), inability to prove causality\n- Lack of data: TTM duration, temperature, and mode were not assessed.\n- Observational study design: potential for\nThe take-home message?\nThis retrospective study showed that in patients with out-of-hospital cardiac arrest, targeted temperature management may help mitigate the association between increasing\n[epinephrine](/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d) doses and decreasing [odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c) of favorable neurological outcomes and survival. Further prospective studies are needed to verify these findings.\n- AMBOSS links:\n[Grundlagen der Reanimation](/de/wissen/Grundlagen_der_Reanimation#Z2eec26f6bbfd145d133e7674ac992bd5)\n- Title of study: Analysis of\n[epinephrine](/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d)dose, targeted temperature management, and neurologic and survival outcomes among adults with out-of-hospital cardiac arrest [82]\n- Authors: Yang BY et al.\n- Journal: JAMA Netw Open\n- Study funding: American Heart Association\nIntermittent fasting effective for weight loss\nOne-Minute Telegram 57-2022-2/3\n- Background: Intermittent fasting (i.e., the limitation of dietary intake to a restricted time window) has been proposed as a method to enhance weight loss and increase associated health benefits. Is early time-restricted eating (eTRE) more effective than a non-time-restricted eating window?\n- Study population\n- 90 adults with obesity\n- 80% female; mean\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04)39.6 (SD 6.7); mean age 43 years (range 25\u201375 years)\n- Methods\n- Randomized controlled trial\n- All participants received weight loss counseling involving energy restriction (ER).\n- Randomization 1:1 for a total study duration of 14 weeks:\n- ER + eTRE: 8-hour eating window from 7:00 to 15:00\n- ER + control eating window (CON): self-selected \u2265 12-hour window\n- Main results\n- ER + eTRE compared to ER + CON\n- Weight loss: -2.3 kg (95% CI, -3.7 to -0.9)\n- Diastolic blood pressure: -4 mm Hg (-8 to 0)\n- Fewer mood disturbances\n- No significant differences in body fat, ratio of fat loss to weight loss or other cardiometabolic risk factors, food intake, physical activity, or sleep outcome\n- The self-reported eating window of participants in the eTRE group was 7.6 hours compared to 12.3 hours in the CON group.\n- Average eTRE adherence: 6 days per week\n- ER + eTRE compared to ER + CON\n- Limitations include:\n- Statistical\n[power](/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e): small sample size\n- Short duration: no data on sustained benefits\n- Generalizability: 80% of participants were women.\n- Statistical\nThe take-home message?\nAlthough total caloric intake did not differ between groups, restricting eating to the first 8 hours of the day was more effective for weight loss than a \u2265 12-hour eating window. However, the clinical relevance of this finding is questionable, as the effect size was small. Larger studies are needed to further clarify the effectiveness and cardiometabolic impacts of intermittent fasting.\n- AMBOSS links:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Metabolisches Syndrom](/de/wissen/Metabolisches_Syndrom#Zef9b1fe4e2f7f7f318f55631b1f02f85)\n- Original study: Effectiveness of early time-restricted eating for weight loss, fat loss, and cardiometabolic health in adults with obesity: a randomized clinical trial [83]\n- Authors: Jamshed H et al.\n- Journal: JAMA Intern Med\n- Study funding: NIH & National Institute of Diabetes and Digestive and Kidney Diseases\n[HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981) reinfection rates low among drug users receiving [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) agonists\nOne-Minute Telegram 57-2022-3/3\n- Background: Previous data has shown that\n[hepatitis C](/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b) [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870)( [HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981)) reinfection after successful treatment in people who inject drugs may be as high as 5.9 per 100 person-years. [84] What are the rates of [HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981)reinfection after successful treatment in patients receiving [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)agonist therapy (OAT)?\n- Study population\n- Methods\n- Main results\n-\n[HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981)reinfection rate per 100 person-years\n- Overall CO-STAR study (n = 286): 1.7 (95% CI, 0.8\u20133.0)\n- Overall\n[extension](/de/wissen/Terminologie#Zbdfd278a2badf97a52d598dc2cd2c497)study (n = 199): 1.2 (0.4\u20132.7)\n- Among patients without recent IV drug use: 0.5 (0.0\u20132.6)\n- Among patients with recent IV drug use: 1.9 (0.5\u20134.8)\n- Among patients with recent needle and/or syringe sharing: 6.4 (0.2\u201335.5)\n- Drug use over time (\n[extension](/de/wissen/Terminologie#Zbdfd278a2badf97a52d598dc2cd2c497)study)\n- Positive urine drug testing: 60% at enrollment; 53% after 3 years\n- Self-reported drug use: 50% at 6 months; 45% after 3 years\n-\n- Limitations include:\n- Potential\n[selection bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de): Participants who were < 80% adherent to OAT at [baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293)were excluded from the study.\n- Potential attrition\n[bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0): Loss to follow-up was 10% at 1 year and 29% at 3 years.\n- Generalizability: Participants were predominantly White men.\n- Statistical\n[power](/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e): small sample size\n- Potential\nThe take-home message?\n[HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981) reinfection rates after successful treatment were overall low among patients receiving [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec) agonist therapy but higher in those continuing IV drug use, especially when needle and/or syringe sharing. Further research is needed on interventions to prevent reinfection in this population.\n- AMBOSS links:\n[Hepatitis C](/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b)| [Opioide (Intoxikation und Abh\u00e4ngigkeit)](/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z2617c4a1c8650f5bf241213ea0311b58)\n- Original study: Reinfection and risk behaviors after treatment of\n[hepatitis C](/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b) [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870)infection in persons receiving [opioid](/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec)agonist therapy: a cohort study [85]\n- Authors: Grebely J et al\n- Journal: Ann Intern Med\n- Study funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.\nEdition 56 - August 13, 2022\n[Monkeypox](/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c) infection: New perspectives on the current [monkeypox](/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c) outbreak?\nOne-Minute Telegram 56-2022-1/3\n- Research question: How is the\n[monkeypox](/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c) [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870)transmitted, and what are the symptoms and outcomes of an infection in the current outbreak?\n- Study design: international case series\n- Study population: 528 symptomatic patients with\n[PCR](/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca)-confirmed [monkeypox](/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c) [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870)infection\n- Methods: Data were collected at 43 sites in 16 countries between April and June 2022 using a case-report spreadsheet.\n- Main results\n- Patient characteristics\n- 98% were\n[men who have sex with men]; [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)age was 38 years.\n- 75% were White.\n- 41% had\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)infection, and 29% had another concomitant [STI](/de/wissen/Sexuell_\u00fcbertragbare_Infektionen#Zf2a474fc86c5ef68694e80ca13cd405b).\n- 98% were\n- Suspected mode of transmission: sexual activity in 95% of cases\n-\n[Median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b)incubation period: 7 days (range: 3\u201320 days)\n- Clinical features at presentation included:\n- Rash or skin lesions (95%), mostly in the anogenital region (73%)\n- Fever (62%)\n- Lymphadenopathy (56%)\n- 13% of patients required hospitalization, most commonly for pain management.\n- Severe courses were rare, and no patients died.\n- Clinical presentation was similar in\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-positive and [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-negative patients.\n- Patient characteristics\n- Limitations include\n- Variability in the\n[PCR](/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca)testing methods across the different sites\n- Only patients who sought medical care were included, potentially leading to\n[selection bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de).\n- Variability in the\n- Study funding: None disclosed\nThe take-home message?\nThis study showed that during the current outbreak, now considered a Public Health Emergency in the US [86],\n[monkeypox](/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c) has disproportionally affected [men who have sex with men] and that the clinical presentation (rash and/or anogenital and [mucosal] lesions) and disease course were similar regardless of [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604) status. Approximately 1 in 10 patients required hospitalization, mostly for pain management, and no deaths were reported.\n- Title of study:\n[Monkeypox](/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c) [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870)infection in humans across 16 countries \u2014 April\u2013June 2022 [87]\n- Authors: Thornhill JP et al.\n- Journal: NEJM\nDoubling the dose of\n[levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87)-based emergency contraception to improve [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f) in individuals with obesity\nOne-Minute Telegram 56-2022-2/3\n- Research question: Individuals with obesity experience higher rates of emergency contraception failure with\n[levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87)(LNG). [88] Does doubling the dose more effectively inhibit [ovulation](/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa)in this population?\n- Study design: randomized controlled trial\n- Study population: 70 healthy individuals of reproductive age with regular menstrual cycles,\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04)> 30, and weight \u2265 176 lbs\n- Methods\n- Determination of dominant follicle emergence via transvaginal ultrasound\n- Participants were randomized to receive\n[oral]emergency contraception with LNG at either 1.5 mg (regular dose) or 3 mg (double dose).\n- Daily monitoring for\n[ovulation](/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa)(follicle rupture) was performed with transvaginal ultrasonography for up to 7 days.\n- Main results\n- Limitations include\n- Study funding: NIH grant\nThe take-home message?\nDoubling the dose of\n[levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87)-based emergency contraception showed no benefits with regard to preventing or delaying [ovulation](/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa) in individuals with obesity. Previous studies have suggested that ulipristal acetate may be more effective as emergency contraception in this population. [88]\n- Title of study: Double dosing\n[levonorgestrel](/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87)-based emergency contraception for individuals with obesity: A randomized controlled trial [89]\n- Authors: Edelman AB et al.\n- Journal: Obstet. & Gynecol.\n[Vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) for fracture prevention\nOne-Minute Telegram 56-2022-3/3\n- Research question: Does supplementation of\n[vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)prevent fractures in the general population?\n- Study design\n- Study population\n- 25,871 men (\u2265 50 years) and women (\u2265 55 years)\n- 50.6% were women\n- Age range was 67.1\u00b17.1 years.\n- Methods\n- Main results\n- Compared to\n[placebo], supplemental [vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84)was not significantly associated with a lower risk of:\n- Total fractures (HR, 0.98; 95% CI, 0.89\u20131.08)\n- Nonvertebral fractures (0.97; 0.87\u20131.07)\n- Hip fractures (1.01; 0.70\u20131.47)\n- These outcomes were similar across race, ethnicity,\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04), and age.\n- There were no differences in the incidence of\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)(hypercalcemia and kidney stones) between groups.\n- Compared to\n- Limitations include\n- Study funding: National Institute of Arthritis and Musculoskeletal and Skin Diseases\nThe take-home message?\nIn this randomized controlled trial, supplementation of\n[vitamin D](/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84) did not reduce the risk of bone fractures in a general population of men aged \u2265 50 years and women aged \u2265 55 years.\nEdition 55 - July 30, 2022\nDo weekend warriors benefit from exercise as much as those who work out more regularly?\nOne-Minute Telegram 55-2022-1/3 - Exercising only on the weekend - being a \u201cweekend warrior\u201d - is a convenient option for achieving the World Health Organization's recommended levels of moderate to vigorous physical activity (MVPA), but does the number of activity sessions per week impact the health benefits?\nThis prospective, survey-based cohort study followed 350,978 adults (mean age 41.4 years, 50.8% women, 67.8% non-Hispanic White) for a\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) of 10.4 years and their data was linked to their National Death Index records.\nBased on self-reported physical activity, participants were classified as either physically inactive (MVPA < 150 minutes/week) or physically active (\u2265 150 minutes/week of moderate activity or \u2265 75 minutes/week of vigorous activity). The physically active group was further subdivided into a regularly active group (\u2265 3 sessions/week) and a weekend warrior group (1\u20132 sessions/week).\nCompared to the inactive group, both the regularly active group (HR, 0.85; 95% CI, 0.83\u20130.88) and the weekend warrior group (0.92; 0.83\u20131.02) had reduced all-cause mortality rates, though the reduction in the weekend warrior group was nonsignificant. However, differences in the rates of all-cause and cause-specific mortality between the regularly active and weekend warrior groups were nonsignificant.\nLimitations include that activity levels were self-reported and therefore may not have accurately reflected the participants\u2019 actual activity levels, that the number of deaths in the weekend warrior group was low, which may have limited the study\u2019s\n[power](/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e) to detect a reduction in mortality in this group, and that residual [confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1) cannot be ruled out.\nThe take-home message?\nIn this long-term prospective trial, all-cause mortality was lower in participants who achieved the recommended amount of MVPA compared to those who did not. Mortality rates did not differ significantly between those who exercised throughout the week and those who performed 1\u20132 sessions per week (\u201cweekend warriors\u201d).\n- Title of study: Association of the \u201cweekend warrior\u201d and other leisure-time physical activity patterns with all-cause and cause-specific mortality: a nationwide cohort study [92]\n- Authors: dos Santos M et al.\n- Journal: JAMA Internal Medicine\nUpdated USPSTF recommendations on dietary supplements to prevent cardiovascular disease and cancer\nOne-Minute Telegram 55-2022-2/3 - The USPSTF has updated its 2014 recommendations on the use of\n[vitamin](/de/wissen/Vitamine#Z6ff1b6359e20f0dbe35655f2aff6154c), mineral, and multivitamin supplementation for the prevention of cardiovascular disease and cancer. [1] Recommendations were based on data from 84 RCTs and 6 cohort studies that addressed the harms and benefits of supplementation.\nRecommendations include:\n- Beta carotene supplements should not be used for the prevention of cardiovascular disease or cancer. Beta carotene was associated with an increased risk of lung cancer in individuals at increased risk of lung cancer.\n-\n[Vitamin E](/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d)supplements should not be used for the prevention of cardiovascular disease or cancer. [Vitamin E](/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d)may be associated with an increased risk of hemorrhagic stroke.\n- There is insufficient evidence to recommend for or against the use of multivitamin supplements or single- or paired-nutrient supplements (excluding beta carotene and\n[vitamin E](/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d)) for the prevention of cardiovascular disease or cancer.\nLimitations include that these recommendations only apply to community-dwelling, nonpregnant adults with no known underlying health conditions, restricting generalizability to patient groups.\nThe take-home message?\nAfter reviewing current evidence, the USPSTF reaffirmed its 2014 recommendations against the use of beta carotene and\n[vitamin E](/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d) supplements and again concluded that evidence is insufficient to recommend for or against other dietary supplements for the prevention of cardiovascular disease or cancer.\n- Title of study:\n[Vitamin](/de/wissen/Vitamine#Z6ff1b6359e20f0dbe35655f2aff6154c), mineral, and multivitamin supplementation to prevent cardiovascular disease and cancer: US Preventive Services Task Force recommendation statement [6]\n- Authors: USPSTF\n- Journal: JAMA\n- Title of study:\n[Vitamin](/de/wissen/Vitamine#Z6ff1b6359e20f0dbe35655f2aff6154c)and mineral supplements for the primary prevention of cardiovascular disease and cancer: updated evidence report and systematic review for the US Preventive Services Task Force [93]\n- Authors: O\u2019Connor EA et al.\n- Journal: JAMA\n- AMBOSS links:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)\nUptake of\n[hepatitis C](/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b) treatment in people who inject drugs\nOne-Minute Telegram 55-2022-3/3 -\n[Hepatitis C](/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b) [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870) ( [HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981)) infection is a curable disease that disproportionately affects people who inject drugs (PWID), but uptake of [HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981) treatment in this population has historically been low.\nThis longitudinal observational study was conducted in the US from 2006 to 2019 and included a community-based cohort of 1323 former and current PWID with detectable\n[HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981) [RNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d) at [baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293). Of those, 82% were Black, 71% male, and 66% [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)-negative. Liver cirrhosis was assessed by semiannual transient elastography. Mortality data was obtained from a national database.\n- The proportion of participants with detectable\n[HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981) [RNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d)and cirrhosis declined from 100% and 15%, respectively, at the beginning of the study to 48% and 8%, respectively, at the end of the observation period.\n- The\n[absence](/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Z93dedd171a6efaddb5d27c931860ee21)of [HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981) [RNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d)was significantly associated with reduced [odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c)of cirrhosis (OR, 0.28; 95% CI, 0.17\u20130.45) and reduced risk of all-cause mortality (HR, 0.54; 0.38\u20130.77).\n- Overall, 39% of participants reported receiving\n[hepatitis]treatment during the observation period.\nLimitations include that this study was conducted in a single city, restricting generalizability. In addition, these results may lead to overestimation of treatment uptake among the general PWID population, as participation in the study likely increased the participants\u2019\n[awareness] of their [HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981) status and the availability of treatment.\nThe take-home message?\nIn this US community-based cohort study of PWID,\n[HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981) [RNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d) was undetectable in more than half of the initially [HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981)-positive study participants at the end of a 13-year observation period, even though PWID have historically been uninsured or insured only with Medicaid, which may adversely affect treatment uptake. Undetectable [HCV](/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981) [RNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d) correlated with a significant reduction in the [odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c) of cirrhosis and the risk of all-cause mortality.\n- Title of study: Impact of\n[hepatitis C](/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b)treatment uptake on cirrhosis and mortality in persons who inject drugs: a longitudinal, community-based cohort study [94]\n- Authors: Cepeda JA et al.\n- Journal: Annals of Internal Medicine\n- AMBOSS links:\n[Hepatitis C](/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b)\nEdition 54 - July 16, 2022\nGoogle searches for abortion pills after SCOTUS leak\nOne-Minute Telegram 54-2022-1/3 - On June 24, 2022, the US Supreme Court overruled the landmark 1973 Roe vs. Wade decision, shifting determination over abortion laws to state legislatures. How this decision will affect the way individuals seek information about and access to abortion remains unclear.\nThis study analyzed Google searches for abortion medications (i.e., mifepristone, misoprostol) before and after the Supreme Court\u2019s decision was leaked in May 2022. Searches for abortion medications spiked to 162% higher than expected (95% CI, 149\u2013175%) immediately after the leak. The searches were significantly higher in states with more restrictive reproductive health care policies (according to the Women\u2019s Policy Research ranking). [95]\nLimitations include that the motivation for the searches and the demographics of searchers were not available.\nThe take-home message?\nThis study shows that searches for abortion medications spiked after the leak of the Supreme Court's Roe vs. Wade reversal, raising concern about the potential for an increase in medically unsupervised abortions. Further research is needed to determine how changes in abortion laws will impact the way individuals seek and attain induced abortions.\n- Title of study: Internet searches for abortion medications following the leaked Supreme Court of the United States draft ruling [96]\n- Authors: Poliak A et al.\n- Journal: JAMA Internal Medicine\n- AMBOSS Links:\n[Schwangerschaftsabbruch](/de/wissen/Schwangerschaftsabbruch#Z4c5fe8d3f0dfa9acf4e0963adf0f9782)\nRacial and ethnic disparities in the residency match\nOne-Minute Telegram 54-2022-2/3 - The US physician workforce does not reflect the demographic composition of the US. Greater diversity in the workforce may reduce health care disparities. [97][98]\nThis study compared the total number of applicants to the number of matched residents based on self-reported race and ethnicity in 11 competitive medical specialties. The applicants were categorized into one of three groups: Asian, White (non-Hispanic), and underrepresented in medicine (URM), which comprised African American, American Indian or Alaska Native, Hispanic, and Native Hawaiian or Pacific Islander.\n- In all 11 competitive specialties, the proportion of URM individuals among matched residents was significantly lower than their proportion among all applicants.\n- In 2 of 11 specialties, the proportion of Asian individuals among matched residents was significantly lower than their proportion among all applicants.\n- In 6 of 11 specialties, the proportion of matched White residents among matched residents was significantly higher than their proportion among all applicants.\nLimitations include that changes in residency\n[recruitment](/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27) practices that may have occurred since 2018 are not reflected in this analysis and that categories of race and ethnicity provided in residency applications do not adequately reflect human diversity.\nThe take home message?\nIn this study, candidates from ethnic and racial groups that are underrepresented in the US physician workforce were significantly less likely to match into competitive specialties for graduate medical education (GME) training. This underscores the need to reevaluate current GME\n[recruitment](/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27) strategies to increase diversity in the health care workforce.\n- Title of study: Racial and ethnic differences in resident selection in 11 specialties, 2013\u20132018 [99]\n- Authors: Bowe S et al.\n- Journal: JAMA\nShould we rethink resuscitation in septic shock?\nOne-Minute Telegram 54-2022-3/3 - Fluid resuscitation is a cornerstone of the treatment for septic shock, as is reflected in the 2021 Surviving\n[Sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38) Guidelines. However, recent observational studies suggest that fluid overload may contribute to higher [sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)-related mortality, even though the overall quality of evidence is low. [100][101][102]\nIn this multinational study, patients treated for septic shock in an ICU who had already received at least 1 L of intravenous fluids (\n[IVF](/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab)) were randomized within 12 hours of septic shock onset to a restrictive-fluid group (n = 770; [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) [IVF](/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab) = 1798 mL), with additional [IVF](/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab) given only if patients met strict predetermined clinical indications, and a standard-fluid group (n = 784; [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) [IVF](/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab) = 3811 mL), in which more liberal use of additional [IVF](/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab) was permitted.\nThe primary outcome was 90-day mortality.\n- Restrictive-fluid group: 42.3%\n- Standard-fluid group: 42.1%\n- Adjusted absolute difference: 0.1% (95% CI, - 4.7\u20134.9)\nAt 90 days, there was no difference in serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c), survival without life support, and survival after discharge.\nLimitations include that the study was not blinded, that data on cointerventions and hemodynamic factors were not collected, that the study was not powered to detect differences in subgroups, and that all study sites were exclusively in Europe, which may limit generalizability.\nThe take home message?\nIn this trial, there was no difference in survival or serious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c) in patients treated for septic shock with a restrictive fluid strategy compared to those treated with standard fluid therapy. Further prospective research is needed to determine if a restrictive fluid strategy may nevertheless be beneficial in specific subsets of patients with septic shock.\n- Title of study: Restriction of intravenous fluid in ICU patients with septic shock [103]\n- Authors: Meyhoff TS et al.\n- Journal: NEJM\n- AMBOSS links:\n[Sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)| [Fl\u00fcssigkeits- und Volumentherapie](/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z87e9a247724c9b2410076167606f4c20)\nEdition 53 - July 2, 2022\nCan\n[vitamin C](/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056) reduce mortality in [sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)?\nOne-Minute Telegram 53-2022-1/3 - Acute\n[vitamin C](/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056) deficiency is common in critically ill patients and may contribute to oxidative organ injury and, potentially, poor outcomes. [104] A recent meta-analysis suggested a possible reduction in mortality with adjunctive high-dose [vitamin C](/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056) in patients with [sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38), but the treatment effects were of low certainty, emphasizing the need for further high-quality trials. [105]\nThis international trial included 872 patients who had been in the ICU for less than 24 hours, had a proven or suspected infection, and were receiving a\n[vasopressor]. Patients were randomized to receive either high-dose [vitamin C](/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056) (50 mg/kg IV; n = 435) or [placebo] (n = 437) every 6 hours for up to 96 hours.\nOn day 28 of the trial, the composite of death or persistent organ dysfunction occurred in 44.5% of patients in the\n[vitamin C](/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056) group and in 38.5% of patients in the [placebo] group (risk ratio, 1.21; 95% CI, 1.04\u20141.40).\nLimitations include the lack of sufficient data and\n[power](/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e) to enable detailed subgroup analysis and that the trial was conducted in three high-income countries, and therefore the generalizability to lower-income countries may be limited.\nThe take-home message?\nPrevious research had suggested the possible benefits of high-dose\n[vitamin C](/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056) in critically ill patients. However, in this trial, its use in the treatment of ICU patients with [sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38) who were receiving [vasopressors] was associated with higher mortality and persistent organ dysfunction when compared with [placebo].\n- Title of study: Intravenous\n[vitamin C](/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056)in adults with [sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)in the intensive care unit [106]\n- Authors: Lamontagne F et al.\n- Journal: NEJM\n- AMBOSS Links:\n[Sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38)\nHow accurate are brachial blood pressure cuff devices?\nOne-Minute Telegram 53-2022-2/3 - Measuring blood pressure (BP) with a brachial BP cuff device is a convenient alternative to invasive aortic BP measurement, but may lack accuracy. [107]\nThis cross-sectional study recruited 500 patients (29% female) due to undergo a clinically indicated coronary angiography. Patients with severe aortic stenosis or atrial\n[fibrillation] were excluded. BP was measured invasively at the end of angiography and noninvasively using an automated BP monitor, which provided brachial cuff BP and a noninvasive measure of central BP estimated from pulse waves.\nUsing invasive aortic systolic BP (SBP) measurements as values of reference, brachial cuff SBP was more accurate in men than in women (mean difference in men, \u20130.3 mm Hg; mean difference in women, \u20136.5 mm Hg; P < 0.001). Conversely, noninvasive measurement of central SBP (calibrated for mean arterial pressure and diastolic BP) was more accurate in women than in men.\nHowever, 55% of the total effect of sex on brachial cuff SBP accuracy was attributable to height; the direct effect of sex on brachial cuff SBP accuracy was insignificant.\nLimitations include restricted generalizability, as 94% of participants were white, 29% were female, and all participants had an indication for coronary angiography. Additionally, the trial was conducted using only a single type of device for noninvasive BP monitoring.\nThe take-home message?\nWhile brachial cuff SBP measurements were found to be accurate in men, this study shows that the method was less accurate in women, mainly because of their smaller stature. Noninvasive central SBP (derived from brachial pulse waves) appeared to be the most accurate noninvasive method in women.\n- Title of study: Accuracy difference of noninvasive blood pressure measurements by sex and height [108]\n- Authors: Abbaoui Y et al.\n- Journal: JAMA Network Open\n- AMBOSS Links:\n[Arterielle Hypertonie](/de/wissen/Arterielle_Hypertonie#Z3d73ccc1b405184a8d3087bd8b727eb4)| [Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)\nCan\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) and lifestyle intervention reduce cardiovascular risk in patients with impaired [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) tolerance?\nOne-Minute Telegram 53-2022-3/3 - Lifestyle changes and\n[glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) control in patients with impaired [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) tolerance result in reduced [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) levels and reduced progression to diabetes. [109] This trial addressed whether these interventions may also improve cardiovascular outcomes.\nIn this\n[RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28), 3234 participants with impaired [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) tolerance were randomized into 1 of 3 groups: [metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) 850 mg twice daily, [placebo], or intensive lifestyle intervention aiming to reduce body weight by \u2265 7%. Participants were followed for 3 years.\nSubsequently, unmasked\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) was continued in the [metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) group and all participants were offered less intensive lifestyle intervention. Follow-up continued for an average of 18 years.\nAlthough both the use of\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) and lifestyle intervention reduced the rate of diabetes onset, they had no significant effect on the primary outcome (first occurrence of nonfatal myocardial infarction, stroke, or cardiovascular death) compared to [placebo]:\nLimitations include that\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) adherence fell over time and that lifestyle intervention was less intensive after the initial 3 years of follow up, which may have affected the results.\nThe take-home message?\nIn this trial with a total follow-up period of 21 years, neither the use of\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0) nor lifestyle intervention lead to a reduction in myocardial infarction, stroke, or cardiovascular death in patients with impaired [glucose](/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57) tolerance when compared with [placebo].\n- Title of study: Effects of long-term\n[metformin](/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0)and lifestyle interventions on cardiovascular events in the diabetes prevention program and its outcome study [110]\n- Authors: Goldberg RB et al.\n- Journal: Circulation\n- AMBOSS Links:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Diabetes mellitus](/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261)\nQ2 2022\n-\n[One-Minute Telegram 52-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z9cddb4f57b545c1e4012ae886616c95e)\n-\n[One-Minute Telegram 51-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z27e295d8a27c2c3b67c2e8e99f51dc05)\n- Is all chest pain created equal?\n- Does the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)vaccine reduce long COVID symptoms?\n- Are\n[glucocorticoids](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151)a safe and effective treatment for [IgA](/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb)nephropathy?\n-\n[One-Minute Telegram 50-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zbbbf3249eb39e520bb070a2bbcfa291f)\n-\n[One-Minute Telegram 49-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z57dc066e31fde74306d081b357368ca5)\n-\n[One-Minute Telegram 48-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z7592f5f262fd375963fb843027ec13c6)\n- Predicting severe\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)in pregnant women\n- Can any alcohol consumption be considered healthy?\n-\n[Ivermectin](/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed)in COVID: yay or nay?\n- Predicting severe\nEdition 52 - June 18, 2022\nMistreatment and discrimination contribute to physician\n[burnout](/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70).\nOne-Minute Telegram 52-2022-1/3 - Physician\n[burnout](/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70), defined as emotional exhaustion, depersonalization, and a feeling of low personal accomplishment, is a common phenomenon. It has a negative impact on physicians\u2019 well-being and may also affect patient care. Mistreatment and discrimination of physicians by patients or their relatives may be factors contributing to the development of [burnout](/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70). [111][112][113][114]\nIn this cross-sectional study utilizing a national survey, 6512 US physicians reported mistreatment and discriminatory behaviors by patients, their families, and visitors in the preceding year with the following frequencies:\n- Racially or ethnically offensive remarks: 29.4%\n- Offensive sexist remarks: 28.7%\n- Unwanted sexual advances: 20.5%\n- Refusal to allow them to provide care because of the physician\u2019s personal attributes: 21.6%\nFemale and non-White physicians were significantly more likely to report mistreatment or discrimination. The experience of mistreatment or discrimination was independently associated with higher\n[odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c) of [burnout](/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70).\nLimitations include the potential for recall and response\n[bias](/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0) and that causality and the direction of the observed associations could not be determined in this survey-based cross-sectional study.\nThe take-home message?\nThis survey-based study found that mistreatment and discrimination of physicians by patients and their relatives was common and disproportionately directed at female and non-White physicians. The experience of mistreatment and discrimination were independently associated with physician\n[burnout](/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70).\n- Title of study: Physicians\u2019 experiences with mistreatment and discrimination by patients, families, and visitors and association with\n[burnout](/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70)[115]\n- Authors: Dyrbye LN et al.\n- Journal: JAMA Network Open\n- AMBOSS Links:\n[Arzt-Patient-Beziehung](/de/wissen/Arzt-Patient-Beziehung#Ze9cc0bcf462357fd49f54a85760dde5e)\nDoes tranexamic\n[acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f) reduce perioperative morbidity in noncardiac surgery?\nOne-Minute Telegram 52-2022-2/3 -Tranexamic\n[acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f) (TXA), an antifibrinolytic drug, has been shown to reduce perioperative bleeding in procedures associated with high blood loss, including cardiac surgery and cesarean section. Whether prophylactic TXA can safely reduce perioperative bleeding associated with other surgical procedures remains unclear. [116][117]\nIn this non-inferiority trial, patients at risk for bleeding and cardiovascular events who were scheduled for noncardiac surgery were randomly assigned to receive a 1-g intravenous bolus of TXA (n = 4757) or\n[placebo] (n = 4778) at the start and end of surgery.\nPrimary outcomes:\n- Composite bleeding outcome (life-threatening bleeding, major bleeding, bleeding into a critical organ): Patients in the TXA group had a lower incidence (9.1%) at 30 days compared to those in the\n[placebo]group (11.7%; HR, 0.76; 95% CI, 0.67\u20130.87).\n- Primary safety outcome (composite of myocardial injury, non-hemorrhagic stroke, arterial thrombosis, symptomatic venous thromboembolism): Predetermined criteria for noninferiority were not met at 30 days (TXA vs.\n[placebo]group HR 1.02; 95% CI, 0.92\u20131.14).\nLimitations include that the study was terminated for financial reasons before\n[recruitment](/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27) was completed and that the ability to identify perioperative thrombotic complications (a potential adverse effect of TXA use) was limited.\nThe take-home message?\nProphylactic tranexamic\n[acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f) for noncardiac surgery in patients at risk for bleeding and adverse cardiac events reduced blood loss and critical bleeding events but did not meet noninferiority criteria for cardiovascular safety.\n- Title of study: Tranexamic\n[acid](/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f)in patients undergoing noncardiac surgery [118]\n- Authors: Devereaux PJ et al.\n- Journal: NEJM\n- AMBOSS Links:\n[Perioperatives Management](/de/wissen/Perioperatives_Management#Z3a7bd0c1bd5a355d4ac6d1ae3fc9717c)\nDoes sweetening coffee reduce its positive impact on mortality?\nOne-Minute Telegram 52-2022-3/3 - Moderate coffee consumption has been associated with reduced mortality, but whether adding a sweetener influences this association has not been investigated. [119]\nThis prospective cohort study from the UK included a total of 171,616 participants. Self-reported coffee consumption was assessed at\n[baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293) and outcomes were evaluated over a [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) follow-up of 7.0 years.\nParticipants who drank unsweetened coffee had a lower risk of all-cause mortality compared to the coffee abstainers. The association was U-shaped with the lowest risk of mortality in consumers of 2.5\u20134.5 drinks/day. Those who sweetened their coffee with sugar had a similar U-shaped association with reduced mortality, albeit with non-significant results at low (< 1.5 cups) and high (> 3.5 cups) daily coffee consumption. Use of artificial sweeteners was not consistently associated with reduced mortality. These results were independent of the type of coffee (instant, ground, decaffeinated) and important confounders, such as lifestyle factors.\nLimitations include the possibility of unassessed residual confounders, the reliance on self-reported data potentially leading to misclassification, and that exposure, which was assessed at\n[baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293) only, may not reflect actual exposure over time. Also, the number of participants using an artificial sweetener in coffee was relatively low, diminishing the [power](/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e) to detect an association.\nThe take-home message?\nThis observational study contributes to the growing body of evidence that moderate coffee consumption is associated with a decreased overall mortality. This effect persisted with the use of sugar but not with the use of artificial sweeteners.\n- Title of study: Association of sugar-sweetened, artificially sweetened, and unsweetened coffee consumption with all-cause and cause-specific mortality [120]\n- Authors: Liu D et al.\n- Journal: Annals of Internal Medicine\nEdition 51 - June 4, 2022\nIs all chest pain created equal?\nOne-Minute Telegram 51-2022-1/3 - People of color and women have worse outcomes for acute myocardial infarction (AMI) than White adults and men, respectively. [121] Whether those disparities are related to differences in\n[triage] and emergency department (ED) care is unclear.\nThis study analyzed data from the\n[CDC]\u2019s National Hospital Ambulatory Medical Care Survey (NHAMCS) on 4152 adults aged 18\u201355 with a history of ED visits for chest pain. Admission to hospital, wait times, and care received by adults in the ED were compared for women (56.8%) versus men and people of color (34.9%, of whom 89% were non-Hispanic Black) versus White individuals.\n- Women experienced longer wait times prior to provider evaluation than men (48.1 mins vs. 37.2 mins, p < 0.001)\n- Men were more likely than women to be:\n- Seen by a provider at any given time (HR, 1.15; 95% CI, 1.05\u20131.26)\n- Admitted to the hospital (17.9% vs. 12.4%; AOR, 1.40; 1.08\u20131.81)\n- People of color experienced longer wait times prior to provider evaluation than White individuals.\n- Women: 57.8 mins vs. 42.7 mins (p = 0.006)\n- Men: 44.0 mins vs 34.0 mins (p = 0.006)\n- People of color were less likely than White individuals to be seen by a provider (HR, 0.82; 0.73\u20130.93)\nLimitations include that the authors only considered visits for chest pain, ignoring other presenting symptoms of AMI; the absolute number of AMIs was small; and there was limited data on non-Black people of color.\nThe take-home message?\nThis study demonstrated that women and people of color experience longer ED wait times and are less likely to be seen by a provider when presenting with chest pain than men and White individuals, respectively. Further study is needed to determine how these findings correlate with the worse outcomes in these groups for AMI.\n- Title of study: Sex and race differences in the evaluation and treatment of young adults presenting to the emergency department with chest pain [122]\n- Authors: Banco D et al.\n- Journal: JAHA\n- AMBOSS Links:\n[Akutes Koronarsyndrom](/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b)| [Thoraxschmerz](/de/wissen/Thoraxschmerz#Z9da5bbffd83806c9e96cd8e0913f92ef)| [Koronare Herzkrankheit](/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1)\nDoes the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) vaccine reduce long COVID symptoms?\nOne-Minute Telegram 51-2022-2/3 - Long COVID can severely impact quality of life, but no effective treatments exist at this time. While evidence suggests that long COVID occurs less frequently in people who were vaccinated before infection, [123] the question of whether vaccination after infection can alter the course of long COVID remains unclear.\nThis observational cohort study included data on 28,356 individuals aged 18\u201369 years who had participated in the UK Office for National Statistics\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) Infection Survey and had received at least one dose of a [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) vaccine after infection. Activity-limiting long COVID was reported by 4747 individuals (16.7%). Long COVID symptom trajectories were estimated before and after vaccination.\nThe\n[odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c) of activity-limiting long COVID after vaccination and prior to vaccination were:\n- First dose: OR, 0.877 (95% CI, 0.805\u20130.955)\n- Second dose: OR, 0.909 (0.844\u20130.979)\nLimitations include the observational design of the study and that the presence of long COVID was determined by survey reporting alone.\nThe take-home message?\nThis study demonstrated an association between vaccination after\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) and reduction in long COVID symptoms. While an observational study cannot prove causality between [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) vaccination and reduction in long COVID symptoms, it adds to the robust body of evidence for the benefits of vaccination against [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) even following infection.\n- Title of study: Trajectory of long COVID symptoms after\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)vaccination: community based cohort study [124]\n- Authors: Ayoubkhani D et al.\n- Journal: BMJ\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nAre\n[glucocorticoids](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151) a safe and effective treatment for [IgA](/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb) nephropathy?\nOne-Minute Telegram 51-2022-3/3 - While immunomodulators are commonly used to treat\n[IgA](/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb) nephropathy, questions regarding the safety and [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f) of immunosuppression remain. [125]\nIn this international, double-blind randomized controlled trial, 503 adults with biopsy-proven\n[IgA](/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb) nephropathy, > 1 g/day proteinuria, and an [eGFR] 20\u2013120 mL/min/1.73 m2 were randomized 1:1 after \u2265 3 months of optimal care to receive methylprednisolone (n = 257) or [placebo] (n = 246). The initial cohort of patients in the methylprednisolone group (n = 136) received a dose of 0.6\u20130.8 mg/kg/day (max. dose 48 mg/day) for 2 months followed by a 6\u20138 month taper. The study was temporarily halted due to concerns about serious infections among participants in the methylprednisolone group. Subsequently, a reduced-dose cohort was enrolled (0.4 mg/kg/day, max. dose = 32 mg/day; n = 121). Patient follow-up continued for a minimum of 2 years.\nComposite primary outcome\nAnnual event rate of 40% decline in\n[eGFR], end-stage [renal](/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f) disease, and death due to kidney failure\n- Methyprednisolone: 7.3 (95% CI, 5.7\u20139.4)\n-\n[Placebo]: 12.1 (9.7\u201315.1)\n- HR, 0.53 (0.39\u20130.72)\n- Full dose: HR, 0.58 (0.41\u20130.81)\n- Reduced dose: HR, 0.27 (0.11\u20130.65)\nSecondary outcomes\nCompared to the\n[placebo] group, treatment-group participants experienced:\n- Slower rates of decline in\n[eGFR]\n- Lower rates of kidney failure requiring dialysis or transplant\n- Unsustained reduction in proteinuria (in g/day)\n- No difference in mortality\nSerious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c) were higher in the methylprednisolone group than in the [placebo] group, especially in the participants with the higher dose protocol.\nLimitations include that the trial was paused, that the protocol was modified due to\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c), and that the majority of participants came from a single country (China).\nThe take-home message?\nIn this\n[RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28) of individuals with [IgA](/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb) nephropathy, the use of methylprednisolone reduced the composite outcome of reduced [eGFR], end-stage [renal](/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f) disease, and kidney disease-related death but was associated with an increased risk of serious [adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c). The 2021 [KDIGO] guideline urges extreme caution in the use of [glucocorticoids](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151) in [IgA](/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb) nephropathy. [126]\n- Title of study: Effect of\n[oral]methylprednisolone on decline in kidney function or kidney failure in patients with [IgA](/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb)nephropathy: The TESTING randomized clinical trial\n- Authors: Lv J et al.\n- Journal: JAMA\n- AMBOSS Links:\n[Chronische Nierenerkrankung](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849)| [Akute Nierensch\u00e4digung](/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4)\nEdition 50 - May 21, 2022\nThe\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) debate rages on: 2022 USPSTF updated recommendations\nOne-Minute Telegram 50-2022-1/3 - The USPSTF has updated its 2016 recommendations after commissioning a systematic review and microsimulation of outcomes on hypothetical cohorts (stratified by age, sex, and CVD risk level) to determine the benefits and harms of\n[aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) ( [ASA]) use for the primary prevention of [atherosclerotic cardiovascular disease](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8) ( [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)) and colorectal cancer ( [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)). [127]\nCardiovascular disease: Outcomes were based on data from 11 RCTs and 1 pilot trial (n = 134,870).\n- Low-dose\n[ASA]was associated with a significant decrease in major cardiovascular events, e.g., nonfatal MI and stroke (OR, 0.90; 95% CI, 0.85\u20130.95).\n- However, low-dose\n[ASA]was not significantly associated with a reduction in all-cause mortality or cardiovascular mortality.\n- Low-dose\n[ASA]was associated with a significant increase in major bleeding, i.e., GI bleeding, intracranial bleeding, and hemorrhagic stroke (OR, 1.44; 1.32\u20131.57).\nUSPSTF recommendation for initiation of low-dose\n[ASA] to prevent [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)\n- Adults 40\u201359 years with a 10-year\n[ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)risk \u2265 10%: low net benefit; practice shared decision-making (Grade C recommendation)\n- Adults \u2265 60 years: no cardiovascular benefit and increased risk of major bleeding; do not initiate (Grade D recommendation)\n- Of note, the\n[ACC](/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32)/AHA recommends considering low-dose [ASA]for primary prevention of [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)in adults 40\u201370 years at high risk of [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)and low risk of bleeding. [80]\nColorectal cancer\n- There was limited\n[RCT](/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28)evidence to support an association between low-dose [ASA]and decreased [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)incidence (OR, 1.07; 0.92\u20131.24; n=4 trials) or mortality (OR, 1.36; 0.97\u20131.91; n=2 trials).\n- Findings were highly variable depending on the duration of follow-up.\n- The evidence regarding the benefit of low-dose\n[ASA]in reducing [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)incidence or mortality was inconclusive.\nThe take-home message?\nThis 2022 USPSTF update reduces the age range and grade of recommendation for using low-dose\n[ASA] in the primary prevention of [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8). Starting low-dose [aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66) is not recommended in adults \u2265 60 years. Based on evidence of a small net benefit, low-dose [ASA] may be considered on an individual basis in adults 40\u201359 years with a 10-year [ASCVD](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8) risk \u2265 10% and a low risk of bleeding. Whether low-dose [ASA] reduces the risk of [CRC](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7) remains unclear.\n- Title of study:\n[Aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement [8]\n- Authors: US Preventive Services Task Force\n- Journal: JAMA\n- Title of study:\n[Aspirin](/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66)Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force [128]\n- Authors: Guirguis-Blake J et al.\n- Journal: JAMA\n- AMBOSS Links:\n[Atherosklerose und kardiovaskul\u00e4re Pr\u00e4vention](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c)| [Kolorektales Karzinom](/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7)\nOne-size-fits-none: age and\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04) thresholds for diabetes screening\nOne-Minute Telegram 50-2022- 2/3 -\n[Diabetes mellitus](/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261) is more prevalent, more likely to be undiagnosed, and more likely to result in adverse outcomes in Black, Hispanic, and Asian Americans compared to White Americans. The current USPSTF recommendation on prediabetes and type 2 diabetes is to screen all adults aged 35\u201370 years with a [BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04) \u2265 25 kg/m2. [129]\nThis cross-sectional study included data from 19,335 nonpregnant adults aged 18\u201370 years from the National Health and Nutrition Examination Survey (NHANES). The authors used a logistic\n[regression](/de/wissen/Psychotherapeutische_Verfahren_(Klinik)#Ze4c5a7bc0f8094b3f645dae5659e34c0) model to estimate the prevalence of diabetes at various [BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04) levels among individuals in different self-identified racial/ethnic groups.\nThe estimated prevalence of diabetes in individuals with a\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04) \u2265 25 kg/m2 at 35 years of age was:\n- Asian Americans: 3.8% (95% CI, 2.8\u20135.1%)\n- Black Americans: 3.5% (2.7%-4.7%)\n- Hispanic Americans: 3.0% (2.1%-4.2%)\n- White Americans: 1.4% (1.0\u20132.0%)\nAssuming a prevalence of 1.4% is an acceptable threshold to begin screening for diabetes, the equivalent\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04) (in kg/m2) to begin screening at age 35 was estimated as follows:\n- Asian Americans: 20 (range, <18.5\u201323)\n- Black Americans: < 18.5 (<18.5\u201323)\n- Hispanic Americans: 18.5 (<18.5\u201324)\n- White Americans: 25\nLimitations include that socioeconomic, cultural, genetic, and other factors could not be considered based on the available information. Furthermore, the prevalence threshold for screening for diabetes has not been clearly established.\nThe take-home message?\nThis cross-sectional study demonstrated that Asian, Black, and Hispanic Americans have a higher prevalence of\n[diabetes mellitus](/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261) at younger ages and lower [BMIs](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04) than White Americans. Prospective research is needed to explore the possible benefits of more individualized screening thresholds to reduce racial/ethnic disparities in diabetes care.\n- Title of study: Diabetes screening by race and ethnicity in the United States: equivalent body mass index and age thresholds [130]\n- Authors: Aggarwal R et al.\n- Journal: Ann Intern Med.\n- AMBOSS Links:\n[Diabetes mellitus](/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261)\nA new drug combination to treat obesity in adolescents\nOne-Minute Telegram 50-2022-3/3 - The combination of phentermine (PHEN) and topiramate (TPM) has been approved for use in adults with overweight or obesity since 2012, but it remains unclear whether it is also safe and effective for adolescents. [131]\nIn this multicenter randomized, double-blind,\n[placebo]-controlled trial, 227 adolescents with obesity were stratified by age group and sex and assigned in a 1:1:2 ratio to receive [placebo] (n = 56), mid-dose PHEN/TPM (7.5 mg/46 mg; n=54), or top-dose PHEN/TPM (15 mg/96 mg; n = 113) once daily for 56 weeks. All participants were counseled to follow a diet and lifestyle modification program.\n- Primary endpoint\n- Secondary endpoints\n- Compared to\n[placebo], both the mid- and top-doses resulted in:\n- Significant reductions in\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04), waist circumference, and triglycerides\n- Improvements in\n[HDL](/de/wissen/Lipide#Zff6f4fd80161180060c203429a9a9536) [cholesterol](/de/wissen/Cholesterin#Z0384844f074a4123ce72fa1ff809ee92)\n- Significant reductions in\n- There were no differences among the groups for changes in fasting\n[insulin](/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce), glycemic markers, total or [LDL](/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163) [cholesterol](/de/wissen/Cholesterin#Z0384844f074a4123ce72fa1ff809ee92), systolic blood pressure, or quality of life.\n- Compared to\n- Safety endpoints\n- At least one\n[adverse event](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)was reported by 51.8% of participants in the [placebo]group, 37.0% in the mid-dose group, and 52.2% in the top-dose group.\n- Seven participants stopped the study early due to\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)(3 in the [placebo]group, 1 in the mid-dose group, and 3 in the top-dose group).\n- At least one\nLimitations include a high drop-out rate (mainly due to loss to follow-up rate and voluntary withdrawal from the study), which the authors attribute to the study having been conducted during the initial wave of the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) pandemic.\nThe take-home message?\nThis industry-sponsored study demonstrated that PHEN/TPM, when used as an adjunct to lifestyle therapy, provided a safe treatment option for reducing\n[BMI](/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04), waist circumference, and other metabolic parameters in adolescents with obesity.\n- Title of study: Phentermine/topiramate for the treatment of adolescent obesity [132]\n- Authors: Kelly AS et al.\n- Journal: NEJM Evidence\n- AMBOSS Links:\n[Metabolisches Syndrom](/de/wissen/Metabolisches_Syndrom#Zef9b1fe4e2f7f7f318f55631b1f02f85)\nEdition 49 - May 7, 2022\nImproving\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) care in Black and Latinx patients\nOne-Minute Telegram 49-2022-1/3 -\n[Asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) disproportionately impacts Black and Latinx populations in the US. This study explored whether an intervention including one-time instruction on and free access to on-demand, symptom-triggered inhaled [glucocorticoids](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151) could improve outcomes in [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) care. [133]\nIn this open-labeled trial, 1201 Black and Latinx adults with moderate-to-severe\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc), who were already using daily inhaled [glucocorticoids](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151), received a single instructional session on inhaler use. The participants were then randomized to an intervention group (n = 600), which added an inhaled [glucocorticoid](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151) (beclomethasone dipropionate 80 \u03bcg) for acute symptom relief to usual care, and a control group (n = 601), which continued usual care only. Monthly questionnaires were used to estimate the rate of severe [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) exacerbations over 15 months.\n- Primary endpoint\n- The annualized rate of severe\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc)exacerbations was lower in the intervention group (0.69 per year; 95% CI, 0.61\u20130.78) than in the usual care group (0.82 per year; 0.73\u20130.92); HR, 0.85; 0.72\u20130.99.\n- The annualized rate of severe\n- Secondary endpoints\n-\n[Asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc)control (assessed by the [Asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc)Control Test) improved more in the intervention group than in the usual care group. [134]\n- Quality of life (assessed by the\n[Asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc)Symptom Utility Index) improved more in the intervention group than in the usual care group. [135]\n- Participants in the intervention group missed fewer days of school or work (13.4; 11.9\u201315.2) than those in the usual care group (16.8; 14.9\u201318.9): rate ratio, 0.80; 0.67\u20130.95.\n-\nSerious\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c) did not differ between groups. The intervention group used approximately one more inhaled [glucocorticoid](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151) inhaler per year and one fewer quick-reliever metered-dose inhaler compared to those in the usual care group.\nLimitations include that the analysis was open-label and patient outcomes were based on self-reports.\nThe take-home message?\nThis trial demonstrated that a single instruction session followed by free, unlimited access to an inhaled\n[glucocorticoid](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151) for symptom relief led to a significant and sustained decrease in severe [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) exacerbations over 15 months in Black and Latinx patients.\n- Title of study: Reliever-triggered inhaled\n[glucocorticoid](/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151)in Black and Latinx adults with [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc)[136]\n- Authors: Israel E et al.\n- Journal: NEJM\n- AMBOSS Links:\n[Asthma bronchiale](/de/wissen/Asthma_bronchiale#Z29bfa453b270bf9d5df2a9deec02645f)\nProne positioning in nonintubated patients with\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nOne-Minute Telegram 49-2022-2/3 - The\n[prone position](/de/wissen/Patientenlagerung_im_OP#Z6e35e6d036966b6e4fd2f962e7223e54) is an established element of treatment for patients with acute respiratory [distress](/de/wissen/Stressmodelle#Z6c7eef5a913c582156005f60a0dd88f1) [syndrome], and it is recommended for mechanically ventilated patients with [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7). Previous prospective and retrospective studies on this intervention in nonintubated patients with [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) have shown reduced mortality and a reduced need for [intubation](/de/wissen/Allgemeinan\u00e4sthesie#Zea846d3465d1a392fbf008b5131bf900), but further benefits of prone positioning in this population remain an open question. [137][138][139]\nThis nonrandomized, controlled trial assigned nonintubated patients with\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)-related hypoxemia to either prone positioning (n = 258) or usual care (n = 243). Patients in the intervention group spent a [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) of 4.2 hours (IQR, 1.8\u20136.7 hours) in the [prone position](/de/wissen/Patientenlagerung_im_OP#Z6e35e6d036966b6e4fd2f962e7223e54) per day.\nThe primary outcome was the maximum amount of supplemental oxygen required on day 5 based on a modified\n[WHO] [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) [ordinal](/de/wissen/Angewandte_Statistik#Z5b4c61ad31f494b7fe6dd62ed480cba7) outcome scale, in which an AOR \u2265 1.0 indicated a shift toward worse outcomes. [140]\n-\n[Odds](/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c)of a worse outcome in the intervention group at day 5: AOR 1.63; 95% credibility interval, 1.16\u20132.31\n- Day 14: 1.29; 0.84\u20131.99\n- Day 28: 1.12; 0.67\u20131.86\nLimitations include that the study was not randomized and that a higher proportion of patients were discharged within 5 days in the usual care group compared with the intervention group.\nThe authors speculate that prone positioning early in the disease may have led to worse outcomes by accelerating progression of lung damage, obscuring evidence of clinical deterioration, or leading to events of desaturation.\nThe take-home message?\nIn this trial of hypoxemic, awake patients with\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) who were not receiving mechanical [ventilation](/de/wissen/Atemwege_und_Lunge#Zbffa82a865686699ed8a6fc3276b5293), the [prone position](/de/wissen/Patientenlagerung_im_OP#Z6e35e6d036966b6e4fd2f962e7223e54) provided no clinical benefit and may have worsened outcomes at day 5 after enrollment.\n- Title of study: Assessment of awake prone positioning in hospitalized adults with\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7): A nonrandomized controlled trial [141]\n- Authors: Tang Qian E at al.\n- Journal: JAMA Internal Medicine\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nA care bundle to reduce bloodstream infections in hemodialysis\nOne-Minute Telegram 49-2022-3/3 - Patients receiving hemodialysis through a central catheter are at risk of developing catheter-related bloodstream infections (CRBSIs). Although nonrandomized clinical studies have shown a reduction in CRBSIs after implementation of care bundles, randomized trial data is lacking. [142]\nThis trial evaluated whether the implementation of a care bundle consisting of recommendations for catheter\n[insertion], maintenance, and removal can reduce the rate of CRBSIs.\n6364 patients were included in a stepped wedge, cluster-randomized design. 315 episodes of confirmed CRBSI occurred during the study period. There was no significant difference in the rate of CRBSI during the\n[baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293) (n = 158) and intervention (n = 157) phases of the trial (incidence rate ratio 1.37; 95% CI 0.85\u20132.21).\nLimitations include that a third of the participating\n[renal](/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f) services deviated from the prespecified interventions and that many elements of the intervention had already been implemented into routine practice prior to the study. Accordingly, CRBSI rates were lower than expected in both groups, and the study\u2019s [power](/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e) to detect the effects of the intervention may not have been sufficient.\nThe take-home message?\nThe care bundle implemented in this trial did not reduce the rate of CRBSIs in patients receiving hemodialysis through a central catheter.\n- Title of study: Multifaceted intervention to reduce haemodialysis catheter related bloodstream infections: REDUCCTION stepped wedge, cluster randomised trial [143]\n- Authors: Kotwal S et al.\n- Journal: BMJ\n- AMBOSS Links:\n[Nierenersatzverfahren](/de/wissen/Nierenersatzverfahren#Z6289f9bf0b468450f183c4371b8a97c2), [Nosokomiale Infektionen](/de/wissen/Nosokomiale_Infektionen#Za5a553ef57f8f6efb10b91f86ac27d52)\nEdition 48 - April 23, 2022\nPredicting severe\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) in pregnant women\nOne-Minute Telegram 48-2022-1/3 - Pregnancy is considered a potential risk factor for a severe course of\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7), but individual risk assessments are not currently available, as most large trials excluded pregnant women.\nThis multicenter study used retrospective data collected from the beginning of the pandemic to May 2021 from 793 unvaccinated pregnant and early postpartum (within 10 days of birth) women with symptomatic\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) (confirmed by [PCR](/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca)) to identify risk factors and develop two COvid Maternal Intensive Therapy (COMIT) models to predict ICU admission. A total of 44 participants (5.5%) were admitted to the ICU, of whom 10 died (1.3%).\n- miniCOMIT\n- fullCOMIT\n- Cut-off points with high sensitivity and specificity were selected for each model and used to classify the study population as high-risk or low-risk for severe\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7).\n- miniCOMIT outcomes in high-risk (46.1%) compared to low-risk women\n- Admission to ICU: 10.5% vs. 1.4%\n- Death: 2.2% vs. 0.5%\n- Preeclampsia: no significant difference\n- fullCOMIT outcomes in high-risk (26.4%) compared to low-risk women\n- Admission to ICU: 19.5% vs. 1.4%\n- Death: 5.2% vs. 0.2%\n- Preeclampsia: 5.7% vs. 1.0%\n- miniCOMIT outcomes in high-risk (46.1%) compared to low-risk women\nLimitations include that the model was only validated internally (i.e., within the same dataset) and that results may not be generalizable to vaccinated populations.\nThe take-home message?\nThis study developed two prediction models (available as online calculators) [144] to help estimate the risk of critical illness due to\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) in unvaccinated pregnant and early postpartum women. Early identification of high-risk patients using these models could potentially improve clinical outcomes and hospital resource allocation.\n- Title of study: An internally validated prediction model for critical\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)infection and intensive care unit admission in symptomatic pregnant women [145]\n- Authors: Kalafat E et al.\n- Journal: AJOG\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nCan any alcohol consumption be considered healthy?\nOne-Minute Telegram 48-2022-2/3 - As part of a Mediterranean diet, moderate alcohol consumption has long been considered cardioprotective. [146] However, residual\n[confounding](/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1) may have influenced the results of studies supporting this assumption.\nThis study included data from 371,463 participants from a UK database who were categorized based on their drinking habits, and data analysis related to cardiovascular disease (CVD) was conducted and adjusted for lifestyle factors (e.g., smoking frequency).\nKey findings\n- Alcohol use was strongly associated with an increased risk of coronary artery disease (CAD) and hypertension.\n- The incidence of both hypertension and CAD increased exponentially with increasing alcohol consumption (dose-response gradient).\n- Individuals with light-to-moderate alcohol intake tended to have healthier lifestyles than those who did not drink alcohol, which may account for the apparent cardioprotective effect of modest alcohol consumption seen in previous epidemiological studies.\nLimitations include that the data came from a single UK database, restricting the generalizability to other populations.\nThe take-home message?\nThis study showed that even light-to-moderate alcohol consumption is a risk factor for CVD when adjusting for the beneficial effects of an otherwise healthy lifestyle, and that CVD risk increases exponentially with increasing alcohol consumption.\n- Title of study: Association of habitual alcohol intake with risk of cardiovascular disease [147]\n- Authors: Biddinger\n[KJ]et al.\n- Journal: JAMA Netw. Open\n- AMBOSS Links:\n[Atherosklerotisch bedingte kardiovaskul\u00e4re Erkrankungen](/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8)\n[Ivermectin](/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed) in [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7): yay or nay?\nOne-Minute Telegram 48-2022-3/3 - Recently,\n[ivermectin](/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed) has been used experimentally by some as an over-the-counter treatment for [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7); its effectiveness has also been studied in small clinical trials with conflicting results.\nThis double-blind,\n[placebo]-controlled trial randomized symptomatic adults with [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) and at least one risk factor for disease progression to receive either [ivermectin](/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed) (400 mcg/kg; n = 679) or [placebo] (n = 679) once daily for 3 days.\nThe primary composite outcome was the rate of hospitalization or prolonged (> 6 hours) admission to the emergency department due to clinical worsening of\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) within 28 days of randomization. For the primary outcome, no significant difference was observed between the [ivermectin](/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed) (14.7%) and [placebo] groups (16.3%), with an RR of 0.9 (95% credible interval, 0.7\u20131.16).\nAdditionally, there was no significant difference in the incidence of secondary outcomes (e.g., death from any cause) or\n[adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c) between the two groups.\nLimitations include that only one\n[ivermectin](/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed) regimen was investigated.\nThe take-home message?\nThis extensive, double-blind,\n[placebo]-controlled trial showed that a 3-day course of [ivermectin](/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed) did not lower the incidence of hospitalization or prolonged emergency department visits due to [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) compared to [placebo]. These results further support the [FDA] recommendation [148] against using [ivermectin](/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed) to treat [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7).\n- Title of study: Effect of early treatment with\n[ivermectin](/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed)among patients with [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)[149]\n- Authors: Reis G et al.\n- Journal: NEJM\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nQ1 2022\n-\n[One-Minute Telegram 47-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zfdb56825a57d0b0fc88f04a699909709)\n- How effective are vaccines against omicron?\n- Do balanced salt solutions provide a benefit over saline in ICU patients?\n- How many cases of breast cancer are overdiagnosed through screening?\n-\n[One-Minute Telegram 46-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z7acf43ad9082d39607862da0872c2acf)\n-\n[One-Minute Telegram 45-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zb3ca4a5369213fe90b766e280110f2e3)\n-\n[One-Minute Telegram 44-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Z86857a958faf86ff5918411353031e6f)\n- The ACP\u2019s new diverticulitis guidelines\n- To screen or not to screen for atrial\n[fibrillation]: 2022 updated USPSTF recommendations\n- Valentine\u2019s Day edition: Don\u2019t go piercing my heart!\n-\n[One-Minute Telegram 43-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zcbca50c081dd26cf58a83ea57066fc9e)\n- Is\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc)a risk factor for [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)?\n- How effective is a\n[booster]with the Pfizer\u2013BioNTech vaccine against the delta variant?\n- Is\n[fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90)effective in treating multidrug-resistant [E. coli](/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec)?\n- Is\n-\n[One-Minute Telegram 42-2022](/de/wissen/One-Minute_Telegram_Archiv_2022#Zadcaa56aee4c724771a39432fa4e4a53)\n- How effective are\n[mRNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b)vaccines in preventing hospitalizations due to the omicron variant?\n- Breakthrough infections after\n[SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3)vaccination in patients with immune dysfunction\n- Does cataract surgery decrease the risk of dementia?\n- How effective are\nEdition 47 - March 26, 2022\nHow effective are vaccines against omicron?\nOne-Minute Telegram 47-2022-1/3 - Shortly after the emergence of the omicron variant (\n[B.1.1.529](/de/wissen/COVID-19#Z818a161a9af87d1ad3b8925c620cdf0e)) of [SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3), laboratory studies suggested a weak neutralizing antibody response in vaccinated persons to this variant, but clinical evidence of this has so far been missing. This trial compared the effectiveness of different vaccines in preventing symptomatic omicron infection. [150]\nThis case-control study included 2,663,549 individuals older than 18 years of age presenting with symptoms consistent with\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7); 886,774 had a positive sequencing for the omicron variant, 204,154 had a positive sequencing for the delta variant, and 1,572,621 had a [PCR](/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca) test negative for [SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3).\nVaccine effectiveness against symptomatic omicron infection was very low for AstraZeneca\n[Vaxzevria](/de/wissen/COVID-19-Impfstoffe#Ze43273a125bb8a84da0f17f0afdd6cb0). The [mRNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b) vaccines (Pfizer-BioNTech [Comirnaty](/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1) and Moderna [Spikevax](/de/wissen/COVID-19-Impfstoffe#Zded93a359e7ea86b7766237f21b4b42a)) showed higher effectiveness at 2\u20134 weeks after vaccination (Pfizer-BioNTech 65.5%; 95% CI, 63.9\u201367%, Moderna 75.1%; 70.8\u201378.7%), but effectiveness declined significantly at 25+ weeks (Pfizer-BioNTech, 8.8%; 7.0\u201310.5%; Moderna, 14.9%; 3.9\u201324.7%).\nVaccine boosters significantly increased effectiveness against symptomatic omicron infections:\n- AstraZeneca (2 doses) plus Pfizer-BioNTech\n[booster]\n- At 2\u20134 weeks: 62.4% (61.8\u201363.0%)\n- At 10+ weeks: 39.6% (38.0\u201341.1%)\n- AstraZeneca (2 doses) plus Moderna\n[booster]\n- At 2\u20134 weeks: 70.1% (69.5\u201370.7%)\n- At 5\u20139 weeks: 60.9% (59.7\u201362.1%)\n- Pfizer-BioNTech (2 doses) plus Pfizer-BioNTech\n[booster]\n- At 2\u20134 weeks: 67.2% (66.5\u201367.8%)\n- At 10+ weeks: 45.7% (44.7\u201346.7%)\n- Pfizer-BioNTech (2 doses) plus Moderna\n[booster]\n- At 2\u20134 weeks: 73.9% (73.1\u201374.6%)\n- At 5\u20139 weeks: 64.4% (62.6\u201366.1%)\n- Moderna (2 doses) plus Pfizer-BioNTech\n[booster]\n- At 2\u20134 weeks: 64.9% (62.3\u201367.3%)\n- Moderna (2 doses) plus Moderna\n[booster]\n- At 2\u20134 weeks: 66.3% (63.7\u201368.8%)\nThe study also reported the vaccine's effectiveness against the delta variant, which, in comparison to effectiveness against omicron, was higher at all intervals after vaccination and for all the combinations of primary courses and\n[booster] doses investigated.\nLimitations include that data was not available for primary vaccination with two different vaccines (e.g., 1st dose AstraZeneca, 2nd dose Moderna) or for the vaccines\u2019 effectiveness against severe disease, hospitalization, and death.\nThe take-home message?\nThis study shows that two doses of any vaccine have a limited and waning effect against symptomatic\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) due to the omicron variant, with AstraZeneca\u2019s [Vaxzevria](/de/wissen/COVID-19-Impfstoffe#Ze43273a125bb8a84da0f17f0afdd6cb0) offering the least protection. A third dose ( [booster]) of an [mRNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b)-based vaccine significantly improves neutralizing activity with less waning of effect than is seen following the second dose. Fortunately, a growing body of evidence suggests that [mRNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b)-based vaccines protect well against severe disease and death caused by any [SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3) variant. [151]\n- Title of study: Covid-19 vaccine effectiveness against the omicron (\n[B.1.1.529](/de/wissen/COVID-19#Z818a161a9af87d1ad3b8925c620cdf0e)) variant [152]\n- Authors: Andrews N et al.\n- Journal: NEJM\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nDo balanced salt solutions provide a benefit over saline in ICU patients?\nOne-Minute Telegram 47-2022-2/3 - Fluid therapy in critically ill patients usually consists of balanced multielectrolyte solution (BMES) or 0.9% sodium chloride solution (saline). Whether BMES can reduce adverse outcomes compared to saline is a subject of ongoing debate. [153][154]\nIn this multicenter double-blinded trial, 5037 ICU patients were randomized to receive either BMES (n = 2515) or saline (n = 2522).\n[Baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293) characteristics were similar in both groups (age 61.9\u00b116.5 years, 38.7% women, [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) APACHE II score = 19).\nThe\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) duration of treatment (6.0 days, IQR 3.0\u201310.0) and volume of fluid received in the ICU (3.9 liters, 2.0\u20136.7) were comparable between groups.\nThere was no significant difference in 90-day mortality, new\n[renal](/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f) replacement therapy, maximum creatinine levels, or the number of [adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c) between the two groups.\nLimitations include that administration of fluids outside the ICU was not recorded, and that outcome data was not available for a small number of patients.\nNotably, a recently updated metaanalysis that incorporated the results of this study suggests a trend toward reduced mortality with the use of BMES over saline. [155]\nThe take-home message?\nThis study demonstrated no difference in 90-day mortality or the rate of new\n[renal](/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f) replacement therapy in critically ill patients who received either BMES or saline in the ICU, but further studies are needed to identify the patient groups that may benefit from the respective fluids.\n- Title of study: Balanced multielectrolyte solution versus saline in critically ill adults [156]\n- Authors: Finfer F et al.\n- Journal: NEJM\n- AMBOSS links:\n[Fl\u00fcssigkeits- und Volumentherapie](/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z87e9a247724c9b2410076167606f4c20)\nHow many cases of breast cancer are overdiagnosed through screening?\nOne-Minute Telegram 47-2022-3/3 - Screening for breast cancer can lead to overdiagnosis, defined as treatment of cancer that would not have caused symptoms within the patient\u2019s remaining lifetime. However, the rate of overdiagnosis due to screening is currently unknown.\nIn this trial, the rate of overdiagnosis was estimated using data from a biennial screening program of the US Breast Cancer Surveillance Consortium (BCSC). The analysis used mathematical modeling and included 35,986 patients between the ages of 50 and 74 years who had had \u2265 1 mammogram between 2000 and 2018. 82,677 mammograms resulting in 718 breast cancer diagnoses were included in the analysis. Screening test sensitivity was estimated to be 81.4% (95% CI, 73.1\u201388.7%).\nOf all screen-detected cancers, 15.4% (95% prediction interval 9.4\u201326.5%) were estimated to be overdiagnosed, with 6.1% (0.2\u201320.1%) being due to\n[indolent] preclinical cancer and 9.3% (5.5\u201313.5%) due to progressive cancer in patients who would have died of other causes before clinical cancer manifestation. The overdiagnosis rate was lowest in the first screening at age 50 (11.5%; 3.8\u201328.3%) and gradually increased until the last screen at age 74 (23.6%; 17.7\u201331.9%). Overdiagnosis at age 50 was primarily due to [indolent] cancer; overdiagnosis at age 74 was primarily due to progressive cancer that did not affect the patient\u2019s longevity.\nLimitations include that only patients who had received their first screening examination within the BCSC were included, leading to low event numbers that, in turn, were insufficient to fit the model to patient features or\n[tumor](/de/wissen/Allgemeine_Onkologie#Z96dbcb525ee590dbfa7e193aeb93cb24) subtypes.\nThe take-home message?\nResults from this study suggest that almost 1 in 7 cases of breast cancer detected by mammography screening in patients aged 50\u201374 years is overdiagnosed. The risk of overdiagnosis (potentially leading to unnecessary studies and treatment) increases with patient age, mainly due to the diagnosis of progressive cancer in patients who would have died of other causes before dying of cancer.\n- Title of study: Estimation of breast cancer overdiagnosis in a U.S. breast screening cohort [157]\n- Authors: Ryser\n[MD](/de/wissen/Gesetzliche_Krankenversicherung#Z07c6fe7783c09554a5f967aa95baadcf)et al.\n- Journal: Annals of Internal Medicine\n- AMBOSS links:\n[Mammakarzinom](/de/wissen/Mammakarzinom#Zd6f1c1662017c7aba756050900de29a5)\nEdition 46 - March 12, 2022\n2022 updated recommendations from the Advisory Committee on Immunization Practices (ACIP)\nOne-Minute Telegram 46-2022-1/3 - The ACIP is composed of 15 medical and public health experts who provide recommendations to the Centers for Disease Control regarding the selection and timing of vaccines for children and adults in the United States.\nImportant recommendations and updates in 2022 include the following:\n- Pneumococcal vaccination\n- Recommended for adults > 65 years of age\n- Recommended for adults 19\u201364 years of age with specific underlying medical conditions and/or risk factors (e.g., cigarette smoking, lymphoma,\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604))\n-\n[Hepatitis B](/de/wissen/Hepatitis_B_und_HBV-Infektion#Z0cc1ba9a62130e5544df273f6b9fb8aa) [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870)( [HBV](/de/wissen/Allgemeine_Virologie#Zf1cb8aa6863e4655a8fef04d1bfc005f)) vaccination\n- Recommended for adults 19\u201359 years of age\n- Recommended for adults \u2265 60 years of age who are at risk of\n[HBV](/de/wissen/Allgemeine_Virologie#Zf1cb8aa6863e4655a8fef04d1bfc005f)infection (e.g., [chronic liver disease], [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)infection, incarceration)\n-\n[Influenza](/de/wissen/Influenza#Za72c6651780a156d4f79b3975508d09a)vaccination\n- Recommended for everyone > 6 months of age who does not have contraindications\n- No longer contraindicated in patients with a history of severe allergic reactions to an\n[influenza](/de/wissen/Influenza#Za72c6651780a156d4f79b3975508d09a)vaccine, if a different type of vaccine is available\n-\n[Zoster](/de/wissen/Herpes_zoster#Z3931bebadc321aba40d6b0dd818663e7) [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870)(RZV) vaccination\n- Recommended for adults > 50 years of age\n- Recommended for adults \u2265 19 years of age who are or will become immunodeficient or immunosuppressed due to disease or therapy\n- Consider delaying vaccination if the patient is pregnant.\nOther vaccination recommendations (e.g.,\n[varicella](/de/wissen/Windpocken#Zdf8d7df5776aab061bd719ff8a029345), MMR, VPH, [hepatitis A](/de/wissen/Hepatitis_A#Z121c9271bef15b6d00bfe6be3a04ec32)) remain largely unchanged.\nThe take-home message?\nThe 2022 ACIP updated recommendations to the US immunization schedule have been released. The full updated vaccination schedule for adults and children can be found at the\n[CDC] website. [158]\n- Title of study: Recommended adult immunization schedule, United States, 2022 [159]\n- Authors: Murthy N, et. al\n- Journal: Annals of Internal Medicine\n2022 updated American College of Gastroenterology (ACG) guidelines for\n[GERD](/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307)\nOne-Minute Telegram 46-2022-2/3 - Gastroesophageal reflux disease (\n[GERD](/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307)) is one of the most common diseases seen in primary care. Since publication of the 2013 American College of Gastroenterology (ACG) guidelines for [GERD](/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307), understanding of the disease has evolved and numerous developments in its diagnosis and management have occured.\nImportant recommendations and updates include the following:\n- Diagnostic testing:\n- Start with an 8-week empiric course of a proton pump inhibitor (\n[PPI](/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16)) in patients with classic symptoms of heartburn and [regurgitation]but no alarm symptoms.\n- Symptom relief during\n[PPI](/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16)treatment but recurrence after treatment suggests [GERD](/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307).\n- Perform an initial diagnostic endoscopy in patients with:\n- Chest pain without heartburn (following a cardiac evaluation).\n- Alarm symptoms (e.g., dysphagia, weight loss, GI bleeding).\n- Perform a follow up endoscopy after\n[PPI](/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16)therapy if:\n- Symptoms do not resolve with treatment.\n- Symptoms return after discontinuation of\n[PPIs](/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16).\n- Start with an 8-week empiric course of a proton pump inhibitor (\n- Diet and lifestyle recommendations:\n- Avoidance of the following:\n- Meals up to 3 hours before bedtime\n- Tobacco use\n- Trigger foods (e.g., coffee, chocolate, carbonated beverages, spicy or acidic foods)\n- Weight loss (for patients with overweight)\n- Elevate the head of the bed (for nighttime\n[GERD](/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307)symptoms)\n- Avoidance of the following:\n- Medical interventions:\n- Surgical interventions:\n- Antireflux surgery is recommended as an option for long-term therapy.\n- Roux-en-Y surgery is recommended as an option in patients with obesity.\n- Magnetic sphincter\n[augmentation]and transoral incisionless fundoplication are new additions to the guidelines if medical treatment fails.\nThe take-home message?\nThe 2022 ACG guidelines update the previous recommendations for diagnosis and medical management of\n[GERD](/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307) and provide new recommendations for its surgical and procedural management.\n- Title of study: ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease [160]\n- Authors: Katz P, et al.\n- Journal: American Journal of Gastroenterology\n-\n[Amboss](/de/wissen/Ohr#Z2e6489810ab8a5524d8534501fcab9be)-Links: [Gastro\u00f6sophageale Refluxkrankheit](/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307)\nWhat are the long-term cardiovascular outcomes of\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)?\nOne-Minute Telegram 46-2022-3/3 - Although the acute cardiovascular complications of\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) have been extensively studied, the long-term risks of cardiovascular disease have not been fully investigated. [161]\nIn this observational cohort trial, investigators analyzed data from the US Department of Veterans Affairs national health care databases to identify 153,760 individuals who survived the first 30 days following recovery from\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7). After this period, these individuals were assessed every 30 days for roughly one year and compared with 5,637,647 individuals without [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) from the same databases.\nCompared to contemporary controls, the risk of the following prespecified composite outcomes were higher in\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) survivors:\n- Stroke or transient ischemic attacks (\n[TIA](/de/wissen/Isch\u00e4mischer_Schlaganfall#Z4b57583b8491f668d90c29037dcf5fd5)): HR, 1.53 (95% CI 1.45\u20131.61)\n- Atrial\n[fibrillation], sinus tachycardia, sinus bradycardia, ventricular arrhythmias, and atrial [flutter]: 1.69 (1.64\u20131.75)\n- Pericarditis and\n[myocarditis](/de/wissen/Myokarditis#Zf2d8a0d86bbd2561839fe616b5b1a3c0): 2.02 (1.77\u20132.30)\n- Acute coronary disease, myocardial infarction (MI), ischemic cardiomyopathy, and\n[angina]: 1.66 (1.52\u20131.80)\n- Heart failure, nonischemic cardiomyopathy, cardiac arrest, and cardiogenic shock: 1.72 (1.65\u20131.79)\n- Pulmonary embolism, deep vein thrombosis, and superficial vein thrombosis: 2.39 (2.27\u20132.51)\n- Major adverse cardiac events (MI, stroke, and all-cause mortality): 1.55 (1.50-1.60)\nImportantly, the increased risk of cardiovascular disease following\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) was also demonstrated in individuals without cardiovascular risk factors or a previous history of cardiovascular disease.\nLimitations include that cause of death could not be considered, as this was not included in the databases, and that the demographic composition of the dataset was predominantly white (76.78%) and male (90.31%), restricting generalizability.\nThe take-home message?\nThis trial demonstrates that individuals who recovered from\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) have an increased risk of cardiovascular disease in the months following the disease. Ongoing care of individuals who have recovered from [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) should include monitoring for cardiovascular disease, even if it was not present prior to the infection.\nEdition 45 - February 26, 2022\n[Oral] outpatient treatment of [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) with [molnupiravir](/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d)\nOne-Minute Telegram 45-2022-1/3 - Primary prevention of\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) has been hampered by disappointingly low vaccination rates, necessitating the development of medications that reduce the progression of the disease. A promising candidate is [molnupiravir](/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d), a [prodrug](/de/wissen/Leber#Z7346e666b4aff9a5c5eefeed844aed78) of N-hydroxycytidine (NHC) that is incorporated into viral [RNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d) upon phosphorylation and causes errors throughout the viral [genome](/de/wissen/Aufbau_von_DNA_und_RNA#Zde5024dfafa13379e580abaf073d8dba), rendering the [virus](/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870) unable to replicate.\nIn this phase 3, double-blind trial, patients were randomized 1:1 to either\n[molnupiravir](/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d) (800 mg PO twice daily for 5 days) or a [placebo] within five days of mild to moderate [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) symptom onset. Between May 6 and November 4, 2021, 1433 non-hospitalized, unvaccinated adults, who had at least one risk factor for severe illness (i.e., age > 60 years; cancer; obesity; diabetes; chronic lung, heart, or kidney disease) were included.\nOn day 29 after the beginning of treatment, patients taking\n[molnupiravir](/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d) were less likely to have been admitted to hospital or to have died (composite primary outcome) than those taking the [placebo] (6.8% vs. 9.7%, difference -3.0; 95% CI, -5.9 to -0.1). The number of [adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c) did not differ significantly between groups. Notably, patients with [SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3) antibodies at the beginning of the trial did not benefit.\nLimitations include that only unvaccinated patients took part in this study and patients with more severe disease (i.e., those expected to require hospitalization for\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) within the next 48 hours) were excluded, restricting generalizability.\nThe take\u2011home message?\nThis trial demonstrated the effectiveness of\n[oral] [molnupiravir](/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d) in lowering the risk of hospitalization and death in unvaccinated, non-hospitalized adults with mild to moderate [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) and at least one risk factor for severe illness.\n- Title of study:\n[Molnupiravir](/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d)for [Oral]Treatment of Covid-19 in Nonhospitalized Patients [163]\n- Authors: Bernal AJ et al.\n- Journal: NEJM\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nNew\n[protein](/de/wissen/Aminos\u00e4uren_und_Proteine#Z6760651e0606c30942f14701885fce12)-based vaccine against [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7): [Nuvaxovid](/de/wissen/COVID-19-Impfstoffe#Zac3bd4e161d94c3206a8aa61a4193fc3) (NVX-CoV2373)\nOne-Minute Telegram 45-2022-2/3 - Lack of vaccine availability and vaccine hesitancy continue to curb efforts to control the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) pandemic. The development of non- [mRNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b) vaccines that do not require special storage may help bridge the vaccination gap.\nThe newly developed vaccine\n[Nuvaxovid](/de/wissen/COVID-19-Impfstoffe#Zac3bd4e161d94c3206a8aa61a4193fc3) (NVX-CoV2373) combines a recombinant spike [protein](/de/wissen/Aminos\u00e4uren_und_Proteine#Z6760651e0606c30942f14701885fce12) assembled into nanoparticles with a saponin-based [adjuvant](/de/wissen/Allgemeine_Onkologie#Zc921888bd82ae63d81e2094ef067f0fd) (Matrix-M). It can be stored for up to 6 months at household refrigerator temperatures.\nIn this phase 3, observer-blinded,\n[placebo]-controlled trial conducted in the US and Mexico, adults > 18 years of age were randomized in a 2:1-ratio to receive two doses of NVX-CoV2373 or [placebo] 21 days apart. Between December 27, 2020, and February 18, 2021, 19,714 participants received at least one dose of the vaccine and 9868 received the [placebo].\nPer-protocol analysis of the observation period of 3 months showed the following results:\n- Vaccine\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)against symptomatic [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7): 90.4% (95% CI, 82.9\u201394.6)\n- Vaccine\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)against moderate-to-severe disease: 100% (87\u2013100)\nDuring a\n[median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) safety follow-up of 2 months, [adverse events](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c) were mostly mild to moderate and self-limited with a [median](/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b) duration of 1\u20132 days. In addition, none of the safety signals reported in trials with other [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) vaccines (e.g., CVT, [myocarditis](/de/wissen/Myokarditis#Zf2d8a0d86bbd2561839fe616b5b1a3c0)) were observed.\nLimitations include a low number of older participants, that long-term safety and\n[efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f) results are not yet available, and that 89% of infections were due to the alpha variant of [SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3). Accordingly, the vaccine\u2019s effectiveness against the delta or omicron variant is still unclear.\nThe take\u2011home message?\n[Nuvaxovid](/de/wissen/COVID-19-Impfstoffe#Zac3bd4e161d94c3206a8aa61a4193fc3) (NVX-CoV2373) has similar [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f) against [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) as existing vaccines and a good safety profile. Further studies will have to address the vaccine's [efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f) against variant strains and its duration of effect.\n- Title of study:\n[Efficacy](/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f)and safety of NVX-CoV2373 in adults in the United States and Mexico [164]\n- Authors: Dunkle LM, et al.\n- Journal: NEJM\n- AMBOSS Links:\n[COVID-19-Impfstoffe](/de/wissen/COVID-19-Impfstoffe#Z7f362fdcfafe10f6e62547d8ea247b21)| [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nWhen is major elective surgery safe after a\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) infection?\nOne-Minute Telegram 45-2022-3/3 - Physicians are increasingly having to deal with the question of when patients with a current or recent\n[SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3)-infection can safely undergo elective major surgery.\nIn this retrospective cohort study, investigators screened the\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) Research Database for unvaccinated patients who had been diagnosed with [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) between March 1, 2020, and May 30, 2021, and underwent major elective surgery during that time as well. [165]\nThe 5479 patients included were categorized into four groups, depending on the time of surgery and the time of diagnosis: pre-\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) (no infection; n = 2621), peri- [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) (0\u20134 weeks after infection; n = 780), early post- [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) (4\u20138 weeks after infection; n = 445), and late post- [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) (\u2265 8 weeks after infection; n=1633).\nRisk of postoperative complications compared to the pre-\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) surgery cohort:\n- Peri-\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)infection (0\u20134 weeks)\n- Postoperative pneumonia: adjusted OR, 6.46; 95% CI 4.06\u201310.27\n-\n[Sepsis](/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38): 3.67; 2.18\u20136.16\n- Respiratory failure: 3.36; 2.22\u20135.10\n- Pulmonary embolism: 2.73; 1.35\u20135.53\n- Early post-\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)infection (4\u20138 weeks)\n- Postoperative pneumonia: 2.44; 1.20\u20134.96\n- Late post-\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)infection (> 8 weeks)\n- No increased risk of postoperative complications\nLimitations include that the study was retrospective, only unvaccinated adults were included, the onset and severity of\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) infection were not reported in the database, and that postoperative mortality rates were not available.\nThe take\u2011home message?\nThe risk of a perioperative complication following major elective surgery is increased in patients with a recent\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) infection. The risk returns to [baseline](/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293) 8 weeks after infection, suggesting increased patient safety if surgery can be delayed until that time.\nEdition 44 - February 12, 2022\nThe ACP\u2019s new diverticulitis guidelines\nOne-Minute Telegram 44-2022-1/3 - The American College of Physicians (ACP) has released its first-ever guidelines on the diagnosis and management of acute left-sided colonic diverticulitis and on the use of colonoscopy after acute left-sided colonic diverticulitis. The ACP issued one recommendation and classified additional guidance as suggestions only.\nRecommendation: In patients with acute left-sided colonic diverticulitis, physicians should not use mesalamine to prevent recurrent diverticulitis.\nSuggestions:\n- Use abdominal\n[CT](/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f)imaging if there is diagnostic uncertainty.\n- Treat patients with acute uncomplicated disease in an outpatient setting.\n- Abstain from antibiotic therapy in select patient groups, including those who are immunocompetent, have no signs of systemic inflammatory response, do not require hospitalization, or are not medically\n[frail].\n- Refer patients for a colonoscopy for detection of colorectal cancer \u2265 6\u20138 weeks after an initial episode of complicated left-sided colonic diverticulitis has resolved (if they have not had a colonoscopy within the past 2 years).\n- Discuss elective surgery to prevent recurrent diverticulitis after initial treatment in patients who have either persistent/frequently recurring uncomplicated diverticulitis or complicated diverticulitis.\nLimitations include that, due to the low quality of the evidence (i.e., there being appreciable uncertainty), the guidelines include only one recommendation (against the use of mesalamine), the rest of the statements being suggestions only.\nThe take\u2011home message?\nIn these first-ever ACP guidelines, the authors, citing the low quality of evidence, issued suggestions rather than recommendations for acute management and follow-up in patients with acute left-sided diverticulitis, including when to use imaging studies, antibiotics, and follow-up colonoscopy and surgery. The only recommendation based on high-quality evidence issued was that against the use of mesalamine to prevent recurrent diverticulitis.\n- Title of study: Diagnosis and Management of Acute Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of Physicians [167]\n- Authors: Qaseem A et al.\n- Journal: Annals of Internal Medicine\n- Title of study: Colonoscopy for Diagnostic Evaluation and Interventions to Prevent Recurrence After Acute Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of Physicians [168]\n- Authors: Qaseem A et al.\n- Journal: Annals of Internal Medicine\n- AMBOSS links:\n[Divertikulitis](/de/wissen/Divertikulose,_Divertikelkrankheit_und_Divertikulitis#Zef9b81a8be3a2511a46e79e9e075b8c7)\nTo screen or not to screen for atrial\n[fibrillation]: 2022 updated USPSTF recommendations\nOne-Minute Telegram 44-2022-2/3 - The USPSTF (an independent expert panel) has commissioned an update to their 2018 recommendations on screening for atrial\n[fibrillation] (Afib) in asymptomatic adults, which yielded the following main results:\nScreening tests:\n- The utility of screening with a 1-time ECG for Afib compared to no screening was inconsistent. Given the low prevalence of undiagnosed subclinical Afib, screening with a 1-time ECG is likely to yield more false-positive than true-positive results.\n- Screening with continuous (for several weeks) or intermittent (twice daily for 2 weeks or 1 year) ECG may increase the probability of detecting Afib compared to no screening.\nBenefits of early detection and treatment through screening:\n- The only recent study powered to detect health outcomes from Afib screening was the STROKESTOP trial, which found no differences in stroke incidence (the originally planned primary outcome) in the screened population compared to the control group. [169]\n- The screened group did have a lower probability of a composite outcome (i.e., ischemic stroke, hemorrhagic stroke, systemic embolism, bleeding leading to hospitalization, and all-cause mortality), but the effect size was small (unadjusted HR, 0.96; 95% CI, 0.92\u20131.00).\nHarms of screening:\n- Studies reviewed found no evidence of increased risk of harmful events (e.g., major bleeding, hospitalization) in the screened population compared to the control groups.\n- However, since these events were rare in both groups, the estimates were imprecise and no definitive conclusion could be reached.\nLimitations include that most of the analyzed studies were from the US and Europe, reducing generalizability.\nThe take\u2011home message?\nThe USPSTF found that, as already in 2018, there was insufficient evidence to recommend for or against screening for asymptomatic Afib in patients aged \u2265 50 years. Of note, the American Heart Association and the American Stroke Association have previously stated that screening for Afib in patients \u2265 65 years may be useful in the primary care setting. [170]\n- Title of study: Screening for atrial\n[fibrillation]: Updated evidence report and systematic review for the US Preventive Services Task Force [171]\n- Authors: Kahwati LC et al.\n- Journal: JAMA\n- Title of study: Screening for atrial\n[fibrillation]: US Preventive Services Task Force recommendation statement [12]\n- Authors: US Preventive Services Task Force\n- Journal: JAMA\n- AMBOSS links:\n[Kardioversion bei Vorhofflimmern](/de/wissen/Vorhofflimmern#Z71ebf59eb644eef509d98bc3d9aff434)\nValentine\u2019s Day edition: Don\u2019t go piercing my heart!\nOne-Minute Telegram 44-2022-3/3 - Valentine's Day is approaching and, as tradition dictates, our thoughts will be revolving once again around sweethearts and heartache. But, as this study shows, Cupid\u2019s leaden arrow may not be the only dart capable of breaking your heart. Researchers set out to describe the cardiac manifestations associated with Hymenoptera stings (e.g., bee, wasp, hornet) using data from electronic medical records from a tertiary care hospital in South India. Within 2 years, thirteen patients with Hymenoptera stings presented to the emergency department, six of whom had cardiac manifestations raising concern for Kounis\n[syndrome] (an [acute coronary syndrome](/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b) that is associated with conditions that cause mast cell activation, e.g., hypersensitivity reactions). Patients with cardiac manifestations had a mean age of 71.7 years, and all had a history of multiple bee stings. Furthermore, all patients had ECG changes and associated [troponin](/de/wissen/Myokardinfarkt#Z76e59820131171b9227851bfd9cc39ba) changes, with most reporting shortness of breath. Only one patient reported chest pain. No patients had [STEMI](/de/wissen/Myokardinfarkt#Za340e577f9ff67b72ee87080e1d8758b), but two patients went into cardiogenic shock. Thankfully, all patients survived. The results highlight the importance of suspecting cardiac complications in patients with Hymenoptera stings, and they put into perspective Cupid's mischievousness: a heartache is the lesser evil compared to a heart attack. [172]\nThe take\u2011home message?\nThis Valentine's Day bee kind to your heart.\nEdition 43 - January 29, 2022\nIs\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) a risk factor for [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)?\nOne-Minute Telegram 43-2022-1/3 - While it stands to reason that individuals with\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) are at increased risk of a severe course with [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7), evidence to support this assumption has been scarce. The present study sought to bridge this knowledge gap by analyzing the Scottish Early Pandemic Evaluation and Enhanced Surveillance of [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) (EAVE II) database. [173]\nAmong the 4,421,663 individuals included in the database between March 1, 2020, and July 27, 2021, the researchers identified 561,279 adults with\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc), 39,253 (7.0%) of which had confirmed [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7). Of these, 4828 (12.3%) were hospitalized, 1600 (4.1%) required ICU treatment, and 1206 (3.1%) died.\nThe rate of hospitalization and the composite outcome of ICU admission or death were higher in patients with\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc), especially those with a recent hospitalization for an [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) attack, compared to patients without [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc). Outcomes were also found to be positively associated with the number of courses of [oral] [corticosteroids](/de/wissen/Nebenniere#Z9a2acbeff6c31eb814158d6ece9b95a1) that patients received in the preceding two years:\n- Hospitalization:\n- All\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc)patients: HR 1.27 (95% CI 1.23\u20131.32)\n- Hospitalization in the 2 years prior: 3.01 (2.59\u20133.49)\n-\n[Oral] [corticosteroids](/de/wissen/Nebenniere#Z9a2acbeff6c31eb814158d6ece9b95a1)in the 2 years prior:\n- \u2265 3 courses 1.54 (1.46\u20131.61)\n- 2 courses: 1.37 (1.26\u20131.48)\n- 1 course: 1.30 (1.23\u20131.37)\n- No courses: 1.15 (1.11\u20131.21)\n- All\n- ICU admission and death\n- All\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc)patients: HR 1.13 (95% CI 1.05\u20131.22)\n- Hospitalization in the 2 years prior: 2.24 (1.56\u20133.20)\n-\n[Oral] [corticosteroids](/de/wissen/Nebenniere#Z9a2acbeff6c31eb814158d6ece9b95a1)in the 2 years prior:\n- \u2265 3 courses 1.44 (1.31\u20131.58)\n- 2 courses: 1.27 (1.09\u20131.48)\n- 1 course: 1.04 (0.93\u20131.16)\n- No courses: 1.06 (0.97\u20131.17)\n- All\nLimitations include a higher rate of\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) testing in adults with [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) compared to those without, which may have been caused by differences in health care seeking behaviors. Furthermore, the study did not directly assess [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) severity or control.\nThe take\u2011home message?\nThis national incident cohort study from Scotland provides evidence that adults with\n[asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) are at an increased risk of [SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3) infection-related hospitalization, ICU admission, and death, especially if they have received \u2265 2 courses of [oral] [corticosteroids](/de/wissen/Nebenniere#Z9a2acbeff6c31eb814158d6ece9b95a1) or have been hospitalized for [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc) within the preceding two years.\n- Title of study: Risk of serious\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)outcomes among adults with [asthma](/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc)in Scotland: a national incident cohort study [174]\n- Authors: Shi T et al.\n- Journal: Lancet Respiratory Medicine\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nHow effective is a\n[booster] with the Pfizer\u2013BioNTech vaccine against the delta variant?\nOne-Minute Telegram 43-2022-2/3 - Israel has been at the forefront of\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) vaccinations and has now published data on the effectiveness of a [booster] dose with the [BNT162b2](/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1) [mRNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b) vaccine (Pfizer-BioNTech).\nData on 4,696,865 persons aged 16 and older who had received two vaccine doses at least 5 months prior was extracted from Israel\u2019s Ministry of Health database for the period between July 30 and October 10, 2021, during which the delta variant of\n[SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3) dominated. The rate of new infections was lower in the [booster] group ( [booster] received \u2265 12 days ago) by a factor of 9.0\u201317.2 (dependent on age group) compared to the non- [booster] group (i.e., those who had received only two vaccine doses) and by a factor of 4.9\u201310.8 compared to the early post- [booster] group ( [booster] received 3\u20137 days ago). The rates of severe illness were lower in the [booster] group by a factor of 21.7 (95% CI, 10.6\u201344.2) in those aged 40\u201359 years and 17.9 (95% CI, 15.1\u201321.2) in those aged 60 years and older. Mortality was lower in the [booster] group by a factor of 14.7 (95% CI, 10.0 to 21.4) in those aged 60 years and older.\nLimitations include that risk-avoidance behaviors and coexisting conditions were not registered and that the delta variant was dominant during the time period analyzed, so that information on the\n[booster]\u2019s effectiveness against the omicron variant is not represented.\nFurthermore, the time to breakthrough infection after completing immunizations was significantly shorter in individuals with immune dysfunction compared to those without immune dysfunction.\nThe take\u2011home message?\nThis analysis showed that a\n[booster] dose of the Pfizer\u2013BioNTech vaccine was highly effective against the delta variant. When comparing persons who had received a third vaccine dose with those who had received only two doses, rates of infection were substantially lower across all age groups, and rates of severe illness and death were substantially lower in older age groups.\n- Title of study: Protection against COVID-Scientific name19 by\n[BNT162b2](/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1) [booster]across age groups [175]\n- Authors: Bar-On YM et al.\n- Journal: NEJM\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nIs\n[fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90) effective in treating multidrug-resistant [E. coli](/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec)?\nOne-Minute Telegram 43-2022-3/3 - The spread of multidrug-resistant (MDR)\n[E. coli](/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec) has been exacerbated by the slow pace in developing newer antibiotics. However, developing new antibiotics may not be the only solution, as researchers are also reconsidering the effectiveness of drugs, like [fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90), that has been on the market for years. [176]\nThis multicenter noninferiority clinical trial analyzed data on 143 patients with bacteremic urinary tract infections due to MDR\n[E. coli](/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec). The patients were randomized 1:1 to receive IV [fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90) or a comparator (ceftriaxone or [meropenem](/de/wissen/Antibiotika_-_\u00dcbersicht#Z71eef8b6d57208d40c345b2f29112e9c) for ceftriaxone-resistant isolates) and treated for 10\u201314 days (with the majority of patients switching to [oral] treatment after 4 days, as allowed per protocol).\nIn the\n[intention-to-treat](/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19) analysis, the primary outcome of clinical and microbiological cure 5 to 7 days after the end of treatment was reached by 68.6% of patients treated with [fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90) and 78.1% of patients treated with a comparator drug, resulting in a risk difference of -9.4% (1-sided 95% CI, -21.5% to \u221e; P=0.1) that failed to meet the prespecified noninferiority criterion of less than -7% risk difference. However, the rates of clinical and microbiological failure with [fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90) vs. comparator were similar (14.3% vs. 19.7%, P=0.19), and the failure to meet noninferiority was mainly due to a higher rate of [adverse event](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c)-related discontinuations among patients treated with [fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90) (8.5% vs. 0%, P=0.006). The most serious [adverse event](/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c) was heart failure which occurred in 6 patients (4 of whom required drug discontinuation) who were all aged over 80 years old and had a medical history of either chronic heart failure or [chronic kidney disease](/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849).\nLimitations include the small sample size and the lack of blinding.\nThe take\u2011home message?\nIn this randomized clinical trial,\n[fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90) narrowly missed noninferiority criteria when compared to ceftriaxone and [meropenem](/de/wissen/Antibiotika_-_\u00dcbersicht#Z71eef8b6d57208d40c345b2f29112e9c) in the treatment of patients with bacteremic urinary tract infections due to multidrug-resistant [E. coli](/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec). However, the data suggest that [fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90) may be an effective alternative to ceftriaxone or [meropenem](/de/wissen/Antibiotika_-_\u00dcbersicht#Z71eef8b6d57208d40c345b2f29112e9c) in select patients, e.g., those with allergies to other antibiotics or low risk of sodium overload from intravenous [fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90).\n- Title of study: Effectiveness of\n[fosfomycin](/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90)for the treatment of multidrug-resistant [Escherichia coli](/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec)bacteremic urinary tract infections: A randomized clinical trial [177]\n- Authors: Sojo-Dorado J et al.\n- Journal: JAMA Network Open\n- AMBOSS Links:\n[Urozystitis](/de/wissen/Urozystitis#Zaa43cef15b87ed9d03c1b383c48b2284)\nEdition 42 - January 15, 2022\nHow effective are\n[mRNA](/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b) vaccines in preventing hospitalizations due to the omicron variant?\nOne-Minute Telegram 42-2022-1/3 - Population-based studies have suggested that the omicron (\n[B.1.1.529](/de/wissen/COVID-19#Z818a161a9af87d1ad3b8925c620cdf0e)) variant can evade immunity from prior infection and vaccination. [178] Whether this influences the hospitalization rates due to [COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7) is an important question that investigators are just beginning to answer.\nThis retrospective study was conducted in a South African population and was based on healthcare data. The effectiveness of the\n[BNT162b2](/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1) vaccine against hospitalizations was estimated during the period when the delta variant was predominant (September 1 to October 31; proxy delta period) and during the period when the omicron variant was predominant (November 15 to December 7; proxy omicron period).\nIn total, 133,437\n[PCR](/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca) tests were considered during the proxy delta period, and 78,173 tests were considered during the proxy omicron period.\n- Overall test positivity (independently of vaccination status):\n- 24.4% during the proxy omicron period\n- 6.4% during the proxy delta period\n- Test positivity among the fully immunized (\u2265 14 days after the second dose of\n[BNT162b2](/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1)vaccine):\n- 33% during the proxy omicron period\n- 8.2% during the proxy delta period\n- Proportion of hospitalized patients with a positive\n[PCR](/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca)who were fully immunized:\n- 28.2% during the proxy omicron period\n- 8.3% during the proxy delta period\n- Vaccine effectiveness to prevent hospitalization:\n- 70% (95% CI, 62 to 76) during the proxy omicron period\n- 93% (95% CI, 90 to 94) during the proxy delta period\nLimitations include that this study analyzed a single community (restricting generalizability), and that it did not include information on the severity of the disease in those patients who were hospitalized.\nThe take\u2011home message?\nIn this population-based, retrospective study, two doses of the\n[BNT162b2](/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1) (Pfizer\u2013BioNTech) vaccine was 70% effective in preventing hospitalization during the omicron period, which was lower than the estimated effectiveness during the delta period (93%). This highlights the importance of [booster] dosages and development of variant-specific vaccines.\n- Title of study: Effectiveness of\n[BNT162b2](/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1)vaccine against omicron variant in South Africa [179]\n- Authors: Bekker LG et al.\n- Journal: NEJM\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nBreakthrough infections after\n[SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3) vaccination in patients with immune dysfunction\nOne-Minute Telegram 42-2022-2/3 - Persons with a weakened immune system were excluded from the initial\n[SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3) vaccine effectiveness trials. To bridge this evidence gap, this retrospective cohort study analyzed the risk for breakthrough infections in partially and fully vaccinated patients with immune disorders (i.e., [HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604) infection, multiple sclerosis, rheumatoid arthritis, solid organ transplant, and bone marrow [transplantation](/de/wissen/Transplantation#Zdf6ba0c07310d1c961cdfe548595db6f)) from December 10, 2020, to October 14, 2021.\nData were obtained from the National Covid Cohort Collaborative (N3C), which provided information on 664,722 partially and fully vaccinated individuals. Out of this sample, a total of 35,512 patients with an immune disorder were identified.\n- The overall breakthrough infection rate (IR) in fully immunized individuals was 5.0 per 1000 person-months.\n- Compared to individuals with full vaccination and without immune dysfunction, the overall incidence of breakthrough infection was higher in individuals with an immune dysfunction:\n- Individuals without immune dysfunction: IR of 7.1 per 1000 person-months\n- Individuals with solid organ transplant: 15.7 per 1000 person-months\n- Individuals with rheumatoid arthritis: 9.3 per 1000 person-months\n- Individuals with\n[HIV](/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604)infection: 9.1 per 1000 person-months\n- Individuals with multiple sclerosis: 8.9 per 1000 person-months\n- Individuals with bone marrow transplant 8.6 per 1000 person-months\nFurthermore, the time to breakthrough infection after completing immunizations was significantly shorter in individuals with immune dysfunction compared to those without immune dysfunction.\nLimitations include that vaccinations received outside the hospital setting may have been underreported.\nThe take\u2011home message?\nThis trial provides evidence that vaccinated individuals with compromised immune systems are at higher risk for breakthrough infections with\n[SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3). This emphasizes the importance of mask-wearing and social distancing, and the need to investigate additional measures such as [booster] vaccinations in this population.\n- Title of study: Association between immune dysfunction and\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)breakthrough infection after [SARS-CoV-2](/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3)vaccination in the US [180]\n- Authors: Sun J et al.\n- Journal: JAMA Internal Medicine\n- AMBOSS Links:\n[COVID-19](/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7)\nDoes cataract surgery decrease the risk of dementia?\nOne-Minute Telegram 42-2022-3/3 - Visual impairment may contribute to cognitive decline in older individuals, but whether surgery to restore vision can delay the onset of dementia has not been thoroughly investigated. [181]\nIn this prospective, longitudinal nonrandomized cohort study, 3038 participants aged 65 years or older with cataract or glaucoma and no signs of dementia were screened every two years for the onset of dementia.\nParticipants who received a cataract extraction (n = 1382) had a reduced risk of dementia compared to those who did not (n = 1656; HR 0.71; 95% CI, 0.62\u20130.83). However, the effect was not observed in participants with glaucoma who received glaucoma surgery vs. those who did not (n = 728; HR, 1.08; 0.75\u20131.56).\nLimitations include the nonrandomized nature of the study and the possibility of coding errors due to the indications for surgery as well as the diagnoses of cataract and glaucoma having been extracted from electronic medical records. Furthermore, 91% of study participants were self-reported White race, limiting generalizability to other populations.\nThe take\u2011home message?\nWhile cataract surgery, which restores vision, appears to reduce the risk of dementia in older individuals, the same effect was not observed in participants who received glaucoma surgery, which does not restore vision. This corroborates the association of vision loss and dementia, suggesting new paths for prevention of cognitive decline.\n- Title of study: Association between cataract extraction and development of dementia [182]\n- Authors: Lee CS et al.\n- Journal: JAMA Internal Medicine", "language": null, "image": "https://manus-media.amboss.com/pa-images/facebook-preview-1.jpg", "pagetype": "website", "links": ["https://www.amboss.com", "https://www.amboss.com/de/account/register?nextLink=%2Farticle%2FPu0Wr3", "https://www.amboss.com/de/account/login?nextLink=%2Farticle%2FPu0Wr3", "https://www.amboss.com/de/account/register", "https://www.amboss.com/de/disclaimer", "/de/wissen/Ohr#Z2e6489810ab8a5524d8534501fcab9be", "/de/wissen/One-Minute_Telegram_Archiv_2021#Zedc2f5a9b0e39469c09137ff9a4dcb1e", "/de/wissen/One-Minute_Telegram_Archiv_2020#Ze765573a3b5d8aa28f098b044fb31e6e", "/de/wissen/One-Minute_Telegram_Archiv_2022#Zf711b4870ad13181acb218f8fd0622f2", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z355dd0b48218ecfed69684867197617d", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z082a198bfd1623e0f33a6bc551593706", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", null, "/de/wissen/One-Minute_Telegram_Archiv_2022#Zd95085b87e17463a84517e38b3969fe5", null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z2ef2e61010b49cf63cdedddd29e9f47e", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/One-Minute_Telegram_Archiv_2022#Zae733a415ab7ec45063f7531ca946121", "/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Allgemeine_Endokrinologie#Z5f7d7972b934850e5dc5e2efdb60e476", "/de/wissen/Klimakterium#Z6968f8f221cf989eebc438d5fde47c8e", "/de/wissen/Klimakterium#Zac4b020fde98661beb72a24ef0b8c067", "/de/wissen/Sexualhormone#Z3125e0c64f510742be94df34078cd5d7", "/de/wissen/Klimakterium#Zac4b020fde98661beb72a24ef0b8c067", "/de/wissen/Sexualhormone#Z3125e0c64f510742be94df34078cd5d7", null, "/de/wissen/Schlafbezogene_Atmungsst\u00f6rungen#Zaebb63000e831edd3e9c58bf2efbbd9e", "/de/wissen/Schlafbezogene_Atmungsst\u00f6rungen#Zaebb63000e831edd3e9c58bf2efbbd9e", "/de/wissen/Syphilis#Z2978df89d56acd6a80ead95a0b83e30d", "/de/wissen/Syphilis#Z2978df89d56acd6a80ead95a0b83e30d", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Isch\u00e4mischer_Schlaganfall#Z6e7c1441e1326e8a7ff985260cd12d31", "/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266", "/de/wissen/Schlafbezogene_Atmungsst\u00f6rungen#Zaebb63000e831edd3e9c58bf2efbbd9e", "/de/wissen/Syphilis#Z2978df89d56acd6a80ead95a0b83e30d", "/de/wissen/Klimakterium#Z6968f8f221cf989eebc438d5fde47c8e", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", null, "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Grundlagen_der_Reanimation#Z56dd86d31686ff69493223c49fc7e4c6", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", "/de/wissen/Kammerflattern_und_-flimmern#Z5002c993f89f145d9abc89b7718e10cd", "/de/wissen/Herzrhythmusst\u00f6rungen#Z0adf32b5318acb24e79e61cb74b19e5a", "/de/wissen/Grundlagen_der_Reanimation#Z2eec26f6bbfd145d133e7674ac992bd5", "/de/wissen/Grundlagen_der_Reanimation#Z80fec1741f2c473afd7e79f3850c01c7", null, "/de/wissen/Allgemeine_Onkologie#Z96dbcb525ee590dbfa7e193aeb93cb24", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de", "/de/wissen/Arzt-Patient-Beziehung#Z7566eec9f8d0ee04b7494fddfdf78e42", "/de/wissen/Untersuchung_und_Gespr\u00e4ch#Z1f3539196e38cec918c8e608227e5627", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Z93dedd171a6efaddb5d27c931860ee21", "/de/wissen/\u00dcbersicht_Geriatrie#Z1184db8a6ce52feb7970e8cbc965742e", "/de/wissen/Demenz#Z550bcfc577560faea37bbddda0e01e7b", "/de/wissen/Morbus_Alzheimer#Z355d10c7e7f39ad060b2a6c28268f874", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z0bcf219f7dd2c28bf4e24b8581e76e81", "/de/wissen/Allgemeine_Parasitologie#Z800da2c0c51c6f64339721abecbdf95a", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", null, null, "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", null, null, "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Malaria#Zbf5a231c10fbf07ba7c213e2dd494d1f", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Menstruationszyklus_und_Zyklusanomalien#Z283c4dff28dc7e7c4c5131a8a539d187", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z34d41b30a792b17afcdd32b43ce85f19", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Menstruationszyklus_und_Zyklusanomalien#Za9dde6254dc902b890e9b4bf33be57b8", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Allgemeine_Virologie#Zd33e47448cef27ccc69577a4a25749a9", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", null, "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, null, "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z9faede06af720d5eefc8282fbea07721", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zf1157dfb62b05f3e741ccd036588d15f", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z22bbeb78e62fcd17cbdcc573e8ff87cd", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z5c892255c4fb7d1881dd4e503d8aad18", "/de/wissen/\u00dcbersicht_des_Verdauungssystems#Zaa3f0692fb4127b17e934892e975ec10", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zf1157dfb62b05f3e741ccd036588d15f", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z22bbeb78e62fcd17cbdcc573e8ff87cd", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z5c892255c4fb7d1881dd4e503d8aad18", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zf1157dfb62b05f3e741ccd036588d15f", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z5c892255c4fb7d1881dd4e503d8aad18", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z22bbeb78e62fcd17cbdcc573e8ff87cd", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Perioperatives_Management#Z3a7bd0c1bd5a355d4ac6d1ae3fc9717c", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc", null, "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc", "/de/wissen/Blutgerinnung_und_h\u00e4morrhagische_Diathesen#Z46b0c948d5f6dc94d213b58c18037670", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc", "/de/wissen/Blutgerinnung_und_h\u00e4morrhagische_Diathesen#Z46b0c948d5f6dc94d213b58c18037670", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Z7d350957bfc20f511eb53f8d589b8adc", "/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Vitamin-K-Antagonisten_und_direkte_orale_Antikoagulanzien#Zfb1cda072cc01083f54cf4994cb89911", null, null, "/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a", "/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de", "/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a", null, "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266", "/de/wissen/Elektrolytst\u00f6rungen_Kalium#Z946655e8d52337a1e834b7224308cea4", "/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a", "/de/wissen/Laboratoriumsmedizin#Zbb8375deba4850bda2ecad81d8dcdb10", "/de/wissen/Laboratoriumsmedizin#Zf9be1a2cd69e5462e03f10aee4604b96", "/de/wissen/Laboratoriumsmedizin#Zd9645d3e1b61cd1f72076a85667c1e3a", null, null, null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", null, null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", null, null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, null, "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", null, null, "/de/wissen/Unipolare_Depression#Z1306410c7b9121ddcd89ca401566a5ed", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Unipolare_Depression#Z992ea889338baceb63e016ee83bfc473", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Kolonpolypen#Z7d836a80066e57b74c74add53eea2731", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/Hand#Zbec311d267e59b3560e01b78c0e2b870", "/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b", "/de/wissen/Wundbehandlung#Z762a7005d27ad3b5c668c1c1464d21a1", "/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Zef26c06cb65b06456ccd4c6763eda385", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Nicht-Opioid-Analgetika#Z1929fda1e1db3ec2e22e43bf2db50c3d", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", null, "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z9f4a33561601fe529f3c7dfbe30ba130", "/de/wissen/Schmerztherapie#Zb6afc2d58dceca8cf94c49d2488655a7", "/de/wissen/Schmerztherapie#Z96e267f8c130a28a13641263162bf5d5", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Signaltransduktion#Z1fd25aa0c628bffbc87aca80bc99759d", null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Zed86c2e393675ed178e06abfbbb3f4bc", "/de/wissen/Antibiotika_-_\u00dcbersicht#Zed86c2e393675ed178e06abfbbb3f4bc", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Z58bcc7711752096ecca5b2bfd6b56f92", "/de/wissen/Suizidalit\u00e4t#Z090c4f23b9ddf810e4921befa5d31468", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z865d37347a16e85f2cb7f1265b6c766b", "/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98", "/de/wissen/Antidiabetika#Z61dd0ba2238ee701aa5ef71a72f52d43", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98", "/de/wissen/Antidiabetika#Z61dd0ba2238ee701aa5ef71a72f52d43", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/Antidiabetika#Z507fd3b1c402711573658092f4e03f98", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Antidiabetika#Z61dd0ba2238ee701aa5ef71a72f52d43", "/de/wissen/Diabetes_mellitus#Zafd99d5f511edbccb9b7e30f02978af4", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Arthrose#Z02ddc3c6fe4fae13fc187533ee2e65ba", "/de/wissen/One-Minute_Telegram_Archiv_2022#Zf5c4ddaf1a8881d5d1237ecf2a8aede3", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z73dc9dd39e0d7e100513ef4b19a69ee3", "/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z7f8f958f877813a83e2388e630e74695", "/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z51ecbae767f453990a5f850451916dd2", "/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c", "/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z03e4363950b8f023d5c14bddabeeec06", "/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b", "/de/wissen/One-Minute_Telegram_Archiv_2022#Ze758a4bd3263bafdeb559d13f4a30e11", "/de/wissen/One-Minute_Telegram_Archiv_2022#Zcdaae1ceb4ae92b3c880994fec0298f1", "/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Isch\u00e4mischer_Schlaganfall#Z132d7774d1cef997981d05c36a439551", "/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/RAAS-Inhibitoren#Z4cb19ed9db989ac77a27bb618fe50541", "/de/wissen/Lipidsenker#Zc0c8744cee387048609bafe6c953e2dd", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Isch\u00e4mischer_Schlaganfall#Z132d7774d1cef997981d05c36a439551", "/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Vorhofflimmern#Ze8f59c6fdb873abb8b66b786d0397266", null, "/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187", "/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187", "/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187", null, "/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187", "/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187", null, "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/Alkohol_(Intoxikation_und_Abh\u00e4ngigkeit)#Z52baf857a1289ec95344be1a8fe96f59", "/de/wissen/Halluzinogene_(Intoxikation_und_Abh\u00e4ngigkeit)#Z85f01850d4920624b07f9373073a8187", null, "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zd0459584edd44b5da8fb1e7b193d633e", "/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1", "/de/wissen/Myokardinfarkt#Z05d22ce34ae3c47e1ae4298d65578dca", "/de/wissen/Lipidsenker#Zd0a8cd906313c9da1ec7e9bcbbe94d4b", "/de/wissen/Lipidsenker#Zc145351a2741c9a7a6170cb206eb6c25", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Stressmodelle#Z6c7eef5a913c582156005f60a0dd88f1", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/Stressmodelle#Z6c7eef5a913c582156005f60a0dd88f1", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Stressmodelle#Z6c7eef5a913c582156005f60a0dd88f1", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d", "/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/Grundlagen_der_Reanimation#Z2eec26f6bbfd145d133e7674ac992bd5", "/de/wissen/Sympathomimetika#Z6442693651a822abad73b1bdad02cb7d", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Metabolisches_Syndrom#Zef9b1fe4e2f7f7f318f55631b1f02f85", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Terminologie#Zbdfd278a2badf97a52d598dc2cd2c497", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", null, "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Terminologie#Zbdfd278a2badf97a52d598dc2cd2c497", "/de/wissen/Terminologie#Zbdfd278a2badf97a52d598dc2cd2c497", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b", "/de/wissen/Opioide_(Intoxikation_und_Abh\u00e4ngigkeit)#Z2617c4a1c8650f5bf241213ea0311b58", "/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/Opioide#Z932f6ac6614fddfe1977e37d73b7d7ec", "/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c", "/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c", "/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca", "/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Sexuell_\u00fcbertragbare_Infektionen#Zf2a474fc86c5ef68694e80ca13cd405b", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb0d0a6354852d24efe462b33bd4690de", "/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c", null, null, "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Sammelsurium_der_Infektiologie#Zfb76f7c955a22445707566f15640e73c", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", "/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", null, "/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa", "/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa", "/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa", "/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", "/de/wissen/Ovar#Zf501ebe24e53be4f8ec6c197362570fa", "/de/wissen/Hormonelle_Kontrazeption#Za19481f4cd7a29d21f9d72b952de9c87", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", null, null, null, "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", null, "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Vitamine#Z6be0176b39350d4af3964fc26f431f84", "/de/wissen/Multiple_Sklerose#Zfc37457ca8f0aea91134b8e6e325e935", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", "/de/wissen/Vitamine#Z6ff1b6359e20f0dbe35655f2aff6154c", "/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d", "/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d", "/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d", "/de/wissen/Vitamine#Zcc3966fa2cc78ee4586d724bcc14e03d", "/de/wissen/Vitamine#Z6ff1b6359e20f0dbe35655f2aff6154c", "/de/wissen/Vitamine#Z6ff1b6359e20f0dbe35655f2aff6154c", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b", "/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d", "/de/wissen/Epileptische_Anf\u00e4lle_und_Epilepsien#Z93dedd171a6efaddb5d27c931860ee21", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", null, null, "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Allgemeine_Virologie#Z2d8a26ce69ee816e9fdf5fd41592c981", "/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b", "/de/wissen/Hepatitis_C#Zea41d9f610b41c8bcb1377f59e4ff96b", "/de/wissen/Schwangerschaftsabbruch#Z4c5fe8d3f0dfa9acf4e0963adf0f9782", "/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27", "/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab", "/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab", "/de/wissen/Sterilit\u00e4t,_Infertilit\u00e4t_und_Impotenz#Z28cfbff24bb8492ec860a3ae467441ab", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z87e9a247724c9b2410076167606f4c20", "/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056", "/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", null, "/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056", null, "/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056", null, "/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e", "/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", null, null, "/de/wissen/Vitamine#Z1f2b7d076337a086cf8032ec94b59056", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", null, "/de/wissen/Arterielle_Hypertonie#Z3d73ccc1b405184a8d3087bd8b727eb4", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", null, "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", null, "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", null, null, "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Kohlenhydrate#Z7444cdfd18d587802aa4ad63a0f6da57", null, "/de/wissen/Antidiabetika#Z844473d0d0277bb5630f7ad66be085c0", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z9cddb4f57b545c1e4012ae886616c95e", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z27e295d8a27c2c3b67c2e8e99f51dc05", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb", "/de/wissen/One-Minute_Telegram_Archiv_2022#Zbbbf3249eb39e520bb070a2bbcfa291f", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z57dc066e31fde74306d081b357368ca5", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z7592f5f262fd375963fb843027ec13c6", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/Studientypen_der_medizinischen_Forschung#Za32c4b865a6b42d97c485db50e405ab0", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/Unipolare_Depression#Zb41ceebc50587ff5a2f360f3ca255f70", "/de/wissen/Arzt-Patient-Beziehung#Ze9cc0bcf462357fd49f54a85760dde5e", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", null, null, null, "/de/wissen/Audiometrische_Verfahren_in_der_HNO#Z7557366df45a5d8254c0fba4a82c9b27", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/S\u00e4ure-Basen-Haushalt#Zb05ef5c16afed1435f1625918811375f", "/de/wissen/Perioperatives_Management#Z3a7bd0c1bd5a355d4ac6d1ae3fc9717c", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e", null, null, "/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b", "/de/wissen/Thoraxschmerz#Z9da5bbffd83806c9e96cd8e0913f92ef", "/de/wissen/Koronare_Herzkrankheit#Zfbf6e89e4c99b090c46d60c93fdd8ff1", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb", "/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb", null, null, null, "/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f", null, null, null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", "/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb", null, "/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb", null, "/de/wissen/Spezifisches_Immunsystem#Z19d82223ef9a0aaa29370a30dba188fb", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Akute_Nierensch\u00e4digung#Zdff233a18555ad0f8f0c208c072da6e4", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", null, "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", null, null, null, null, "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Medikamente_gegen_Husten_und_bronchiale_Obstruktion#Z3f6dd950678a8bcdd0077eab31629f32", null, "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Studientypen_der_medizinischen_Forschung#Z1e0580d334bc09a6165af18f833e9a28", null, "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", null, "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", null, "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", null, "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", null, "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Thrombozytenaggregationshemmer#Z2bf6095ed24962e2237f2691a98fca66", "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Zafe24f854a0196c868effeadc82d6c2c", "/de/wissen/Kolorektales_Karzinom#Z101c980042ecc72a0afd58974673eed7", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Psychotherapeutische_Verfahren_(Klinik)#Ze4c5a7bc0f8094b3f645dae5659e34c0", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Diabetes_mellitus#Z206684328d43bdbe4a41b4993a8b8261", null, null, "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", null, null, "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Lipide#Zff6f4fd80161180060c203429a9a9536", "/de/wissen/Cholesterin#Z0384844f074a4123ce72fa1ff809ee92", "/de/wissen/Insuline#Z9f9bd1a83be14cff5df0a9b232d98fce", "/de/wissen/Lipide#Z7ea70ee2b0932ba258e1b9325987b163", "/de/wissen/Cholesterin#Z0384844f074a4123ce72fa1ff809ee92", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/Metabolisches_Syndrom#Zef9b1fe4e2f7f7f318f55631b1f02f85", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Glucocorticoide#Z927c067ed977050973f887ebb7bbd151", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z29bfa453b270bf9d5df2a9deec02645f", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Patientenlagerung_im_OP#Z6e35e6d036966b6e4fd2f962e7223e54", "/de/wissen/Stressmodelle#Z6c7eef5a913c582156005f60a0dd88f1", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Allgemeinan\u00e4sthesie#Zea846d3465d1a392fbf008b5131bf900", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Patientenlagerung_im_OP#Z6e35e6d036966b6e4fd2f962e7223e54", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Angewandte_Statistik#Z5b4c61ad31f494b7fe6dd62ed480cba7", "/de/wissen/Epidemiologie_und_Wahrscheinlichkeiten#Z12841ac5900343a9f0d2dffc6438260c", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Atemwege_und_Lunge#Zbffa82a865686699ed8a6fc3276b5293", "/de/wissen/Patientenlagerung_im_OP#Z6e35e6d036966b6e4fd2f962e7223e54", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f", "/de/wissen/Medizinische_Statistik_und_Testtheorie#Z59e31e2861112feed228cdcd9631f60e", "/de/wissen/Nierenersatzverfahren#Z6289f9bf0b468450f183c4371b8a97c2", "/de/wissen/Nosokomiale_Infektionen#Za5a553ef57f8f6efb10b91f86ac27d52", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Metabolisches_Syndrom#Z012e2e49483585b4280dc450c5c88d04", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Fieber_und_Entz\u00fcndungsreaktionen#Z235452171038aa98be581b158d73eef1", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Studientypen_der_medizinischen_Forschung#Zb4262971e106e4799561831435f78cd1", null, "/de/wissen/Atherosklerose_und_kardiovaskul\u00e4re_Pr\u00e4vention#Z1622eb60ccc420a80a03c7ffa7579ed8", "/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed", null, "/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, null, "/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Allgemeine_Parasitologie#Za755b40c6d9709948beaf66cb51863ed", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/One-Minute_Telegram_Archiv_2022#Zfdb56825a57d0b0fc88f04a699909709", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z7acf43ad9082d39607862da0872c2acf", "/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/One-Minute_Telegram_Archiv_2022#Zb3ca4a5369213fe90b766e280110f2e3", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d", "/de/wissen/Aminos\u00e4uren_und_Proteine#Z6760651e0606c30942f14701885fce12", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19-Impfstoffe#Zac3bd4e161d94c3206a8aa61a4193fc3", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/One-Minute_Telegram_Archiv_2022#Z86857a958faf86ff5918411353031e6f", null, "/de/wissen/One-Minute_Telegram_Archiv_2022#Zcbca50c081dd26cf58a83ea57066fc9e", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec", "/de/wissen/One-Minute_Telegram_Archiv_2022#Zadcaa56aee4c724771a39432fa4e4a53", "/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/COVID-19#Z818a161a9af87d1ad3b8925c620cdf0e", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/COVID-19-Impfstoffe#Ze43273a125bb8a84da0f17f0afdd6cb0", "/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b", "/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1", "/de/wissen/COVID-19-Impfstoffe#Zded93a359e7ea86b7766237f21b4b42a", null, null, null, null, null, null, null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19-Impfstoffe#Ze43273a125bb8a84da0f17f0afdd6cb0", null, "/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b", "/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/COVID-19#Z818a161a9af87d1ad3b8925c620cdf0e", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Niere#Zec9db35c8000414a143d6d13865e492f", "/de/wissen/Fl\u00fcssigkeits-_und_Volumentherapie#Z87e9a247724c9b2410076167606f4c20", null, null, "/de/wissen/Allgemeine_Onkologie#Z96dbcb525ee590dbfa7e193aeb93cb24", "/de/wissen/Gesetzliche_Krankenversicherung#Z07c6fe7783c09554a5f967aa95baadcf", "/de/wissen/Mammakarzinom#Zd6f1c1662017c7aba756050900de29a5", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Hepatitis_B_und_HBV-Infektion#Z0cc1ba9a62130e5544df273f6b9fb8aa", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/Allgemeine_Virologie#Zf1cb8aa6863e4655a8fef04d1bfc005f", "/de/wissen/Allgemeine_Virologie#Zf1cb8aa6863e4655a8fef04d1bfc005f", null, "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Influenza#Za72c6651780a156d4f79b3975508d09a", "/de/wissen/Influenza#Za72c6651780a156d4f79b3975508d09a", "/de/wissen/Herpes_zoster#Z3931bebadc321aba40d6b0dd818663e7", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/Windpocken#Zdf8d7df5776aab061bd719ff8a029345", "/de/wissen/Hepatitis_A#Z121c9271bef15b6d00bfe6be3a04ec32", null, "/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307", "/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307", "/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307", "/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16", null, "/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16", "/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307", "/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16", "/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16", "/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307", "/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16", "/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16", "/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16", "/de/wissen/Protonenpumpenhemmer#Z1a261423d7711ff93a21677b3f0ecc16", null, "/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307", "/de/wissen/Ohr#Z2e6489810ab8a5524d8534501fcab9be", "/de/wissen/Gastro\u00f6sophageale_Refluxkrankheit#Z89068c46b5e7a2b542fbb1d5467c7307", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Isch\u00e4mischer_Schlaganfall#Z4b57583b8491f668d90c29037dcf5fd5", null, null, "/de/wissen/Myokarditis#Zf2d8a0d86bbd2561839fe616b5b1a3c0", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d", "/de/wissen/Leber#Z7346e666b4aff9a5c5eefeed844aed78", "/de/wissen/Aufbau_von_DNA_und_RNA#Z7a75d43207f7f53a3a6b7a9a01d9225d", "/de/wissen/Aufbau_von_DNA_und_RNA#Zde5024dfafa13379e580abaf073d8dba", "/de/wissen/Grundlagen_der_Mikrobiologie_und_Virologie#Zef93c9a12b4d6394ec16bdd4e2ec8870", "/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d", null, "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Zda1db5cf572ca5a98564686ad538d47d", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Aminos\u00e4uren_und_Proteine#Z6760651e0606c30942f14701885fce12", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19-Impfstoffe#Zac3bd4e161d94c3206a8aa61a4193fc3", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b", "/de/wissen/COVID-19-Impfstoffe#Zac3bd4e161d94c3206a8aa61a4193fc3", "/de/wissen/Aminos\u00e4uren_und_Proteine#Z6760651e0606c30942f14701885fce12", "/de/wissen/Allgemeine_Onkologie#Zc921888bd82ae63d81e2094ef067f0fd", null, null, null, "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Angewandte_Statistik#Z7c0546fc00695bf5211ab50534e91c9b", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Myokarditis#Zf2d8a0d86bbd2561839fe616b5b1a3c0", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/COVID-19-Impfstoffe#Zac3bd4e161d94c3206a8aa61a4193fc3", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/Patientenversorgung_und_Gesundheitssystem#Z9c24089e9b15284c931c20e196ceb36f", "/de/wissen/COVID-19-Impfstoffe#Z7f362fdcfafe10f6e62547d8ea247b21", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Sepsis#Za8342184d7234f30c85377d399badd38", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Kardiotokografie_(CTG)#Z2e7e2d1776c1d22f8722ebdfa4ddd293", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Computertomografie#Zecdffa20151afe8aa683e7171639f78f", null, "/de/wissen/Divertikulose,_Divertikelkrankheit_und_Divertikulitis#Zef9b81a8be3a2511a46e79e9e075b8c7", null, null, null, null, "/de/wissen/Vorhofflimmern#Z71ebf59eb644eef509d98bc3d9aff434", null, "/de/wissen/Akutes_Koronarsyndrom#Zbe5972fcd82d1288eb0fda7ed447f69b", "/de/wissen/Myokardinfarkt#Z76e59820131171b9227851bfd9cc39ba", "/de/wissen/Myokardinfarkt#Za340e577f9ff67b72ee87080e1d8758b", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", null, "/de/wissen/Nebenniere#Z9a2acbeff6c31eb814158d6ece9b95a1", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", null, "/de/wissen/Nebenniere#Z9a2acbeff6c31eb814158d6ece9b95a1", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", null, "/de/wissen/Nebenniere#Z9a2acbeff6c31eb814158d6ece9b95a1", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", null, "/de/wissen/Nebenniere#Z9a2acbeff6c31eb814158d6ece9b95a1", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Asthma_bronchiale#Z09f1d7b945958db2feebe65cebc534dc", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", null, "/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1", "/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", null, null, null, null, null, null, null, null, null, "/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec", "/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z71eef8b6d57208d40c345b2f29112e9c", null, "/de/wissen/Studientypen_der_medizinischen_Forschung#Z12db0a61af1774ca03f632559492fe19", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Qualit\u00e4tsmanagement#Z4819640973dcff73dbf583f1b61eae1c", "/de/wissen/Chronische_Nierenerkrankung#Z82e04c31a8143498765bfb4bcb9af849", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z71eef8b6d57208d40c345b2f29112e9c", "/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z71eef8b6d57208d40c345b2f29112e9c", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Antibiotika_-_\u00dcbersicht#Z4de70e528e0c28f8f6f1de29ba280c90", "/de/wissen/Systematik_der_Bakterien#Z8ffd946870f3b9162976bf75f9dd5aec", "/de/wissen/Urozystitis#Zaa43cef15b87ed9d03c1b383c48b2284", "/de/wissen/Aufbau_von_DNA_und_RNA#Z142a614657f247ff87052228c243de8b", "/de/wissen/COVID-19#Z818a161a9af87d1ad3b8925c620cdf0e", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1", "/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca", "/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1", "/de/wissen/Biochemische_Labormethoden#Z88118df3c49e8662ff7a8ff979911bca", "/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1", null, "/de/wissen/COVID-19-Impfstoffe#Zd5a3aa139970672efde6e1e3d651cad1", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/Transplantation#Zdf6ba0c07310d1c961cdfe548595db6f", "/de/wissen/HIV-Infektion#Ze7d02f019433d2bd6e8c9164f9e84604", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", null, "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "/de/wissen/COVID-19#Za0abd91853146a79d53946ed3db633d3", "/de/wissen/COVID-19#Z133b5d6becb618171a9722fa816a56d7", "https://dx.doi.org/10.7326/m21-2710", "https://read.qxmd.com/doi/10.7326/m21-2710", "https://dx.doi.org/10.7326/m21-2711", "https://read.qxmd.com/doi/10.7326/m21-2711", "https://dx.doi.org/10.1016/s0140-6736(21)01637-8", "https://read.qxmd.com/doi/10.1016/s0140-6736(21)01637-8", "https://dx.doi.org/10.1161/str.0000000000000046", "https://read.qxmd.com/doi/10.1161/str.0000000000000046", "https://dx.doi.org/10.1001/jama.2021.21811", "https://read.qxmd.com/doi/10.1001/jama.2021.21811", "https://dx.doi.org/10.1001/jama.2021.23732", "https://read.qxmd.com/doi/10.1001/jama.2021.23732", "https://dx.doi.org/10.1016/j.ajem.2021.08.003", "https://read.qxmd.com/doi/10.1016/j.ajem.2021.08.003", "https://dx.doi.org/10.1017/s0033291705006264", "https://read.qxmd.com/doi/10.1017/s0033291705006264", "https://dx.doi.org/10.1111/jgs.12607", "https://read.qxmd.com/doi/10.1111/jgs.12607", "https://dx.doi.org/10.1176/ajp.141.11.1356", "https://read.qxmd.com/doi/10.1176/ajp.141.11.1356", "https://dx.doi.org/10.14283/jpad.2019.51", "https://read.qxmd.com/doi/10.14283/jpad.2019.51", "https://dx.doi.org/10.1093/geronj/37.3.323", "https://read.qxmd.com/doi/10.1093/geronj/37.3.323", "https://dx.doi.org/10.1056/evidoa2200121", "https://read.qxmd.com/doi/10.1056/evidoa2200121", "https://dx.doi.org/10.1016/s0140-6736(15)60721-8", "https://read.qxmd.com/doi/10.1016/s0140-6736(15)60721-8", "https://www.clinicaltrials.gov/ct2/show/NCT05400655", "https://dx.doi.org/10.1056/nejmoa2206966", "https://read.qxmd.com/doi/10.1056/nejmoa2206966", "https://dx.doi.org/10.1080/26410397.2021.1911618", "https://read.qxmd.com/doi/10.1080/26410397.2021.1911618", "https://dx.doi.org/10.1016/j.rcpeng.2020.05.001", "https://read.qxmd.com/doi/10.1016/j.rcpeng.2020.05.001", "https://dx.doi.org/10.1097/aog.0000000000005010", "https://read.qxmd.com/doi/10.1097/aog.0000000000005010", "https://dx.doi.org/10.1161/cir.0000000000000351", "https://read.qxmd.com/doi/10.1161/cir.0000000000000351", "https://dx.doi.org/10.1161/jaha.121.024199", "https://read.qxmd.com/doi/10.1161/jaha.121.024199", "https://dx.doi.org/10.1016/s1473-3099(21)00460-6", "https://read.qxmd.com/doi/10.1016/s1473-3099(21)00460-6", "https://dx.doi.org/10.1136/bmj-2021-069676", "https://read.qxmd.com/doi/10.1136/bmj-2021-069676", "https://dx.doi.org/10.1016/j.kint.2020.04.046", "https://read.qxmd.com/doi/10.1016/j.kint.2020.04.046", "https://dx.doi.org/10.1016/j.kint.2021.05.015", "https://read.qxmd.com/doi/10.1016/j.kint.2021.05.015", "https://dx.doi.org/10.1001/jamanetworkopen.2022.26191", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2022.26191", "https://dx.doi.org/10.1001/jamainternmed.2022.3050", "https://read.qxmd.com/doi/10.1001/jamainternmed.2022.3050", "https://dx.doi.org/10.1016/j.jhep.2019.11.012", "https://read.qxmd.com/doi/10.1016/j.jhep.2019.11.012", "https://dx.doi.org/10.7326/m21-4119", "https://read.qxmd.com/doi/10.7326/m21-4119", "https://dx.doi.org/10.1056/nejmoa2116044", "https://read.qxmd.com/doi/10.1056/nejmoa2116044", "https://dx.doi.org/10.1056/nejmoa2116185", "https://read.qxmd.com/doi/10.1056/nejmoa2116185", "https://covid19researchdatabase.org/", "https://dx.doi.org/10.1097/sla.0000000000005308", "https://read.qxmd.com/doi/10.1097/sla.0000000000005308", "https://dx.doi.org/10.1016/j.acvd.2021.10.011", "https://read.qxmd.com/doi/10.1016/j.acvd.2021.10.011", "https://dx.doi.org/10.1016/j.ajem.2022.07.052", "https://read.qxmd.com/doi/10.1016/j.ajem.2022.07.052", "https://dx.doi.org/10.1016/s0735-6757(96)90124-2", "https://read.qxmd.com/doi/10.1016/s0735-6757(96)90124-2", "https://dx.doi.org/10.1111/imj.15135", "https://read.qxmd.com/doi/10.1111/imj.15135", "https://dx.doi.org/10.1080/14656566.2019.1583743", "https://read.qxmd.com/doi/10.1080/14656566.2019.1583743", "https://dx.doi.org/10.2106/jbjs.oa.18.00033", "https://read.qxmd.com/doi/10.2106/jbjs.oa.18.00033", "https://dx.doi.org/10.1097/ajp.0000000000000792", "https://read.qxmd.com/doi/10.1097/ajp.0000000000000792", "https://dx.doi.org/10.1001/jama.2022.16844", "https://read.qxmd.com/doi/10.1001/jama.2022.16844", "https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics", "https://dx.doi.org/10.1001/jamanetworkopen.2021.36662", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2021.36662", "https://dx.doi.org/10.1136/bmj-2021-069931", "https://read.qxmd.com/doi/10.1136/bmj-2021-069931", "https://statusofwomendata.org/state-data/", "https://dx.doi.org/10.1001/jamainternmed.2022.2998", "https://read.qxmd.com/doi/10.1001/jamainternmed.2022.2998", "https://dx.doi.org/10.1001/jamanetworkopen.2021.3789", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2021.3789", "https://dx.doi.org/10.1001/jamainternmed.2013.12756", "https://read.qxmd.com/doi/10.1001/jamainternmed.2013.12756", "https://dx.doi.org/10.1001/jama.2022.6424", "https://read.qxmd.com/doi/10.1001/jama.2022.6424", "https://dx.doi.org/10.1097/ccm.0000000000005337", "https://read.qxmd.com/doi/10.1097/ccm.0000000000005337", "https://dx.doi.org/10.1097/ccm.0000000000002189", "https://read.qxmd.com/doi/10.1097/ccm.0000000000002189", "https://dx.doi.org/10.1016/j.chest.2019.11.050", "https://read.qxmd.com/doi/10.1016/j.chest.2019.11.050", "https://dx.doi.org/10.1056/nejmoa2202707", "https://read.qxmd.com/doi/10.1056/nejmoa2202707", "https://dx.doi.org/10.15288/qjsa.1966.27.469", "https://read.qxmd.com/doi/10.15288/qjsa.1966.27.469", "https://dx.doi.org/10.3389/fpsyt.2022.821208", "https://read.qxmd.com/doi/10.3389/fpsyt.2022.821208", "https://dx.doi.org/10.1001/jamapsychiatry.2022.2096", "https://read.qxmd.com/doi/10.1001/jamapsychiatry.2022.2096", "https://dx.doi.org/10.1001/jama.2016.15450", "https://read.qxmd.com/doi/10.1001/jama.2016.15450", "https://dx.doi.org/10.1001/jama.2022.12138", "https://read.qxmd.com/doi/10.1001/jama.2022.12138", "http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/", "https://www.acc.org/latest-in-cardiology/articles/2014/08/25/14/48/strengths-and-limitations-of-the-ascvd-risk-score-and-what-should-go-in-the-risk-discussion", "https://dx.doi.org/10.1016/j.jacc.2018.11.003", "https://read.qxmd.com/doi/10.1016/j.jacc.2018.11.003", "https://dx.doi.org/10.1161/cir.0000000000000678", "https://read.qxmd.com/doi/10.1161/cir.0000000000000678", "https://dx.doi.org/10.1001/jama.2022.13044", "https://read.qxmd.com/doi/10.1001/jama.2022.13044", "https://dx.doi.org/10.1016/j.chest.2022.05.003", "https://read.qxmd.com/doi/10.1016/j.chest.2022.05.003", "https://pre-empt.obgyn.ubc.ca/home-page/current-projects/comit/", "https://dx.doi.org/10.1016/j.ajog.2021.09.024", "https://read.qxmd.com/doi/10.1016/j.ajog.2021.09.024", "https://dx.doi.org/10.1136/bmj.a1344", "https://read.qxmd.com/doi/10.1136/bmj.a1344", "https://dx.doi.org/10.1001/jamanetworkopen.2022.3849", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2022.3849", "https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19", "https://dx.doi.org/10.1056/nejmoa2115869", "https://read.qxmd.com/doi/10.1056/nejmoa2115869", "https://dx.doi.org/10.1503/cmaj.161390", "https://read.qxmd.com/doi/10.1503/cmaj.161390", "https://dx.doi.org/10.1136/bmj-2022-071204", "https://read.qxmd.com/doi/10.1136/bmj-2022-071204", "https://dx.doi.org/10.1016/j.amjmed.2011.12.013", "https://read.qxmd.com/doi/10.1016/j.amjmed.2011.12.013", "https://dx.doi.org/10.1016/j.jacc.2014.08.021", "https://read.qxmd.com/doi/10.1016/j.jacc.2014.08.021", "https://dx.doi.org/10.1016/j.ijcard.2022.04.085", "https://read.qxmd.com/doi/10.1016/j.ijcard.2022.04.085", "https://dx.doi.org/10.1056/nejmoa2208275", "https://read.qxmd.com/doi/10.1056/nejmoa2208275", "https://dx.doi.org/10.1056/nejmoa2019422", "https://read.qxmd.com/doi/10.1056/nejmoa2019422", "https://dx.doi.org/10.7326/m21-4798", "https://read.qxmd.com/doi/10.7326/m21-4798", "https://dx.doi.org/10.1111/joim.12752", "https://read.qxmd.com/doi/10.1111/joim.12752", "https://dx.doi.org/10.1016/j.mayocp.2021.11.021", "https://read.qxmd.com/doi/10.1016/j.mayocp.2021.11.021", "https://dx.doi.org/10.3390/bs8110098", "https://read.qxmd.com/doi/10.3390/bs8110098", "https://dx.doi.org/10.1186/s12913-021-06371-x", "https://read.qxmd.com/doi/10.1186/s12913-021-06371-x", "https://dx.doi.org/10.1001/jamanetworkopen.2022.13080", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2022.13080", "https://dx.doi.org/10.1016/s0022-5223(19)35634-x", "https://read.qxmd.com/doi/10.1016/s0022-5223(19)35634-x", "https://dx.doi.org/10.1056/nejmoa2028788", "https://read.qxmd.com/doi/10.1056/nejmoa2028788", "https://dx.doi.org/10.1056/nejmoa2201171", "https://read.qxmd.com/doi/10.1056/nejmoa2201171", "https://dx.doi.org/10.1007/s10654-016-0202-2", "https://read.qxmd.com/doi/10.1007/s10654-016-0202-2", "https://dx.doi.org/10.7326/m21-2977", "https://read.qxmd.com/doi/10.7326/m21-2977", "https://dx.doi.org/10.1016/j.ijcard.2013.08.048", "https://read.qxmd.com/doi/10.1016/j.ijcard.2013.08.048", "https://dx.doi.org/10.1161/circulationaha.111.082511", "https://read.qxmd.com/doi/10.1161/circulationaha.111.082511", "https://dx.doi.org/10.1001/jamanetworkopen.2022.37234", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2022.37234", "https://dx.doi.org/10.1001/jamapsychiatry.2022.3352", "https://read.qxmd.com/doi/10.1001/jamapsychiatry.2022.3352", "https://dx.doi.org/10.1001/jama.2021.6238", "https://read.qxmd.com/doi/10.1001/jama.2021.6238", "https://dx.doi.org/10.1093/eurpub/ckv148", "https://read.qxmd.com/doi/10.1093/eurpub/ckv148", "https://dx.doi.org/10.1053/j.gastro.2018.07.017", "https://read.qxmd.com/doi/10.1053/j.gastro.2018.07.017", "https://dx.doi.org/10.1056/nejmoa2208375", "https://read.qxmd.com/doi/10.1056/nejmoa2208375", "https://www.uspreventiveservicestaskforce.org/webview/#!/", "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication", "https://qxmd.com/calculate/calculator_37/acc-aha-cv-risk-calculator-2013", "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-supplementation-to-prevent-cvd-and-cancer-preventive-medication", "https://dx.doi.org/10.1001/jama.2022.8970", "https://read.qxmd.com/doi/10.1001/jama.2022.8970", "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventive-medication", "https://dx.doi.org/10.1001/jama.2022.4983", "https://read.qxmd.com/doi/10.1001/jama.2022.4983", "https://www.uspreventiveservicestaskforce.org/uspstf/index.php/recommendation/menopausal-hormone-therapy-preventive-medication", "https://dx.doi.org/10.1001/jama.2022.18625", "https://read.qxmd.com/doi/10.1001/jama.2022.18625", "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/atrial-fibrillation-screening", "https://www.uspreventiveservicestaskforce.org/uspstf/index.php/recommendation/obstructive-sleep-apnea-in-adults-screening", "https://dx.doi.org/10.1001/jama.2022.20304", "https://read.qxmd.com/doi/10.1001/jama.2022.20304", "https://www.uspreventiveservicestaskforce.org/uspstf/index.php/recommendation/syphilis-infection-nonpregnant-adults-adolescents-screening", "https://dx.doi.org/10.1001/jama.2022.15322", "https://read.qxmd.com/doi/10.1001/jama.2022.15322", "https://dx.doi.org/10.1016/j.resuscitation.2020.09.029", "https://read.qxmd.com/doi/10.1016/j.resuscitation.2020.09.029", "https://dx.doi.org/10.1056/nejmoa2207304", "https://read.qxmd.com/doi/10.1056/nejmoa2207304", "https://dx.doi.org/10.1001/jamanetworkopen.2022.42972", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2022.42972", "http://dx.doi.org/10.1101/2021.11.11.21266068", "https://dx.doi.org/10.1056/nejmc2119270", "https://read.qxmd.com/doi/10.1056/nejmc2119270", "https://dx.doi.org/10.1001/jamainternmed.2021.7024", "https://read.qxmd.com/doi/10.1001/jamainternmed.2021.7024", "https://dx.doi.org/10.1001/jamaophthalmol.2018.2493", "https://read.qxmd.com/doi/10.1001/jamaophthalmol.2018.2493", "https://dx.doi.org/10.1001/jamainternmed.2021.6990", "https://read.qxmd.com/doi/10.1001/jamainternmed.2021.6990", "https://dx.doi.org/10.1001/jamainternmed.2022.2488", "https://read.qxmd.com/doi/10.1001/jamainternmed.2022.2488", "https://dx.doi.org/10.1001/jama.2021.15650", "https://read.qxmd.com/doi/10.1001/jama.2021.15650", "https://dx.doi.org/10.7326/m21-3846", "https://read.qxmd.com/doi/10.7326/m21-3846", "https://dx.doi.org/10.1164/rccm.201202-0350ed", "https://read.qxmd.com/doi/10.1164/rccm.201202-0350ed", "https://dx.doi.org/10.1016/j.jaci.2003.09.008", "https://read.qxmd.com/doi/10.1016/j.jaci.2003.09.008", "https://dx.doi.org/10.1016/j.jaci.2012.07.058", "https://read.qxmd.com/doi/10.1016/j.jaci.2012.07.058", "https://dx.doi.org/10.1056/nejmoa2118813", "https://read.qxmd.com/doi/10.1056/nejmoa2118813", "https://www.covid19treatmentguidelines.nih.gov/management/critical-care/summary-recommendations/", "https://dx.doi.org/10.1016/s2213-2600(21)00356-8", "https://read.qxmd.com/doi/10.1016/s2213-2600(21)00356-8", "https://dx.doi.org/10.1183/13993003.00265-2021", "https://read.qxmd.com/doi/10.1183/13993003.00265-2021", "https://dx.doi.org/10.1016/S1473-3099(20)30483-7", "https://read.qxmd.com/doi/10.1016/S1473-3099(20)30483-7", "https://dx.doi.org/10.1001/jamainternmed.2022.1070", "https://read.qxmd.com/doi/10.1001/jamainternmed.2022.1070", "https://dx.doi.org/10.1056/nejmoa061115", "https://read.qxmd.com/doi/10.1056/nejmoa061115", "https://dx.doi.org/10.1136/bmj-2021-069634", "https://read.qxmd.com/doi/10.1136/bmj-2021-069634", "https://dx.doi.org/10.7326/m16-0577", "https://read.qxmd.com/doi/10.7326/m16-0577", "https://dx.doi.org/10.1001/jama.2022.3337", "https://read.qxmd.com/doi/10.1001/jama.2022.3337", "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-for-prediabetes-and-type-2-diabetes", "https://dx.doi.org/10.7326/m20-8079", "https://read.qxmd.com/doi/10.7326/m20-8079", "https://dx.doi.org/10.1016/s0140-6736(11)60205-5", "https://read.qxmd.com/doi/10.1016/s0140-6736(11)60205-5", "https://dx.doi.org/10.1056/evidoa2200014", "https://read.qxmd.com/doi/10.1056/evidoa2200014", "https://www.cdc.gov/vaccines/schedules/index.html", "https://dx.doi.org/10.7326/m22-0036", "https://read.qxmd.com/doi/10.7326/m22-0036", "https://dx.doi.org/10.14309/ajg.0000000000001538", "https://read.qxmd.com/doi/10.14309/ajg.0000000000001538", "https://dx.doi.org/10.1002/14651858.cd013879", "https://read.qxmd.com/doi/10.1002/14651858.cd013879", "https://dx.doi.org/10.1038/s41591-022-01689-3", "https://read.qxmd.com/doi/10.1038/s41591-022-01689-3", "https://dx.doi.org/10.1016/j.jacc.2019.01.011", "https://read.qxmd.com/doi/10.1016/j.jacc.2019.01.011", "https://dx.doi.org/10.7326/m22-0511", "https://read.qxmd.com/doi/10.7326/m22-0511", "https://dx.doi.org/10.1001/2013.jamasurg.347", "https://read.qxmd.com/doi/10.1001/2013.jamasurg.347", "https://dx.doi.org/10.1001/jama.2022.19626", "https://read.qxmd.com/doi/10.1001/jama.2022.19626", "https://dx.doi.org/10.1056/nejmoa1107039", "https://read.qxmd.com/doi/10.1056/nejmoa1107039", "https://dx.doi.org/10.1111/jth.13140", "https://read.qxmd.com/doi/10.1111/jth.13140", "https://dx.doi.org/10.1161/circulationaha.121.054990", "https://read.qxmd.com/doi/10.1161/circulationaha.121.054990", "https://dx.doi.org/10.1186/s13223-020-00509-y", "https://read.qxmd.com/doi/10.1186/s13223-020-00509-y", "https://dx.doi.org/10.1016/s2213-2600(21)00543-9", "https://read.qxmd.com/doi/10.1016/s2213-2600(21)00543-9", "https://dx.doi.org/10.1056/nejmoa2115926", "https://read.qxmd.com/doi/10.1056/nejmoa2115926", "https://dx.doi.org/10.1038/s41586-019-1791-1", "https://read.qxmd.com/doi/10.1038/s41586-019-1791-1", "https://dx.doi.org/10.1001/jamanetworkopen.2021.37277", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2021.37277", "https://dx.doi.org/10.1007/s00134-018-5107-y", "https://read.qxmd.com/doi/10.1007/s00134-018-5107-y", "https://dx.doi.org/10.1007/s00134-021-06558-0", "https://read.qxmd.com/doi/10.1007/s00134-021-06558-0", "https://dx.doi.org/10.1056/nejmoa2200644", "https://read.qxmd.com/doi/10.1056/nejmoa2200644", "https://dx.doi.org/10.1097/hjh.0000000000002943", "https://read.qxmd.com/doi/10.1097/hjh.0000000000002943", "https://dx.doi.org/10.1001/jamanetworkopen.2022.15513", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2022.15513", "https://dx.doi.org/10.2337/dc17-1116", "https://read.qxmd.com/doi/10.2337/dc17-1116", "https://dx.doi.org/10.1161/circulationaha.121.056756", "https://read.qxmd.com/doi/10.1161/circulationaha.121.056756", "https://www.hhs.gov/about/news/2022/08/04/biden-harris-administration-bolsters-monkeypox-response-hhs-secretary-becerra-declares-public-health-emergency.html", "https://dx.doi.org/10.1056/nejmoa2207323", "https://read.qxmd.com/doi/10.1056/nejmoa2207323", "https://dx.doi.org/10.1016/j.contraception.2011.02.009", "https://read.qxmd.com/doi/10.1016/j.contraception.2011.02.009", "https://dx.doi.org/10.1097/aog.0000000000004717", "https://read.qxmd.com/doi/10.1097/aog.0000000000004717", "https://dx.doi.org/10.1016/j.cct.2015.01.007", "https://read.qxmd.com/doi/10.1016/j.cct.2015.01.007", "https://dx.doi.org/10.1056/nejmoa2202106", "https://read.qxmd.com/doi/10.1056/nejmoa2202106", "https://dx.doi.org/10.1001/jamanetworkopen.2021.33188", "https://read.qxmd.com/doi/10.1001/jamanetworkopen.2021.33188", "https://dx.doi.org/10.1161/circulationaha.119.041974", "https://read.qxmd.com/doi/10.1161/circulationaha.119.041974", "https://dx.doi.org/10.1001/jamainternmed.2022.3946", "https://read.qxmd.com/doi/10.1001/jamainternmed.2022.3946", "https://dx.doi.org/10.1056/nejmoa2200433", "https://read.qxmd.com/doi/10.1056/nejmoa2200433", "https://dx.doi.org/10.7326/m22-1761", "https://read.qxmd.com/doi/10.7326/m22-1761", "https://dx.doi.org/10.1038/s41586-021-04387-1", "https://read.qxmd.com/doi/10.1038/s41586-021-04387-1", "https://dx.doi.org/10.15585/mmwr.mm7112e1", "https://read.qxmd.com/doi/10.15585/mmwr.mm7112e1", "https://dx.doi.org/10.1056/nejmoa2119451", "https://read.qxmd.com/doi/10.1056/nejmoa2119451", "https://dx.doi.org/10.1056/nejmoa1711584", "https://read.qxmd.com/doi/10.1056/nejmoa1711584", "https://dx.doi.org/10.1001/jama.2021.11684", "https://read.qxmd.com/doi/10.1001/jama.2021.11684", "https://dx.doi.org/10.1056/evidoa2100010", "https://read.qxmd.com/doi/10.1056/evidoa2100010", "https://dx.doi.org/10.1056/nejmoa2114464", "https://read.qxmd.com/doi/10.1056/nejmoa2114464", "https://dx.doi.org/10.7326/m21-3577", "https://read.qxmd.com/doi/10.7326/m21-3577", "https://www.amboss.com", "/de/wissen", "https://www.amboss.com/de/other/agb", "https://www.amboss.com/de/other/disclaimer", "https://www.amboss.com/de/other/datenschutz", "#", "https://www.amboss.com/de/impressum", "https://support.amboss.com/hc/de", "https://www.amboss.com/de/account/login?nextLink=%2Farticle%2FPu0Wr3", "https://www.amboss.com/de/account/register?nextLink=%2Farticle%2FPu0Wr3", "https://www.amboss.com/de/disclaimer"]}